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ABSTRACT 
Inflammatory bowel disease is a chronic inflammatory condition of bowel. CT and 
barium fluoroscopy are main stay of radiological investigation but impart high radiation 
dose. MRI is a safe and less invasive technique to assess bowel. The thesis examines the 
use of magnetic resonance Imaging in enteric inflammatory bowel disease. 
A discussion on inflammatory bowel disease and overview of MRI techniques, 
diagnostic features and review of literature is described.  
A national survey about the uptake of MRI for the investigation of IBD showed that 
38% of radiology departments offered enteric MRI and barium studies remaining the 
main imaging investigation performed. A proforma administered to clinicians in OPD 
showed significant increase in their diagnostic confidence for small bowel disease after 
MRE, which had positive impact on therapeutic strategy of 61% of patients.  
The results of a prospective studies investigating MR colonography as a biomarker of 
disease activity are then presented. Quantitative measurements of contrast enhancement 
in normal colon have shown intersegmental differences. Three proposed qualitative 
MRI scores of disease activity correlated with endoscopic disease activity, but 
correlation with histopathological scores was less apparent.  
The use of unprepared colonic MRI in assessment of acute colitis is then investigated. A 
qualitative total colonic inflammation score (TCIS) proposed and validated against 
clinical standards including stool frequency and CRP. It also has prognostic ability for 
length of hospital stay.  Region of interest derived quantitative measurements from the 
 4 
colon wall including T2 signal and contrast enhancement are then compared to a 
validated clinical score of colitis activity. Quantitative markers seemed less robust then 
qualitative scores, although quantified contrast enhancement is correlated with disease 
severity. 
 
Patient experiences of MR Colonography and colonoscopy are investigated by using 
face-to-face qualitative interviews, together with a quantitative questionnaire. Patient 
preference is highly complex but patients expressed overall preference for MRC.  
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Glossary 
IBD – Inflammatory bowel disease 
CDAI - Crohn’s disease activity index 
CC – Colonoscopy 
CDEIS - Crohn’s disease endoscopic index of severity  
SES- CD – Endoscopic Crohn’s disease index  
BaFT – Barium follow through  
DCBE – Double contrast barium enema 
CTE – CT Enterography  
CTC – CT Colonography  
MRE – MR Enterography  
MRC – MR Colonography  
HASTE – Half Fourier acquisition single shot turbo spin echo 
FLASH – Fast Low Angle Shot  
FISP – Fast imaging with steady state precision 
VIBE – Volumetric interpolated breath hold examination 
EPI-DWI – Echo planar diffusion weighted images 
ADC – Apparent Diffusion Coefficient  
TCIS – Total colonic inflammatory score 
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Ethical Approval and Patient Recruitment 
Ethical permission was obtained for all the studies from Ethical committee, University 
College London and good medical practice guidelines followed. (07/H0714/82 and 
07/H0715/71) 
Patients were recruited in four main categories for these studies.  
 
Comparative studies with colonoscopy and assessment of patient experience 
Inflammatory Bowel Disease (IBD) patients 
 
In order to develop MRI parameter values in patients with IBD, patients undergoing 
endoscopy for IBD related indications were recruited after identification in the 
following ways  
a. Via review of the clinical referral letter to the department of 
endoscopy  
b. Via outpatient IBD clinic/inpatient ward. An information sheet, 
consent form and an invitation letter were given to all of these 
patients.  
 
Eligible patients selected from endoscopy unit were sent the patient information sheet 
and consent form by post accompanied by a letter inviting them to take part in the study.  
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Non-IBD patients 
 
 Patients undergoing routine outpatient colonoscopy for non-IBD related indications 
were recruited for the study. They were identified via review of the clinical referral 
letter to the department of endoscopy and were selected such that their age distribution 
was similar to that of the IBD patients. An invitation letter along with patient 
information sheet and consent forms were sent to them by post. The letter was sent at 
least 3 weeks prior to the date of their colonoscopy to give time for them to consider 
participation. 
Patients from these two groups had undergone the standard bowel preparation for the 
planned colonoscopy before attending the hospital on that day. MRI was performed 
before colonoscopy (CC) and signed informed consent was obtained for all.  
 
Patients with acute colitis 
 
Given the clinical severity of acute colitis, all eligible patients were inpatients at UCLH 
Patients were identified in three ways 
a. At the weekly GI luminal MDT attended by gastroenterologists, colorectal 
surgeons and radiologists. All patients with colitis were discussed at this 
meeting. 
b. Via direct referral by gastroenterologists or surgeons looking after the patients 
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c. Via referrals to the department of Imaging for appropriate radiological 
investigation of patients with severe colitis including plain films, CT, MRI or 
ultrasound 
 Eligible patients were given the patient information sheet and consent form, 
accompanied by a letter inviting them to take part in the study. For those patients 
agreeing to take part, signed informed consent before the MRI.  
 
Diagnostic impact study 
An ethical waver for the study was obtained from the UCLH ethics committee. New or 
follow up patients attending gastroenterology clinic between July 2008 till September 
2009 referred for a small bowel MRI were included in this study. 
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1 SECTION ONE  
1.1 INTRODUCTION, HYPOTHESIS, AIMS AND 
STRATEGY 
1.1.1 INTRODUCTION 
 
Idiopathic inflammatory bowel diseases (IBD) (Crohn’s disease and ulcerative colitis) 
are a chronic inflammatory condition of the bowel, predominately affecting the young 
and requiring lifelong medical and often surgical therapy (1). The natural history of the 
diseases is one of intermittent acute exacerbations characterised by an acute 
inflammatory response, separated by periods of relative quiescence. Medical therapy is 
based largely on immunosuppressive medication. Although relatively effective, these 
drugs are not without significant side effects, some of them life threatening, notably 
sepsis secondary to immunosuppression. Furthermore therapeutic agents such as anti-
TNF are expensive and often require intravenous administration. Rational use of 
immunosuppressive therapies in IBD disease therefore relies on accurate identification 
of those patients with acute inflammation –so called “active disease”, who are most 
likely to respond to the treatment, together with assessment of the disease extent. The 
management of IBD and assessment of response to medication largely depends on 
accurately documenting the location, extent and the severity of the inflammation (2, 3). 
 Unfortunately there is no single reliable non-invasive method to identify such patients. 
Clinical assessments based on patient symptomatology (such as the Crohn’s disease 
activity index) are relatively subjective (4), and patients with inactive disease (such as 
those with chronic fibrotic strictures) often attract high scores. Biochemical markers 
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such as ESR and CRP are useful adjuncts (5) but again do not in themselves always 
differentiate reliably between active and chronic disease. Radiological investigations 
such as barium fluoroscopy provide useful information about the small bowel, but give 
little information about disease in the colon, and involve relatively high doses of 
radiation(6), which is problematic for young patients with chronic disease. Furthermore, 
they provide little information regarding extramural manifestations such as abscess 
formation, which can be of great importance in patients being considered for strong 
immunosuppression. 
 
For those patients with colonic disease, conventional endoscopic techniques allow direct 
visual inspection of the mucosa. Endoscopy is an essential tool for diagnosis, 
management and prognostic evaluation of inflammatory bowel disease (7). The 
endoscopic appearances correlating with disease activity are well described and include 
aphthoid ulcerations, fissuring ulcers, cobblestoning and stenosis (8). 
Colonoscopy has a prognostic role during a severe flare of disease both in ulcerative 
colitis and in Crohn's disease; moreover in Crohn's disease the evaluation of recurrent 
disease at anastomosis after surgical resection is a common indication. 
Diagnostic endoscopy is considered a safe procedure but is invasive, often 
uncomfortable and patients are often reluctant to undergo the necessary repeat 
procedures over the course of their disease. Although the incidence of perforation after 
endoscopic procedures of the colon is low, it is very well recognized (9). Furthermore in 
those with colonic stricturing disease, complete colonoscopy may be impossible. 
Radiological assessment of colonic IBD can be performed using both barium enema and 
CT Colonography. Both techniques expose patients to ionizing radiation. Although 
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barium enema facilitates assessment of relatively early mucosal disease, CT 
Colonography provides information on both mural and extra mural disease. (10, 11).  
 
Magnetic resonance imaging has been advocated as a potentially useful investigation for 
assessment of those with IBD without exposing patients to ionising radiation (12-14).  It 
images the whole bowel, providing simultaneous information about mural and 
extramural complications. Furthermore it has also been suggested that specific enteric 
and mesenteric appearances on MRI (such as bowel wall signal and contrast 
enhancement, lymphadenopathy, mesenteric high signal) are related directly to disease 
activity (15, 16) and as such may help rationalise the use of, and monitor response to 
immunosuppressive therapy.  
The thesis examines the use of magnetic resonance Imaging (MRI) in enteric 
inflammatory bowel disease (IBD). The level of dissemination of MRI techniques in 
evaluating enteric IBD in the NHS is investigated via a national survey of radiologists 
and gastroenterologists. The impact of MRI Enterography is then studied using 
specifically designed diagnostic and therapeutic impact proformas applied to clinicians 
treating IBD. The thesis then focuses on the colon. The use of unprepared MRI in 
evaluating patients with acute severe colitis is investigated and a qualitative and 
quantitative MRI scoring system of severity proposed and tested against current clinical 
indices and patient outcome. The post contrast perfusion kinetics of the normal colon 
during MRColonography (MRC) is defined. The ability of MR Colonography to assess 
disease activity in the colon against an endoscopic and histological standard of 
reference is then addressed using qualitative MRI scoring systems. Patient experience of 
MRC is investigated by qualitative interviews, and a quantitative questionnaire applied 
comparing experiences during MRC and colonoscopy (CC). 
 27 
1.1.2 HYPOTHESIS AND AIMS 
 
1. European guidelines increasingly advocate the use of cross sectional techniques 
(MRI and SbUS) but dissemination in UK is patchy and adhoc. 
 
Aim: to assess via postal survey, current utilization of small bowel imaging 
investigations for Crohn’s disease within NHS radiological practice, and to 
gauge current gastroenterological referral patterns 
 
2. MREnterography (MRE) has a positive diagnostic impact in patients under 
investigation for small bowel Crohn’s disease and influences therapeutic 
strategy 
 
Aim: to assess the impact of MRE on clinician diagnostic confidence and 
therapeutic strategy in patients with small bowel Crohn’s disease  
 
3. Abnormal contrast enhancement on MRI is advocated as a biomarker for 
inflammation in colitis, although the enhancement kinetics of normal colon are 
poorly described which can influence the interpretation of diseased colon on 
MRI.  
Aim: to quantitatively assess mural enhancement in endoscopicaly proven 
normal colon and test for inter segmental differences 
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4. Mural characteristics on MR Colonography can be used as a biomarker of 
disease activity in IBD 
 
Aim: to compare qualitative MRI scores of colonic disease activity against 
reference endoscopic and histological scores.  
 
5. MRI and extramural characteristics on unprepared MRI can act as a biomarkers 
of disease active in acute colitis, and may predict ultimate outcome 
 
Aim: To derive and validate a total colonic inflammatory score for assessing 
severity therapeutic response and prognosis in acute colitis. 
 
6. Quantitative measurements of the bowel wall characteristics in acute colitis 
change in response to medical therapy and mirror objective measurements of 
clinical response. 
 
Aim: to establish if quantitative MRI mural characteristics changes in response 
to therapeutic intervention and correlate with clinical markers of therapeutic 
response. 
7. Currently available quantitative questionnaires regarding patient experience of 
MRC and CC are limited by the assumptions implicit in questionnaire design, 
and may not illicit true patient experience. 
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Aim: to apply qualitative techniques to assimilate data on patient experience and 
attitudes during MR Colonography and Colonoscopy and to evaluate how this is 
moderated by clinical indication 
 
8. MRColonography (MRC) is better tolerated by patients, as a less invasive and 
more acceptable alternative to conventional colonoscopy (CC).  
Aim: to evaluate patient experience of MR Colonography in comparison to 
conventional endoscopy using established questionnaires 
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1.1.3 THESIS STRATEGY 
 
The thesis has five sections.   
The first section consists of discussion about epidemiology and pathogenesis of 
inflammatory bowel disease and describes different treatment approaches. . It describes 
the available methods of diagnosis and disease assessment including clinical scores, 
biochemical indices and diagnostic modalities such as colonoscopy, barium enema, CT 
Colonography and MRI and describes the lack of an ideal method for defining the 
diagnosis and prognosis of IBD 
This section also gives an overview of use of MRI for diagnosis and assessment of IBD 
including both MR Enterography and MR Colonography detailing technical aspects, 
diagnostic features and associated diagnostic pitfalls. The chapter includes a review of 
current literature and speculates on the future role of the modality.  
In second section, the first chapter considers uptake of MRI in the NHS and its impact 
in the management of IBD patients.  The findings of a national survey documenting 
current dissemination of MRI are presented.   
The second chapter describes the design of a new diagnostic and therapeutic impact 
proforma to assess the influence of imaging tests in IBD management, and its 
prospective use with regard to MREnterography presented. 
The third section focuses on developing MRI for assessing colonic IBD and consists of 
four studies. 
The first study describes the quantitative MRI mural changes that occur following 
intravenous gadolinium administration in endoscopicaly normal colon and details inter-
segmental differences.  
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The second study presents the results of a prospective study investigating MR 
Colonography as a potential biomarker of disease activity in colonic IBD. Three 
qualitative scoring systems of mural and extra mural tissue characteristics are tested 
against an endoscopic and histological standard of reference.  
The third study investigates unprepared MRI in the assessment of acute severe colitis. 
In particular a qualitative total colonic inflammation score (TCIS) is developed and 
initially validated against clinical and biochemical standards of reference.  
The fourth study describes the potential of quantitative bowel wall measurements on 
unprepared MRI in acute severe colitis to act as biomarkers of disease severity in 
comparison to an established combined clinical score of severity.  
 
The fourth section reports a prospective study investigating patient experiences of MR 
Colonography and colonoscopy using face-to-face qualitative interviews, together with 
a quantitative questionnaire based around the 3 principal components of worry, physical 
experience and satisfaction. 
 
The final section concludes this thesis with a discussion of the main findings and the 
implications for the dissemination of MR Colonography into day-to-day practice. 
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1.2 INFLAMMATORY BOWEL DISEASE 
 
Inflammatory bowel disease is usually categorized into Ulcerative colitis (UC) and 
Crohn’s disease (CD). Although IBD occurs worldwide there is a noticeably higher 
incidence observed in the Westernized or industrialized areas of world. IBD is mainly a 
disease of young people with peak incidence between the ages of 10 -40 years, although 
15 % cases are diagnosed after the age of 60. An incidence rate of 3.1 to 14.6/100,000 is 
seen in North America, whilst in the UK around 240,000 people are affected with IBD. 
The incidence of UC is approximately 10-20 per 100,1000 per year and CD is 5-10 per 
100,000 per year (1, 17-19). 
UC and CD show significant differences in presenting symptoms, disease distribution, 
therapeutic strategy and prognosis. Crohn’s disease commonly affects terminal ileum 
and proximal colon although it can involve whole of gastrointestinal tract. Bowel 
involvement is segmental typically manifesting as “skip lesions” where as UC usually 
affects rectum first (ulcerative proctitis) and in severe form can affect whole of colon as 
pan colitis.  The features of Crohn’s disease (CD) differ between the early and chronic 
stages of the disease. Typically in the early stage of CD there are areas of focal 
inflammation with aphthoid ulcerations and lymphoid hyperplasia. These progress to 
longitudinal and transverse mucosal ulcerations and eventually the ulceration may 
become transmural. Thereafter complications may arise including strictures, sinuses, 
fistulae and perienteric abscesses. Histologically, the chronic inflammatory process is 
typified by non- caseating granuloma formation. In the chronic stage of CD, there is 
fatty infiltration of bowel wall and fibrofatty infiltration of mesenteric fat. When disease 
becomes chronic it is characterized by fibrosis and stricture formation.  
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Conversely UC is a mucosal inflammatory process typified by ulceration of affected 
bowel. The disease characteristically begins in rectum and extends proximally to 
involve a variable parts of, or indeed the colon (11) (Table 1). 
Ulcerative colitis  Crohn’s Disease 
Rectum  + colon Mouth to anus 
Continuous  Discontinuous 
Mucosal Disease Trans mucosal disease (fissure, abscess, 
fistulae)  
Muscular thickening Fibrosis (stenosis) 
Mucin depletion  Lymphoid ulcers, aggregates 
Glandular damage Granuloma  
Colonic bleeding typical Bleeding variable 
Increase risk with smoking Decrease risk with smoking 
 
Table 1:  Comparative features of UC and CD 
 
Due to overlapping features, around 5 % of patients with IBD affecting the colon cannot 
be confidently classified as UC or CD even after considering all clinical, radiological, 
endoscopic and pathological information. Such patients are classified as indeterminate 
colitis (IC), although strictly speaking this is a post colectomy histological diagnosis 
IBD not only involves the GI; extraintestinal manifestation are seen in 40% of the 
patients (20) (21) (Table 2). 
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Musculoskeletal Arthritis, ankylosing spondylitis& 
sacroiliitis 
Skin and mucous membranes Oral ulcers, erythema nodosum, 
pyoderma gangrenosum, cutaneous 
vasculitis 
Ocular Conjunctivitis, Crohn’s keratopathy 
Hepatic Primary sclerosing cholangitis 
Cardiac Endocarditis, myocarditis 
Neurologic Peripheral neuropathy 
Bronchopulmonary Sarcoidosis, fibrosing alveolitis 
 
Table 2: Extra intestinal manifestations of IBD 
 
1.2.1 PATHOGENESIS OF IBD 
 
The pathogenesis of IBD is still not clear; genetic, environmental and immunological 
factors have all been considered. Epidemiological data confirms the familial nature of 
the disease, although suggested “triggers” include, environmental factors such as diet, 
smoking, non-steroidal anti-inflammatory drugs (NSAIDs) and infections.  One fourth 
of IBD patients have an affected family member. Indeed UC and CD can occur in same 
family and share some features in genetic susceptibility. Many epidemiologic, 
immunologic and pathogenic features are common to both disorders, although genetic 
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factors are likely more important in CD. Environmental factors may have opposing 
effects on the two diseases. For example smoking worsens CD, but t decreases the risk 
of UC. 
Epidemiological studies have considered diet, drug and vaccination history, seasonal 
variation, water supply and social circumstances. Extensive research has been 
performed investigating the role of luminal bacteria, biofilms, epithelial barrier 
functions and immune/ epithelial interactions as well as inflammatory process such as 
cell signaling pathways, cytokine profiles, lymphocyte trafficking, cell surface 
molecules and neuroimmune communications (22). Numerous bacteria and virus have 
been proposed as intimately associated with CD and UC including the measles virus, 
mycobacterium paratuberculosis diplostreptococcus and E coli, but as yet an infective 
etiology has not been established with any certainty.   
 
1.2.2 TREATMENT OF IBD 
 
UC may be severe and despite of new medical and surgical treatment, it still has excess 
mortality in the first two years of diagnosis. About 50 % of patient have a relapse in any 
year, which can be life threatening and of those with pancolitis around 20- 30% -will 
need total colectomy and ileal pouch formation. Conversely at least 50% of patients 
with CD will require surgery within the first 10 years of diagnosis and 70-80% within 
their lifetime due to failure of medical therapy or disease complications. 
Medical therapy for IBD is rapidly evolving with new biological agents entering routine 
clinical practice, although therapeutic efficacy must be weighed against their side effect 
profile (Table 3). 
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1.2.2.1 Amino salicylates 
This group includes mesalazine/ 5 ASA, Asacol and Pentasa. The drug class acts on 
epithelial cells by variety of mechanisms to moderate the release of lipid mediators, 
cytokines and reactive oxygen species. Side effects occur in 10 -45% of patients, most 
commonly headache, nausea, epigastric pain and diarrhea but serious idiosyncratic 
reactions including Steven Johnson syndrome, pancreatitis, agranulocytosis or alveolitis 
can occur. Patients need regular monitory of renal functions while on therapy (2, 23, 
24). 
1.2.2.2 Corticosteroids 
Corticosteroids are potent anti- inflammatory agents for moderate to severe relapses of 
both UC and CD. They inhibit of several inflammatory pathways such as suppressing 
interleukin transcription and arachidonic acid metabolism and stimulate of lymphocytes 
within the lamina propria of the gut. Early side effects are cosmetic (acne, moon face, 
edema), sleep and mood disturbance, dyspepsia and glucose intolerance while longer 
use is associated with osteoporosis, osteonecrosis of femoral head, myopathy and 
susceptibility to infections. Complete steroid withdrawal is facilitated by early 
introduction of azathioprine, adjuvant nutritional therapy or early surgery (25). 
1.2.2.3 Thiopurines 
Thiopurines are effective during active disease relapse and are commonly used to 
maintain remission in CD and UC. They are also used as steroid sparing agents and for 
postoperative prophylaxis of complex or fistulating CD. Leucopoenia due to 
myelotoxicity can develop suddenly and unpredictably in between blood tests and 
hepatotoxicity and pancreatitis are well described. There is evidence for an associated 
small (<5%) increased in malignancy. 
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1.2.2.4 Methotrexate  
Methotrexate use is second line in active or relapsing disease refractory to AZA and 
requires regular blood count and liver function tests. Early cytotoxicity is primarily 
gastrointestinal causing nausea, vomiting, diarrhea and stomatitis. In 10-18% of patients 
treatment has to be discontinued due to hepatotoxicity or pneumonitis (26, 27). 
1.2.2.5 Cyclosporine  
Cyclosporine prevents clonal expansion of T-cell subsets and its rapid onset of action, 
which makes it effective in management of severe UC. Use however cannot usually 
continue for more than 3-6 months because of toxicity. Major side effects include renal 
impairment, infections and neurotoxicity leading to increase risk of seizures in patients 
with low cholesterol. Depending on patient’s nutritional status and duration of therapy, 
prophylaxis against Pneumocystis carinii and Aspergillus is required (28, 29). 
1.2.2.6 Infliximab  
Infliximab is an anti-TNF monoclonal antibody with potent anti-inflammatory effects It 
is effective in both active and fistulating CD refractory to steroids and other first line 
immunosuppression. Associated with side effects include joint pains and stiffness, fever 
and myalgia but infection is a risk, notably reactivation or development of TB. Indeed 
there is four to five fold increase risk of TB during this therapy. Infliximab can 
exacerbate existing cardiac failure and there is theoretical risk of inducing 
lymphoproliferative disorders or malignancies (30, 31) (Table 3). 
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Group Mechanism of 
action 
Minor side effects Major side effects  
Amino salicylates 
 
Effects on 
epithelial cells 
Headache, nausea, 
epigastric pain 
diarrhea 
Idiosyncratic reactions 
(Steven Johnson 
syndrome, pancreatitis, 
agranulocytosis or 
alveolitis) 
Corticosteroids IL transcription, 
arachidonic acid 
metabolism 
Cosmetic, sleep 
disturbance, mood 
changes, 
dyspepsia, glucose 
intolerance 
Osteoporosis, myopathy, 
infection 
Thiopurines Pro –apoptotic 
and anti 
metabolite 
Hepatotoxicity, 
pancreatitis 
Myelotoxicity  
Malignancy/Lymphomas 
Methotrexate Anti metabolite 
and anti folate 
Nausea, vomiting, 
diarrhea, stomatitis 
Hepatotoxicity 
Pneumonitis 
Cyclosporine Prevent clonal 
expansion of T 
cells 
Headache, 
dizziness, Acne, 
increase hair 
growth 
Renal impairment, 
neurotoxicity, infection, 
seizures 
Infliximab Anti TNF 
monoclonal 
antibody 
Fever, myalgia, 
joint pains, 
stiffness 
Cardiac failure, TB, 
lymphoproliferative 
disorders 
 
Table 3: Medical therapy used in IBD and common side effects. 
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1.2.2.7 Surgery  
 
Surgery is usually advised for symptomatic disease not responding to intensive medical 
therapy. The decision to undertake r surgery in CD is usually not may be protracted: 
these are usually symptomatic patients who have developed resistance to medical 
therapy or patients with complications. It should be remembered that surgery is not 
curative in CD-there is a high risk of disease recurrence. The commonly performed 
surgical procedures differ between UC and CD. In CD where it is important to preserves 
gut length, resection of bowel is usually limited to macroscopic abnormal segments, 
while in acute fulminant UC subtotal colectomy with or without primary anastomosis or 
total proctocolectomy with ileal pouch formation is performed. Many surgical 
operations in IBD are staged procedures involving formation of defunctioning stoma. 
Unlike in CD, surgery for UC is curative but clearly is a major life changing 
undertaking (3, 32).  
To achieve optimal results, the timing of surgery is crucial. Early surgery may be 
unnecessary and premature while delayed decisions can increase morbidity and 
mortality and poor outcome (33).The effects on  long term quality of life cannot be 
underestimated, for example the,  change in body image following a permanent stoma. 
Restorative panproctocolectomy with ileal pouch formation however can improve the 
quality of life with significant high degree of satisfaction (34) although bowel emptying 
is usually altered for life (35). Complete assessment of extent and severity of disease is 
fundamental prior to any decision to undertake surgery.  
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1.2.3 ASSESSMENT OF IBD 
 
The impact of IBD is disproportionately high on society for its prevalence due to 
chronic ill health of the young population affected. It remains a diagnostic and 
therapeutic challenge given is often uncertain and unpredictable course, and variable 
responses to medical and surgical management. IBD is a lifelong condition and patients 
must undergo repeated examinations to assess current disease extent and activity. It is 
therefore important that such examinations cause as little disruption, risk and discomfort 
to patients as possible. Even now, there is not one simple test that fulfills all the needs 
of the clinician in assessing patients with IBD and gastroenterologists in routine practice 
use combination of clinical assessment, numeric clinical indices, endoscopic findings 
and imaging modalities for this purpose.  
1.2.3.1 Clinical activity scores  
 
1.2.3.1.1 The Crohn’s disease activity index (CDAI)  
The CDAI was developed and validated in 1976 and consists of eight variables (36). 
The index ranges from 0-600 and the cut off between remission and active disease 
originally taken to be 150 while values above 450 indicating active and very severe 
disease. In later work 150 -219 was defined as mildly active and 220-450 as moderately 
active disease (Table 4). 
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Variable Description  Multiplier 
No of liquid stools Sum of 7 days  X2 
Abdominal pain Sum of 7 days 
ratings 
0- None 
1- Mild 
2- Moderate 
3- Severe 
X5 
General well being Sum of 7 days 
ratings 
0- Generally well 
1- Slightly under par 
2- Poor 
3- Very poor 
4- Terrible 
X7 
Extra intestinal 
complications 
No of listed 
complications 
Arthritis/arthralgia, 
iritis/uveitis, erythema 
nodosum, pyoderma 
ganrenosum, aphtous 
stomatitis, anal fissure/ 
fistula/ abscess, fever > 37.8 
0 C 
X20 
Antidiarrheal drugs Use in the previous 
7 days 
0-no 
1-yes 
X30 
Abdominal mass  0-no 
1-questionable 
5- definite 
X10 
Hematocrit Expected-observed 
Hct 
Males- 47 observed 
Females- 42 observed 
X6 
Body weight Ideal/observed ratio [1-(ideal/observed)] x100 X1 (NOT < 
-10) 
Table 4: The Crohn’s Disease Activity Index CDAI  
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Although the CDAI is one of the mostly used clinical indices particularly in the context 
of clinical trials it has undoubted limitations including 
• Interobserver variability of symptom reporting between patients 
• High weighting of scores of “general well being” and intensity of ‘abdominal 
pain’- which are subjective. 
• The calculation requires diary keeping by patients for 7 days, compliance is an 
issue in every day practice. 
• Misleading results in n fistulating and stenosing disease. 
• Limited utility in patients with n previous ileo- colic resection and stoma. 
1.2.3.1.2 Simple Clinical Colitis Activity Index  
 
This score consists of five clinical criteria and has shown positive correlation with 
laboratory markers (albumin, Hemoglobin, platelet count, hematocrit and ESR) and 
more complex scoring system such as Powel – Tuck Index (37) (Table 5). 
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Symptoms  Score 
Bowel frequency (day)  
1-3 0 
4-6 1 
7-9 2 
>9 3 
Bowel frequency (night)  
1-3 1 
4-6 2 
Urgency of defecation  
Hurry 1 
Immediately 2 
Incontinence  3 
Blood in stool   
Trace 1 
Occasionally frank 2 
Usually frank  3 
General well being  
Very well  0 
Slightly below par 1 
Poor  2 
Very poor  3 
Terrible  4 
Extra colonic features  1 per manifestation 
 
Table 5: Simple Clinical Colitis Activity Index  
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1.2.3.1.3 Other clinical activity indices  
 
The Simple Index (Harvey Bradshaw index), the Organization Mondiale de 
Gastroenterologie (OMGE) index and the Cape Town Index have all been shown to 
correlate with each other and also with CDAI (38-40). 
All the clinical indices can at best only give indirect assessment of disease activity. 
Furthermore they are rather complex and time consuming to collate. Use is therefore 
mainly limited to clinical trials. 
 
1.2.3.2 Biochemical Markers of activity 
 
The ideal biochemical marker in IBD should: 
§ Be helpful in identifying patients at risk  
§ Be disease – specific  
§ Be able to monitor disease activity  
§ Be simple  
§ Minimally invasive.  
1.2.3.2.1 ESR- Erythrocyte sedimentation rate 
 
The ESR is a widely used marker of acute phase response, as it provides crude and rapid 
although indirect assessment of plasma protein alterations during the acute phase 
response. The correlation between disease activity and ESR is good in UC and colonic 
CD but relatively poor in small bowel CD. 
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ESR levels are not only influenced by size, shape and number of erythrocytes but also 
by immunoglobulin level so its assessment is not disease specific. Changes in ESR in 
response to therapy often lags behind clinical response, which limits utility for patient 
follow up in routine practice (41, 42). 
1.2.3.2.2 Acute phase proteins  
 
Classical acute phase proteins are CRP, fibrinogen, serum amyloid A and orosomucoid 
(α1 – acid glycoprotein).  
CRP - is one of the most important acute phase proteins, produced exclusively in 
hepatocytes in response to stimuli including infections, inflammation, stress, tissue 
necrosis, trauma and childbirth. Its production is influenced by IL-6 and TNF and it has 
half life of 19 hours with baseline concentration of 0.8mg/L.  
CRP and orosomucoid correlate with the disease activity in IBD but the 5-day half life 
of orosomucoid limits it use. Conversely CRP, has shorter half life, and often increases 
in the presence of active disease before rapidly decreasing after improvement in 
inflammation. It levels are not directly affected by administration of anti inflammatory 
or immunosuppressive drugs (43).  
CRP correlates reasonably well with CDAI in CD (44, 45). Supporting its use as a 
prognostic marker to assess treatment response. A rise in CRP is commonly seen with 
moderate to severe clinical activity in CD and there is reasonable correlation with other 
biomarkers (ESR, thrombocytosis, anemia and hypoalbuminemia) and endoscopic 
findings. However the correlation between CRP and radiological and histologic markers 
of disease activity is less robust (44, 46). 
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1.2.3.2.3 Leucocytes and platelets 
 
Due to increase in polymorphonuclear leukocytes there is commonly a rise in white cell 
count in IBD but this remains a non specific marker of inflammation.  
Platelet count correlates with disease activity both in UC and CD and also with CDAI in 
CD (47). As platelets have wide normal range and can be affected by other factors such 
as hemorrhage use is not widespread in clinical practice for monitoring disease activity 
in IBD. 
1.2.3.2.4 Faecal Calprotectin  
 
Calprotectin is calcium binding neutrophil protein, which stays stable during intestinal 
transit. It is stable in stool sample for up to 7 days at room temperature. It can be easily 
assessed in stools by ELISA test and has reported sensitivity of 95%, specificity of 
93%, positive predictive value 95% and negative predictive value 93% to detect 
colorectal inflammation (48). It can reduce the number of endoscopies required to make 
diagnosis for IBD as normalized concentration indicates mucosal healing (49), but false 
negative results can lead to delayed diagnosis and treatment. 
1.2.3.2.5 Albumin 
 
Serum albumin levels reduce in active disease due to protein loss in gut and 
malnutrition (50) and extremely low levels has prognostic value in predicting medical 
treatment failure in UC.   
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1.2.3.2.6 Neopterin 
 
Neopterin is marker of T cell, monocytes and macrophage stimulation in disorders like 
infections, inflammatory, autoimmune and malignant diseases. Its level in urine and 
serum is elevated in CD and UC but these high levels are not IBD specific so can only 
be used as an additional tool(51, 52). 
1.2.3.2.7 Β2 – Microglobulin 
 
B2-microglobulin is a low molecular weight protein and higher serum levels reflect 
increased release from activated T cells and neutrophils (53). It is a sensitive indicator 
of renal function but serum level also rises in conditions like malignancies, liver 
diseases, sarcoidosis, cardiomyopathy and coeliac disease (54, 55). 
Limited work has been done to assess its use as disease activity marker in IBD and to 
date no correlation has been found in its serum levels and clinical disease activity in UC 
(55) but results are a little more promising in CD (56, 57). 
1.2.3.2.8 ANCA/ASCA 
 
Antineutrophil cytoplasmic IgG antibodies (ANCA) are found in chronic inflammatory 
conditions like rheumatoid arthritis and UC, particularly the perinuclear type (pANCA). 
However, no apparent correlation between the presence and titer of pANCA and IBD 
duration, activity, localization, patient, age, sex or treatment response. A positive 
pANCA is found more commonly in UC compared to CD (58). 
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Another group ASCA (anti-Saccharomyces cerevisiae antibodies) are emerging as 
serological markers of CD and in contrast to pANCA it can reflect disease activity as 
reduction in serum levels is seen after resection of diseased bowel. It may have a role in 
identifying individuals at risk of developing IBD (58, 59). 
 
1.2.3.2.9 Cytokines  
Proinflammatory cytokines such as TNF- α, interleukin-1, interleukin-1ra, interleukin – 
2R and interleukin 6, are produced by activate phagocytes and play an important role in 
the chronic inflammatory process. Increased numbers of TNF- α secreting cells are 
found in inflamed mucosa and treatment with anti-TNF antibodies in both CD and UC 
is now standard therapy in IBD patients refractory to conventional medical therapy has 
shown promising results (60-62). The use of the cytokines as markers of disease activity 
is not yet promising; there are large inter individual variations in the serum levels. 
IL- 1 is a pro inflammatory cytokine and IL- 1ra is IL-1 receptor antagonists. Several 
studies have shown a decrease in the IL-1ra/IL-1 ratio with increase in active IBD, 
perhaps implicating a deficiency in endogenous IL-1ra in pathogenesis of IBD (63). 
 
1.2.3.2.10 Cell adhesion molecules 
Cell adhesion molecules (CAMs), are expressed by immune cells, endothelial cells and 
epithelial cells and some soluble forms are found in blood. Significantly higher levels 
have been reported in active CD and UC compared to inactive disease and these higher 
levels have shown correlation with CRP as well (64-67). 
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Significant overlap is seen between UC and CD, and indeed between IBD and controls 
and between active and inactive disease, making them poor markers of IBD activity. In 
addition, their measurement is difficult and overall they do not easy and convenient and 
do not appear to add any significant information regarding disease management.  
 
1.2.3.3 Colonoscopy 
Since 1970’s colonoscopy has become the gold standard for the diagnosis of IBD (68-
70). Examination of whole colon and multiple random biopsies during colonoscopy in 
clinically suspected cases able to make diagnosis of IBD in 80-90% of affected patients 
(71, 72) and in around 90% it is able to help differentiate between CD and UC (73).  
Colonoscopy requires full bowel preparation, usually with oral laxatives and during 
procedure the majority of patients receive sedation. The endoscopist maneuvers the 
colonoscope within the bowel, using air or carbon dioxide for distension while 
monitoring progress on a video screen. Endoscopy requires considerable operator skill 
and extensive training is mandatory. 
The endoscopic features of IBD include friable mucosa, spontaneous bleeding, aphthoid 
ulcerations, cobblestone appearance and stenosis (74). Endoscopy is regarded as the 
most accurate modality for the assessment of the extent and the severity of disease, 
although clearly it is unable to visualize the small bowel beyond the terminal ileum. 
Luminal stenosis may also limit endoscopic examinations. Endoscopy provides 
exquisite images of the enteric mucosa but in the presence of systemic manifestations 
and transmural inflammation, endoscopic features do not always correlate with clinical 
and biochemical markers (8). 
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Further limitations include technically difficult examinations for example in patients 
with, long mobile or tortuous colon leading to, patient discomfort. Poor bowel 
preparation can lead to difficult or incomplete colonoscopy in 17-23% of cases (75, 76). 
There is a small be well recognized risk of bowel perforation during colonoscopy of 
0.03-0.19% (77-79), with some data that is may be higher in IBD patients (80, 81). 
Surgery following endoscopic perforation has an associated mortality (82, 83).   
Patient experience of colonoscopy may be somewhat negative with the rigors of bowel 
preparation, procedural discomfort, and embarrassment. There is however evidence that 
familiarity with colonoscopy does reduce patient concerns during subsequent repeat 
procedures (84). Gas insufflation and colonic manipulation are the main reasons for 
discomfort, although sedation undoubtedly lessens procedure related pain. The use of 
sedation does risk hypoxia and cardiac arrhythmias, particularly in vulnerable patients 
and necessitates patient monitoring during the procedure by trained staff together with 
provision of post procedure recovery facilities  
Various scoring endoscopic scoring systems for assessing disease severity and activity 
have been developed over time, notably the Crohn’s disease endoscopic index of 
severity (CDEIS), Endoscopic Crohn’s disease index (SES-CD) and Rutgeert’s score. 
1.2.3.3.1 Crohn’s Disease Endoscopic Index of Severity (CDEIS) 
 
This scoring system was developed in 1989 by French group of GETID (Groupe 
d’Etude Therapeutique des Affections Inflammatoires Digestive) (85). It is based upon 
the presence or absence of four types of lesion (superficial ulcers, deep ulcers, ulcerated 
stenosis and non ulcerated stenosis) and the score can range from 0 to 30. Over time it 
has become established as the gold standard for endoscopic evaluation of activity.  It is 
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a reliable and reproducible scoring system, although has shown poor correlation with 
clinical disease activity in some therapeutic trials (85, 86).   
Given the time consuming and relatively complex nature of the scoring system, use in 
every day clinical practice is limited (Table 6). 
                           Rectum Sigmoid & left C Transverse C Right C Ileum  Total 
Deep ulcerations (12 if present) Total 1 
Superficial ulcerations (12 if present) Total 2 
Surface involved by disease (cm) Total 3 
Surface involved by ulcerations (cm) Total 4 
                                                      Total 1 + Total 2 + Total 3 + Total 4= Total A 
                                    Number of segments totally or partially explored n 
                                                                                              Total A ⁄ n= Total B 
                               If an ulcerated stenosis is present anywhere add 3= C 
                            If a non ulcerated stenosis is present anywhere add 3= D 
                                                                                      Total B + C + D= CDEIS 
 
Table 6: Crohn’s Disease Endoscopic Index of Severity 
1.2.3.3.2 Endoscopic Crohn’s disease index (SES-CD)  
SES-CD is based of four endoscopic variables (ulcer size, ulcerated and affected 
surface, stenosis) scoring 0-3 in five ileocolonic segments (Table 7& 8). 
SES-CD:  sum of all variable – 1.4 x (number of affected segments) 
Data has shown the score is reproducible but shows weak correlation to clinical indices 
(SES-CD to CDAI r = 0.371 and SES –CD to CRP r = 0.453), likely due to its inability 
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to account for systemic or fistulating disease and involvement of proximal segments not 
visualized at CC.  
It is simple and faster to calculate as compare to CDEIS but again use is limited in every 
day endoscopic assessment (8). 
 
Variables 0 1 2 3 
Presence of 
ulcers 
None Aphthous ulcers 
(0.1-0.5 cm) 
Large ulcers 
(0.5-2 cm) 
Very larger 
ulcers  
(>2cm) 
Ulcerated 
surface  
None <10% 10-30% >30% 
Affected surface Unaffected 
segment 
<50% 50-75% >75% 
Presence of 
narrowing 
None  Single, can be 
passed 
Multiple, 
can be 
passed  
Cannot be 
passed 
Number of 
affected 
segments  
All variables 
=0 
At least one 
variable > 1 
  
Table 7: SES- CD variables 
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 Ileum Right 
colon 
Transverse 
colon  
Left 
colon  
Rectum  Sum 
Presence of 
ulcers  
     + 
Ulcerated surface      + 
Affected surface      + 
Presence of 
narrowing 
     = 
     Sum of variables  TOT 
Affected segment     TOT- 1.4 x 
(number of 
affected 
segments)= 
E-CDI 
Table 8: SES-CD scoring 
1.2.3.3.3 Rutgeert’s Score (Table 9) 
The Rutgeert’s score is generally accepted as the gold standard endoscopic score for 
assessment and prediction of post surgical disease recurrence. It has five grades of 
endoscopic severity. Studies have found it useful in revealing signs of recurrence in 60-
70% patients within 6-12 months of surgery and also in predicting the course of disease. 
For example mild endoscopic recurrence (<5 aphthous ulcers) within 1 year of resection 
shows a clinical relapse rate of 9 % at 7 years, whereas, severe endoscopic recurrence 
commonly have clinical relapse at 4 years (87, 88). It is useful in providing guidelines 
in further management of such patients or can be used in therapeutic trails to assess 
mucosal healing as a trial end point (89). It does not take into consideration involvement 
of deeper layers, perimesenteric inflammation and the extra mural complications.   
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Grade  Endoscopic findings 
İ0 No lesion in distal ileum 
İ1 < 5 aphthous lesions 
İ2 > 5 aphthous lesions with normal mucosa between the lesions, or skip 
areas of larger lesions confined to ileocolonic anastomosis  
İ3 Diffuse aphthous ileitis with diffusely inflamed mucosa  
İ4 Diffuse inflammation with already larger ulcers, nodule, and / or 
narrowing. 
Table 9: Rutgeert’s score 
There is no single scoring system used widely in every day endoscopic disease 
assessment. In addition, the use of CC in acute exacerbation of disease or to assess 
effectiveness of medical therapy is still not fully defined.  
1.2.3.3.4 Mucosal Healing (MH) 
In 2007, the International Organization of IBD proposed a definition of Mucosal healing 
in UC “the absence of friability, blood, erosions and ulcers in all visualized segments of 
gut mucosa”. It signifies complete healing of all inflammatory and ulcerative lesions 
seen on endoscopy and not just a change in CDEIS or SES-CD after treatment (90).  
In UC, where disease is largely limited to the mucosa, mucosal healing is in theory the 
ultimate therapeutic goal, whereas in CD, a transmural process, it arguably is a minimal 
therapeutic aim. Mucosal healing can be used an objective end point in therapeutic trials 
and in clinical practice is a strong predictor for improve outcome of treatment. Long 
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term maintenance of mucosal healing may decrease structural damage to the bowel, 
thereby resulting in fewer complications and fewer surgical interventions.  
The routine use of endoscopy in patients with complete clinical and biological response 
to treatment is not advocated. Total disappearance of all the mucosal ulceration is 
relevant end point for therapeutic trials but its use in day to day clinical practice remains 
uncertain. The macroscopic evaluation of colonic mucosa at endoscopy is insufficient to 
completely assess disease activity and histological inflammation can exist in the face of 
seemingly normal mucosa.  
Furthermore it is not clear at present whether MH truly reflects resolution of transmural 
injury of the wall in CD (91, 92).     
 
1.2.3.4 Barium Fluoroscopy 
Radiological imaging plays a key role in the diagnosis and management of patients with 
suspected or proven IBD. Barium fluoroscopy has been used for many years to assess 
small bowel disease (either using barium enteroclysis or barium follow though 
techniques) as well as for colonic disease using as the barium enema. 
Small bowel enteroclysis (SBE) and small bowel follow through (SBFT) are the 
traditional radiological techniques used for assessment of small bowel morphology. 
Both enable direct visualization of bowel lining, width of lumen and stenosis, range of 
affected segments and presence of complications. In experienced hands, they have 
similar sensitivity of 85-95% and specificity of 89-94% in detecting radiological signs 
of CD (93). Patients usually prefer SBFT as no nasal or oral intubation is involved. It is 
associated with less radiation exposure, is less time consuming and less expensive (94).     
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The barium enema was first described by Fishcer in 1923 and was refined in 1960’s and 
1970’s. It has been the radiological investigation of choice for the colon (8, 75). It can 
be performed in two main ways, as a single contrast study using barium alone, or as a 
double contrast (DCBE) in which gas is insufflated into the colon so that lesions are 
outlined by a gas-barium interface. The vast majority of studies performed in the United 
Kingdom utilize the double contrast technique. 
Barium enema requires full bowel preparation, usually with oral laxatives. Sedation is 
not generally needed although antispasmodic medication is usually administered (95). 
Colonic distension is achieved using air or carbon dioxide, and there is good evidence 
that the latter results in less patient discomfort (96). The passage of barium and gas into 
the colon is monitored fluoroscopically and an adequate examination necessitates 
significant movement of the patient during the procedure, which may be difficult in the 
elderly or infirm. 
The barium enema has played a key role in diagnosis and management of IBD patients 
(97) and is still used  as additional tool in cases of incomplete or difficult CC (98, 99). 
A well performed barium enema can detect very early mucosal changes such as 
aphthous ulceration and when it comes to differential diagnosis of CD and UC, it has a 
sensitivity of sensitivity of 95-98% (100).  
Akin to CC, barium enema is an operator dependent invasive modality although the 
reported incidence of bowel perforation is only 0.02 -0.04 % (101). Only assessment of 
the lumen is generally achieved and transmural extension of CD and extra luminal 
complications are usually missed. The technique also uses ionizing radiation with total 
effective dose up to 10.7 mSv from a single examination (102, 103).  
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1.2.3.5 Ultrasonography in IBD 
Ultrasonography is easily accessible, inexpensive, non-invasive, painless diagnostic tool 
with the potential widespread clinical use due to ubiquity of ultrasound equipment 
throughout the NSH. It provides information about the bowel wall and extra – intestinal 
manifestations of disease.  
The typical feature for diagnosis of IBD include  
• Bowel wall thickening (> 3 mm) 
•  Presence of a “stiff” bowel wall (reduced peristalsis) 
• Modification or disappearance of bowel wall stratifications in CD and 
preservation of stratification in UC  
• Presence of deep ulcers – interruption of the submucosal hyperechoic rim by a 
hyperechoic tract 
• Loss of haustrations and tubular appearance of colon in long standing disease  
• Extra mural features – fibrofatty proliferation, enlarged lymph nodes, abscess or 
fistulae (104-106). 
Reported sensitivity of US for diagnosis in suspected cases of IBD is 76- 92% while in 
patients with known disease, it is higher (107-109) and correlates well with endoscopic 
features of active disease (110) . It can also accurately detect extra mural complications, 
fistulae, and abscesses. Doppler US has also been used to distinguish between active 
and inactive disease (111, 112).  
Jejunal or duodenal disease is often missed using US, while the rectum and distal 
sigmoid are not visualized fully due to their pelvic location. US with enteral contrast 
have shown higher sensitivity for diagnosis of both small bowel and colonic disease, 
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and even detection of jejunal lesions (113-115) but the spatial resolution of US is not 
high enough to detect the early and superficial mural disease. 
US is extremely operator –dependent and requires skilled staff with expert knowledge 
of IBD. It is difficult to perform on overweight patients as adipose tissue attenuates the 
ultrasound beam. 
 
1.2.3.6 CT Enterography (CTE) and CT Colonography (CTC)   
Computer tomography imaging offers many advantages in assessment of CD-wide 
spread availability, high sensitivity and specificity for detection of luminal and extra 
luminal disease, rapid acquisition of images with high spatial and temporal resolution 
and short overall acquisition time.  
CT Enterography and CT Enteroclysis are modification of conventional CT technique 
optimized for the evaluation of small bowel by administration of large volume of enteric 
contrast agent either orally (CT Enterography) or through a nasojejunal catheter (CT 
enteroclysis). 
In suspected cases of IBD CTE has sensitivity of 83% in comparison to SBE and 80-
88% compared to endoscopy (116-119). For detection of disease and in cases of known 
IBD it has a sensitivity of 80-90% and specificity of 90-98% in comparison to 
endoscopy, SBE and surgery. In general CT is not accurate in detection of early 
superficial lesions (97).  
CT Colonography was described in 1994 by Vining et al, as a relatively non invasive 
and rapid whole colon examination (69). It has advantage of visualizing both luminal 
and extraluminal disease.  
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Typical IBD findings on CT include 
• Segmental wall thickening (“target” or “double halo” appearance) 
• Hyperenhancement after IV contrast- a direct expression of transmural 
inflammation 
• Small bowel wall stratification (visualization of two or three layers of bowel 
wall) 
• Sub mucosal fibro fatty infiltration 
• Stenosis and pre stenotic dilatation 
• Mesenteric fat edema 
• Pericolic mesenteric inflammation 
• Engorged ileal vasa recta (comb sign) 
• Lymphadenopathy 
• Inflammatory phlegmons and abscesses 
 
Studies have reported 80-90 % sensitivity for detection of extraluminal complication 
such as fistulae, sinuses and abscesses (11). CTC is well tolerated by patients as 
compared to barium enema or colonoscopy (72, 120) and there is no need to use 
sedation. 
The use of both CT Colonography and CT Enterography is limited given the exposure 
of the generally young IBD patient cohort to ionizing radiation. There is a theoretical 
risk of cancer induction even at the relatively low doses of diagnostic imaging (10). 
Indeed some suggest 0.7-2% of all cancers and 1% of all cancer related mortality due to 
radiation exposure from CT abdomen and pelvis (121, 122). The effective radiation 
dose to colon from a CTC and CTE is similar to standard CT abdomen and pelvis, 
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(around 13. 2 mSv per study). In theory the risk of inducing cancer is even higher in 
patients with IBD given their need for repeat imaging over the course of their disease 
and thus the cumulative radiation exposure during their life time (10). Attempts have 
been made to reduce radiation dose at CT by reducing the tube current but reducing the 
tube current to 30 mAs although image quality is reduced (123) (Table 10). 
 Colonoscopy DCBE CTC 
Sensitivity for 
IBD diagnosis 
80-90% 90-94% 80-90% 
CD/UC 89% 95-98% Na 
Perforation risk 0.03-0.19% 0.02-0.04% 0.04-0.05% 
Extraluminal 
disease 
evaluation 
No No 
 
Yes  
 
Radiation 
exposure 
No Yes Yes 
Table 10: Comparison of CC, DCBE and CTC 
CTC is not recommended as first line examination when superficial mucosal disease is 
suspected and is clearly contra indicated in acute colitis/toxic megacolon due to the risk 
of perforation. 
1.2.3.7 MREnterography (MRE) and MRColonography (MRC) 
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The use of MRI in IBD has dramatically risen in recent years due to the lack of ionizing 
radiation exposure and superior tissue contrast in comparison to conventional 
fluoroscopy and CT. Advances in MRI hardware and sequences mean high quality 
images of the bowel can be acquired with the time of a single breath hold. MRI was 
initially used for evaluation of perianal disease where it has now become the gold 
standard in the evaluation of IBD related perianal sepsis, surpassing examination under 
anesthetic and improving surgical outcomes.   
Its use in evaluating small bowel and colonic disease is now rapidly evolving. An 
exciting facet of enteric MRI is the potential to not only diagnose and stage IBD, but 
also to accurately assess disease activity. Various parameters including bowel wall 
thickening, bowel wall hyper intensity and hyperenhancement, lymphadenopathy and 
mesenteric inflammation have all been linked to active disease. In terms of technique, 
MRI Enterography/ Enteroclysis involves distension of the small bowel with fluid either 
ingested or infused via nasojejunal tube. MR Colonography requires distension of the 
colon with fluid or gas, usually after some form of bowel preparation  
In common with all cross sectional imaging techniques, MRI facilitates examination of 
the bowel wall and the extra enteric tissues-mesenteric fat stranding, mesenteric 
hypervascularity abscess and fistula formation, and fibro-fatty proliferation are all well 
seen (124, 125). 
Section 1.3 further explores the role of enteric MRI in IBD 
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1.3 MAGNETIC RESONANCE IMAGING IN IBD 
1.3.1 BACKGROUND 
Magnetic resonance imaging has arguably become the most important development in 
medical diagnosis since the discovery of roentgen ray more than 100 years ago. With 
the development of fast imaging sequences and specialized surface coils indications 
now extend to every part of body.  
Up until the relatively recent past, the use of MRI for the assessment of enteric disease 
was limited because of artifacts secondary to respiration and bowel peristalsis, prolong 
imaging time and poor contrast resolution. However over time, technical advances have 
overcome these limitations and high resolution breath hold imaging is now routine. A 
significant advantage of MRI over CT is its lack of ionizing radiation use. This is 
particularly pertinent in the younger population affected by IBD who may need repeated 
imaging during the course of disease. Over and above this advantage, MRI affords 
superior contrast resolution to CT allowing additional diagnostic information not 
possible with X-Ray based technologies 
A more thorough review of the literature pertaining to MRI is given below, but it is 
interesting to briefly describe some of the early data, which paved the way for the 
development of enteric MRI. As far back as 1993 Shoenut et al (126) compared MRI 
findings with endoscopy and surgical findings in 28 patients with known IBD. MRI 
findings were used to categorize bowel inflammation into mild, moderate and severe. 
Using a system based on the length of disease, wall thickness and contrast enhancement, 
Shoenut reported a significant correlation between endoscopic/ surgical findings and all 
these MRI parameters. Just one year later the same authors (127) studied patients with 
clinical suspicion of IBD who underwent had MRI and colonoscopy. They found no 
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significant difference between modalities for the assessment of disease severity (p > 
0.05) and for differentiating between CD and UC (p >0.05). In this exploratory work, 
MRI was considered comparable to endoscopy for determination of disease severity and 
to distinguish between UC and CD. This work undoubtedly stimulated the wealth of 
research, which has now taken place in this field and raised the profile of enteric MRI, 
which was hitherto relatively ignored. 
MRI evaluation of bowel can be undertaken using standard 1.5T or 3T MRI with and 
usually uses multichannel phase array coils. Three imaging sequences form the 
backbone of MRI protocols. A single shot fast spin echo T2 sequence with half-Fourier 
reconstruction (HASTE) allows detailed evaluation of the bowel wall and adjacent 
mesentery The sequence can be disrupted by peristaltic flow artifacts and is best 
employed after spasmolytic administration. A balanced steady state free precession 
(True FISP) is less sensitive to motion artifact and allows evaluation of the bowel wall, 
although its particularly strength lies in assessment of the adjacent mesentery; 
hypervascularity, fibrofatty proliferation and fistulae all are well seen. The third 
sequence is a dynamic fast 3D spoiled gradient echo T1 fat-suppressed post intravenous 
gadolinium sequence (VIBE) to evaluate the extent and pattern of bowel enhancement 
(12, 128). As detailed later in this thesis, additional sequences, notably diffusion 
weighted imaging are showing considerable promise over and above this basic sequence 
complex. 
1.3.2 MRI IN SMALL BOWEL  
MRI evaluation of the small bowel typically combines large volume enteric contrast 
distention of bowel with rapid breath hold T2 and post contrast T1 weighted images in 
the axial and coronal plane (129). Bowel distension is in general a pre-requisite to 
enteric MRI. By distending the bowel, it is possible to evaluate the inner and outer 
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borders of the bowel wall and much better appreciate wall thickening, abnormal 
enhancement and mural signal changes. Such changes are much more difficult to 
appreciate if the bowel is collapsed. Indeed inadequate distension is one of the most 
common causes for failed MRI Enterography. As discussed below, some workers 
advocate the use of MR Enterocylsis-small bowel distension being facilitated by 
infusion of contrast through a nasojejunal tube. Although quality of distension is 
superior to MRI Enterography particularly in the proximal bowel, patient compliance is 
less and in general, MR Enterography is the workhorse of small bowel MRI imaging. 
With its ability to assess disease activity and distribution, and diagnose complications as 
obstruction, perforation, strictures and abscesses, MRI of the small bowel is 
increasingly indicated for first diagnosis of IBD, suspected disease relapse, assessment 
of treatment failure and before planned surgical resection (130).   
Enteric contrast agents used are divided into three groups (131). 
• Positive agents: 
 These demonstrate high signal intensity on T1 and T2 images and are helpful 
delineating the bowel wall. Examples are blue berry and pineapple juice, diluted 
gadolinium and milk with high fat content. In general, positive agents are rarely 
used in clinical practice.  
 
• Negative agents:  
Negative agents have low signal intensity on both T1 and T2 weighted images, 
and include oral superparamegnatic iron oxide particles. They provide better 
visualization of bowel wall edema and mucosal enhancement and help to 
discriminate between intraluminal and extraluminal fluid (abscess). Advocated 
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by several European groups, negative contrast agents tend to have a less pleasant 
taste compared to other agents and are more expensive (132). 
 
• Biphasic agents: 
Biphasic agents have low signal intensity on T1 weighted images and high intensity 
on T2 weighted sequences. Examples include water, polyethylene glycol, diluted 
barium with sorbitol (2%) and mannitol (2.5%), mannitol (2.5%.) with locust bean 
gum (0.2%). The high signal on T2 weighted images facilitate delineation of the 
bowel wall, whilst the low signal on T1 weighted images allows better appreciation 
of contrast enhancement. Although water has biphasic properties, in reality it is a 
very poor oral contrast agent prior to enteric MRI as it is quickly absorbed and 
bowel distension is poor. Biphasic agents used in clinical practice therefore all have 
hyperosmolar properties such they resist absorption by the bowel and remain in the 
lumen, maximizing distension. Hyperosmolar agents, such as polyethylene glycol, 
mannitol (with or without locust bean gum) and the most widely used agents in 
clinical practice are among this group (133). There is some evidence that a 
combination of mannitol (2.5%) and locust bean gum (0.2%) provides the best 
bowel distention (134, 135) but all such agents can cause hyperosmolar diarrhea. 
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 Positive agents Negative agents  Biphasic agents  
Single 
characteristics 
High signal 
intensity on T1 & 
T2 weighted 
images 
Low signal intensity on 
T1 & T2 weighted 
images 
Low signal intensity 
on T1 High signal 
intensity on T2 
weighted images 
Typical 
examples 
Diluted 
Gadolinium 
Blue berry juice  
Pineapple juice 
Milk with high fat 
Superparamegnatic 
iron oxide particles 
Ferumoxsil 
Water 
Polyethylene Glycol 
Barium with sorbitol  
Mannitol  
Mannitol with locust 
bean gum 
VoLumen 
Other features Pleasant taste Unpleasant taste Hyperosmolar 
diarrhea  
Table 11: Comparative qualities of enteric contrast agents  
 
As noted above, enteric contrast agent is administered either orally (MREnterography) 
or through nasojejunal tube (MR Enteroclysis). 
1.3.2.1 MR enteroclysis 
This method involves transnasal or oral placement of a balloon tipped catheter into 
proximal jejunum under fluoroscopic guidance or MRI real time guidance. 
 1.5-2L of enteric contrast is then infused in a controlled fashion to distend the bowel. 
The tube balloon can be inflated to prevent the reflux of fluid into stomach. The high 
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filling volume leads to secondary paralysis of the small bowel and helps avoids motion 
artifacts although additional antiperistaltic agents are usually used.  
  
1.3.2.2 MREnterography (MRE) 
MREnterography is the more commonly performed alternative to enteroclysis and has 
better patient compliance. The patient drinks up to 1.5 l of the oral contrast agent over 
the 40-45 minutes before procedure. Although good quality images can be acquired 
with ingested volumes below 1l, active encouragement of the patient is important to 
ensure compliance with the drink regimen.  
MRI imaging can be performed either in the prone or supine position, although the 
prone position has some advantages; abdominal compression reduces the length of 
breath hold required for image acquisition. Supine position is adequate for patients with 
stomas, enterocutaneous fistulae and for those who cannot lie prone.  
1.3.2.3 Imaging protocol 
Although there are variations in a clinical practice, a typical MREnterography protocol 
is given below 
Protocol for MREnterography (135) 
Metoclopramide 20 mg orally 
Mannitol (2.5%) and locust bean gum (0.2%) 150mL orally every 4 mins, total 1.5L 
Image at 40-60 min 
Thick – slab T2 weighted MR (optional) 
Coronal and axial gradient – echo T2- weighted FISP sequence  
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Hyoscine butylbromide 10 mg or glucagon 0.2 mg IV 
Axial and coronal single shot fast spin echo T2 sequences with half-Fourier 
reconstruction with and without fat suppression 
Coronal 3D unenhanced T1- weighted FLASH (VIBE) sequences 
Hyoscine butylbromide 10 mg or glucagon 0.2 mg IV 
Coronal 3D gadolinium – enhanced T1-weighted FLASH (VIBE) sequences with 30-70 
sec delays 
Axial 3D T1- weighted FLASH sequence at 90 sec. 
MR Enteroclysis  MR Enterography  
Invasive procedure Non invasive 
Poor patient compliance Better patient compliance  
Logistically challenging due to time 
required for placement of nasojejunal 
catheter and bowel distension 
More time efficient. 
Better for diagnosis of suspected jejunal 
disease. Depict early disease and number 
of disease segments. 
Suboptimal distension of jejunum and 
false negative or false positive findings 
due to incomplete bowel loop distention 
Less intraluminal artifacts Intraluminal flow artifacts mimic 
cobblestoning 
Table 12: Comparison of MR enteroclysis and enterography (136, 137) 
 
1.3.2.4 Enteric findings 
Typical features of IBD include (12, 135, 138, 139) 
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1.3.2.4.1 Thickening of wall of diseased segment  
Wall thickness more than 3 mm in distended small bowel loop is abnormal, it 
usually ranges between 5-10mm and is accurately assessed with HASTE 
sequences. Wall thickness is usually greater in CD as compare to UC due to 
transmural inflammatory process. 
1.3.2.4.2 Abnormality in mucosal folds 
 
• Picket fence pattern of diffusely thickened folds 
• Reduction or distortion of folds due to ulceration  
• Cobblestoning- a patchy areas of both high and moderate signal intensity caused 
by longitudinal and transverse ulceration seen on true FISP images  
1.3.2.4.3 Ulcerations 
Moderate to deep ulceration can be seen as thin lines of high signal intensity 
within thickened bowel wall on HASTE images. 
1.3.2.4.4 Strictures – with segment of thick wall 
 
§ Functional - stricture with upstream bowel dilatation 
greater than 3 cm 
§ Non functional - more than 10% narrowing in the lumen 
without dilatation  
1.3.2.4.5 Wall edema  
High T2 signal intensity particularly well seen on fat saturated HASTE images bowel  
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1.3.2.4.6 Mural enhancement 
§ Stratified or layered pattern- bright mucosa due to inflammation and 
hypoenhancing submucosa due to edema.  
§ Diffuse pattern- homogeneous enhancement of entire wall thickness due 
to transmural inflammation 
§ Low –level inhomogeneous enhancement- likely represent fibrosis    
1.3.2.4.7 Pseudosacculation or Pseudodiverticulum 
Fibrosis and shortening of diseased mesenteric wall cause dilatation of anti mesenteric 
border. 
1.3.2.5 Extraenteric findings 
1.3.2.5.1 Comb sign 
Short low- signal intensity parallel lines on true FISP images and as high signal 
intensity lines on VIBE images due increased mesenteric vascularity during 
active disease. 
1.3.2.5.2 Mesenteric edema  
It is seen in advanced active disease. Increased mesenteric signal best seen on fat 
saturated T2 weighted images 
  
1.3.2.5.3 Fat wrapping/ hypertrophy  
 Increased mesenteric fat causes displacement of mesenteric vessels or other 
viscera. It is a specific sign of CD, representing long standing transmural 
inflammation. 
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1.3.2.5.4 Lymph nodes  
Hyper enhancement, enlargement and edema of lymph nodes adjacent to bowel 
seen on fat-saturated HASTE and TrueFISP images  
1.3.2.5.5 Fistulas and sinuses 
Seen as high signal intensity tracts on T2- weighted images or as enhancing 
tracts on post contrast enhanced T1 weighted sequences e.g. enterocolic, 
enteroenteric or enterocutaneous. 
1.3.2.5.6 Abscess 
As well defined, encapsulated collection of pus with high signal intensity on T2 
– weighted and low signal intensity on T1 – weighted images typically with an 
enhancing rim. (131, 139).  
 
1.3.2.6 Review of literature pertaining to MRI in Small bowel IBD 
 
Over the time, significant amount of work has been undertaken regarding use of MRI 
(enterography & enteroclysis). Diagnostic accuracy of MRI has been compared to 
various reference standards and below is the summary of some of these.  
 
1.3.2.6.1 Endoscopic Reference  
Magnano and colleagues compared MRE, US and Doppler US using ileocolonoscopy as 
reference standard in children with known CD. MRE was performed after oral intake of 
polyethylene glycol solution. It depicted stenosis, thickening and hyperemia of bowel 
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wall. Concordance of MR and US for detection of wall thickening and increased 
vascularity was 95% and 80% respectively (140).  
Florie et al (141) used water as intraluminal contrast medium and compared MRI with 
endoscopic grading of disease severity -CDEIS. Wall thickness correlated moderately to 
strongly with CDEIS (r=0.57,p<0.001 and r=0.50, p<0.001) while enhancement 
correlated weakly to moderately (r=0.45,p<0.001 and r=0.42, p<0.001). They also 
compared patient experience and overall preference. Patients found endoscopy more 
painful and hence, expressed preference for MRE as future investigation. In the same 
year, another study of MRE was performed at 3.0 T MRI and also used CDEIS as 
standard of reference (142).  Only a weak to moderate correlation was found between 
bowel wall thickness and CDEIS and between wall enhancement and CDEIS. Again the 
majority patients preferred MRE to ileocolonoscopy.  
Borthne and colleague (143) compared the sensitivity, specificity and diagnostic 
accuracy of MRE (300 mL mannitol in 15% water) and US to endoscopy in children 
with suspected IBD. They assessed wall thickness and contrast enhancement and found 
sensitivity of 81.8%, specificity 100% and diagnostic accuracy of 90% for MRE for 
CD. 50% of patients were willing to repeat the examination in future.   
Diagnostic accuracy of MRE has also been compared to wireless capsule endoscopy 
(WCE). In one such study, Golder and colleagues detected the same number of 
inflammatory lesions in terminal ileum with both modalities but WCE detected 
additional lesions in proximal ileum and jejunum (12 vs. 1) whereas, MRE showed 
extra intestinal pathologies in 28% (144). Two years later, Tillack et al (145) also 
compared MRE with WCE but only in known patients with CD. Both modalities 
showed the same disease features in 56% segments but WCE detected more superficial 
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mucosal disease. However, MRE was better in diagnosing severe inflammatory mural 
changes.  
Sailer et al proposed an MRE score for post surgical recurrence, based on image quality, 
contrast enhancement, mural and extra mural bowel wall changes to assess post 
resection recurrence in CD.  
 
MR0 No abnormal features 
MR1 Minimal mucosal changes 
MR2 Diffuse aphthoid ileitis, moderate recurrence 
MR3  Severe recurrence with trans and extramural changes 
Table 13: MRE score by Sailer et al. 
 
They used the previously validated Rutgreets score as a reference standard and high 
agreement was observed between MRE score and Rutgreets score (146). 
The ability of MRE to precisely detect active small bowel disease has been compared 
with CTE by using endoscopy as reference standard. In one such study in 2009, (147) a 
similar sensitivity of 90.5% for MR enterography and 95.2% for CT enterography (p 
0.32) was reported for detection of active disease and both modalities diagnosed 
additional disease in 24% of patients who had normal ileocolonoscopy. A few years 
later, Fiorino and colleagues (148) again used ileocolonoscopy as reference standard to 
compare both modalities and reported supremacy of MRE in the recognition of 
strictures (p=0.04).  
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1.3.2.6.2 Non endoscopic Reference  
 
Several studies have used, non-endoscopic standards of reference, MRE being 
compared to various biomarkers and other imaging modalities in children as well as 
adults. 
Schunk et al compared bowel wall enhancement on MRI after oral administration of 1L 
of 2.5% mannitol with CDAI and CRP and reported superiority of MRE in distinction 
of active and inactive stenosis (149) which is crucial in planning of treatment. 
In the same year Miao et al (150) compared MRE with oral water with US against a 
combination of  clinical assessment, endoscopy, barium study or surgery as reference 
standard and found  equivalent sensitivity in detection of active disease (87%). 
Laghi et al (151) derived an MRE score based on wall thickness and contrast 
enhancement in children with known CD use CDAI as a global reference standard 
together with  ileocolonoscopy to evaluate disease activity in terminal ileum. They used 
polyethylene glycol as the oral agent. This score exhibited sensitivity of 84% and 
specificity of 100% for recognition of erosive ileitis seen on endoscopy.  
Pilleul et al (152) in 2005 again verified positive correlation between bowel wall 
thickness and pediatric CDAI on MRE with 5% mannitol but no significant correlation 
was established with contrast enhancement. MRE also revealed fistulae (9), strictures 
(8) and intussusception (1) in these patients.  
The role of dynamic contrast MRE to distinguish between active disease and remission 
was evaluated by Pupillo et al (153). They observed early and intense uptake of contrast 
which increased over time until a plateau was seen in diseased segments of bowel while 
in segments with remission uptake was less intense, although, still higher than normal 
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segments. A significant correlation was reported between the peak of contrast uptake 
and CDAI.   
Taylor et al (154) also used dynamic contrast enhanced MRI to correlate with 
histopathological markers of inflammation and angiogenesis. Patients had pre operative 
MRI and slope of contrast enhancement, time to maximum enhancement, enhancement 
ratio, the volume transfer coefficient K (trans) and extracellular volume fraction v (e) 
for the diseased segment of bowel were measured and the resected specimen was re 
imaged. Acute and chronic inflammation scores and micro vascular density (MVD) 
were measured in resected specimen. They found a positive correlation between disease 
chronicity and enhancement ratio (correlation coefficient 0.82, p= 0.002) but negative 
correlation between slope of enhancement and MVD (correlation coefficient -0.86, 
p<0.001), supporting the hypothesis of increased micro vessel permeability with disease 
chronicity and an inverse relation of tissue MVD to mural blood flow. 
In 2009 Martinez and colleagues (155) compared MRE (sodium phosphate and water) 
and Doppler US with clinical scoring and biological tests. Contrary to the previously 
reported equivalent sensitivity of MRE and US for detection of active disease in 2002, 
they found US was more sensitive in localization of diseased segment (91%/83%) 
although grades of hyperemia and contrast enhancement on MRE were higher in 
patients with clinical-biological active disease, in comparison to patients without 
clinical –biological activity (p=0.019,p-0.023). 
Zappa and colleagues in a retrospective study (156) compared the mural and extra mural 
findings of pre operative MRE with the pathological analysis in resected specimen in 53 
known patients of CD. The MRE parameters significantly associated with inflammation 
were wall thickness, wall enhancement, pattern of enhancement, T2 relative hyper 
signal, blurred wall enhancement, comb sign, fistula and abscess.   
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1.3.2.6.3 Combined Endoscopic and non endoscopic reference  
 
Low and colleagues used multiple reference standards including surgical, endoscopic 
and histological findings together with barium studies to compare MRI and CT. MRI 
was performed with 2% oral barium sulfate, rectal water and IV gadolinium while IV 
contrast enhanced CT was performed with positive and negative enteral contrast in 
equal number of patients. Based on wall thickness and contrast enhancement on MRE 
was found superior to CT in depicting disease (85% vs. 65% abnormal segments). It 
was not only better in depicting mild disease (79% vs. 49% segments) but also in 
delineating mural thickening (41% vs. 11% segments) and mural enhancement (89% vs. 
11% segments) (157). 
Koh et al (158) assessed bowel wall thickness, contrast enhancement and perienteric 
changes on MRE (with oral water ) in comparison to CDAI, endoscopy and surgery. 
MRE had overall sensitivity of 91% and specificity of 71% on per patient basis while 
CDAI had sensitivity of 92% and specificity of 28% for active disease. 
The ability of T2 weighted images to detect disease has been compared to contrast 
enhanced T1 weighted sequences. In such an attempt, Maccioni (139) compared the 
diagnostic accuracy of oral contrast enhanced T2 weighted imaging with T1 weighted 
gadolinium enhanced imaging using endoscopy, small bowel barium, CT, US and 
clinical biochemical scoring as references. The authors recommended combined use of 
T2 and T1 weighted imaging achieved better diagnostic accuracy. 
After establishing diagnostic accuracy for IBD, further steps have been taken to gauge 
capacity of MRE to distinguish CD and UC.  Horsthuis in 2010 reported superior 
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diagnostic accuracy of MRE in children for CD than UC (159) against the reference 
standard of (esophagogastroduodenoscopy & ileocolonoscopy) and barium enteroclysis.  
 
1.3.2.6.4 Enterography vs. Enteroclysis 
MR enteroclysis although more invasive than MRE has shown promising results. 
Holzknecht et al (13) used oral magnetic particles in 18 patients with known CD before 
surgical intervention and showed a sensitivity of 95.8-100% for primary diagnosis of 
CD, 94.7% of stenosis and 100% for fistulae not to mention detection of complications 
such as abscesses and affection of ureter. Both MRI techniques have compared in 
suspected as well as known patients with CD. Negaard et al (160) compared MRE (6% 
mannitol) and MREnteroclysis (polyethylene solution) in patients with suspected CD. 
They evaluated bowel distension, wall thickness, contrast enhancement, detection of 
ulcers, stenosis and edema. Bowel distension was better with MR enteroclysis although 
both had high diagnostic accuracy. MRE and MR enteroclysis both showed sensitivity 
of 88%, specificity of 89/84%, positive predictive value 89/82% and negative predictive 
value of 89%. The authors also compared patient experience of both modalities and 
found higher patient preference for MRE due to less abdominal pain and discomfort 
(137).  
Masselli et al also reported better jejunal distention (p < 0.01) and detection of bowel 
wall abnormalities (p <0.01) with MR Enteroclysis but MR enterography was more 
acceptable to patients (136).  
1.3.2.6.5 MRI vs. Barium Studies 
For years Barium studies have been the standard radiological investigation for 
assessment of the small bowel morphology. In 2000, Rieber et al (161) compared 
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conventional Barium enteroclysis and MR enteroclysis in 84 patients with histological 
and endoscopy correlation using wall thickness and detection of stenosis as diagnostic 
criteria. They reported a higher sensitivity and specificity with MR Enteroclysis 92.2% 
vs. 85.4% and 92.6% vs. 76.9% respectively. No abscesses were detected on SBE and 
only 17.7% fistulae were seen while 77.8% fistulae and 17.8% abscess were detected on 
MRE. 
Bernstein el al (162) compared the findings of SBFT and MR enterography with oral 
2% barium sulfate and IV gadolinium in known CD patients and found similar findings 
in majority of patients. SBFT showed additional strictures and fistulae in four patients 
while MRE showed additional information regarding active inflammation in stricture 
areas like wall enhancement, vasa recta changes and lymphadenopathy in 8 patients.  
Detection of proximal ileal disease is crucial because it is inaccessible on 
ileocolonoscopy. Ochsenkuhn and colleagues (163) reported superiority of MRE over 
SBE of MRE for this purpose as well. Using features including wall thickness, contrast 
enhancement and detection of stenosis, they diagnosed proximal ileal disease in 22 of 
25 patients whereas SBE was only able to reveal disease in 4 of these patients. 
A year later, Albert et al (164) not only compared MRI with double contrast 
fluoroscopy and   capsule endoscopy at the same time.  Small bowel Crohn’s disease 
was diagnosed in 78% (MRE), 33%  (Barium) and 93% (WCE) but again MRI was 
superior in identifying transmural CD and extraluminal lesions and exclusion of 
strictures.   
Lee and colleagues (165) compared the accuracy of MRE, CTE and SBFT while using 
ileocolonoscopy as reference standard for small bowel inflammation and imaging 
studies and surgery and physical examination for extraenteric complications. They 
 79 
found 100% sensitivity for both MRE and CTE in comparison to just 37% for SBFT for 
detection of extra enteric complications. Therefore, they presented MRE as effective 
and radiation free diagnostic tool for disease assessment in IBD.  
 
In summary, MR enteroclysis and enterography provide complementary information to 
endoscopy and provide radiation free additional information about extra intestinal 
complications.  
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1.3.3 MAGNETIC RESONANCE COLONOGRAPHY 
 
1.3.3.1 Background  
 
Magnetic resonance imaging Colonography (MRC) has evolved quickly since the first 
main description in 1997. Luboldt et al (166) performed the first MRC in three patients, 
one of them had comparative DCBE and the others also underwent colonoscopy as well. 
MRC was able to demonstrate the colonic tumour and polyps. Luboldt used 1.5-2 L of 
water mixed with gadolinium- diethylenetriaminepentaacetic acid (Gd-DTPA) to 
distend the patient’s colon together with IV Gd-DTPA. MRI (pre and post contrast) and 
MRC was performed in prone and supine positions. The authors suggest MRC could be 
an accurate, minimally invasive and cost effective modality for polyp screening and 
colonic tumour staging.  
Since then, although some are developing the role of MRC in colonic cancer detection, 
the focus for the technique is increasingly for use in IBD (167-169). Studies have shown 
a good correlation between MRI findings and alternate modalities (including 
conventional radiography, CT, endoscopy, and surgery) as well as clinical disease 
activity grading. MRC shows considerable promise as a less invasive alternative to 
colonoscopy in evaluating the location, severity and activity of colonic IBD. 
There are two methods to perform MRC depending on the nature of fluid used to fill the 
colon; the bright lumen or dark lumen technique.  
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1.3.3.2 Bright lumen MRC 
Distention of bowel with fluid labeled with an agent with strong T1- weighted signal is 
referred as “bright lumen”, and the method used by Lubolt in 1997 (166). Typically, a 
gadolinium/water mixture (5mmol/L) is applied rectally after conventional bowel 
cleansing resulting in high signal on both T1 and T2 sequences. Bowel distension can 
be monitored in real time using a fast T2-weighted TrueFisp sequences (170). 1.5-2.5L 
of fluid is usually used to fill the whole colon. When the target is colorectal neoplasia, 
two data sets are collected (one in prone and other in supine position) to move for the 
residual air pockets, which can reduce accuracy. Colorectal lesions appear as solid 
filling defects, which require differentiation from air bubbles and stool residue.  
Changing the patient position during the procedure however does prolonged the 
procedure and may precipitate escape of contrast into small bowel reducing colonic 
distension and diagnostic quality (168). 
The luminal high signal can impair differentiation between lumen and colonic wall and 
mural enhancement is less well appreciated. Detection of abscesses may be improved 
with the technique which may be difficult to distinguish from water filled bowel loops 
when using a dark lumen method (171). 
1.3.3.3 Dark lumen MRC 
Although the dark lumen technique is a recent development, it has largely replaced the 
bright lumen technique as the methods of choice for MRC (14, 168, 171). The dark 
lumen is achieved by filling the colon with water, air or carbon dioxide. One advantage 
of dark lumen is that mural contrast enhancement is readily appreciated. As water itself 
is biphasic, it gives low signal on T1- weighted images and high signal intensity of T2-
weighted images.  
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As well as the advantage in terms of clearer appreciation of the contrast enhancement, 
dark lumen MRC facilitates direct analysis of the bowel wall and appreciation of 
inflammatory changes such as increased contrast uptake and bowel wall thickness, sub-
mucosal edema, mesenteric fat stranding, mesenteric hyper vascularity and fibro-fatty 
proliferation (124). It is also helpful in diagnosing polyps and bowel masses.  
Because residual air has a similar T1 signal to water, the risk of false positive diagnosis 
is reduced compared to the bright lumen technique and there is no need to change 
patient position during the scan (172) which saves time .  
Typical protocol  
Typical MRC protocols require bowel preparation to cleanse the bowel before the 
imaging. Akin to imaging the small bowel, most of colonic segments are 
physiologically collapsed so cannot be assessed properly before the colon is distended 
by administration of a distending media via rectal catheter. The patient is usually 
examined in prone position and two surface array coils are used to obtain homogenous 
and complete MR signal reception. The administration of anti peristaltic agents helps to 
reduce motion artifacts.   
 For optimal evaluation of inflammatory lesions in IBD, imaging should include both 
T2 and T1 weighted sequences.  
 A true –FISP in the coronal plane is acquired to confirm sufficient and homogenous 
bowel filling. The colon wall is well seen on this sequence due to the contrast difference 
between the hypointense wall and the bright lumen.  
Half-Fourier acquisition single-shot turbo-spin echo (HASTE) T2 weighted sequences 
are then acquired in the axial and coronal plane after administration of IV spasmolytic. 
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These -T2 images depict mural edema, pericolonic inflammatory changes and 
mesenteric free fluid (Figure 1).  
 
 
Figure 1:  HASTE – T2 weighted sequence on Dark lumen MRC  
 
Finally, T1 – weighted images (pre and post contrast) are acquired which also help 
assess morphological features, but in addition provide information on disease activity-in 
general the degree of enhancement reflects the severity of inflammation. 
Typically, a fat suppressed fast 3D gradient sequence such as 3D-FLASH or an 
interpolated sequence such as VIBE (volumetric interpolated breath hold examination) 
should be acquired 70-75 s after contrast (gadolinium) injection (Figure 2). 
 84 
 
 
Figure 2: T1 weighted images on Dark lumen MRC  
1.3.3.4 Enteric Findings in IBD  
• Increase wall thickness- Shortening of colonic haustral folds- in moderate to 
severe disease activity although it may be a normal feature in descending and 
sigmoid colon in some healthy individuals. 
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• Mural hyper enhancement- significant increased enhancement after IV contrast 
may correlate with the severity of active inflammation. 
• Mural edema- it is seen as increased signal of colonic wall on T2-weighted 
images. 
• Fibrostenotic lesions of bowel wall- thickened wall with low level contrast 
enhancement, with or without luminal pre stenotic dilatation.  
1.3.3.5 Mesenteric findings 
• Abscess – fluid or heterogeneous content with contrast enhancement of the wall  
• Lymphadenopathy  
• Fistulae and sinuses- linear hyperenhancing tract on post contrast T1-weighted 
sequence and hyper signal on T2 due to the fluid content (Figure3-5).   
 
 
         Figure 3: Increased wall thickness of rectum and increase perimural T2 Signals  
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            Figure 4: Loss of haustral folds in diseased Sigmoid colon 
 
 
 
 
 
 
 
 
 
 
 
        Figure 5: Mural hyper enhancement of rectum  
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1.3.3.6 Review of literature pertaining to MRC in IBD 
Several studies have compared the diagnostic accuracy of MRC with CC for detection 
and assessment of IBD. In one such study Scheryer et al (171) performed MRC and CC 
on same day by using the bright lumen method and graded colonic segments and 
terminal ileum by a three-point scale of inflammation. MRC only achieved 58.8% 
sensitivity for UC and 31.6% for CD on segmental bases. The authors did not 
recommended the use of bright lumen MRC for routine assessment of IBD as detection 
of early inflammation in cases of CD and even severe inflammation in UC was missed 
on MRC. Ajaj et al (14) first employed the dark lumen technique for the detection of 
colorectal neoplasia. MRC achieved sensitivity of 93% and specificity of 100% in 
comparison to CC for diagnosis of colorectal masses and inflammatory lesion by using 
dark lumen method.  
Two years later (15), the same group proposed a diagnostic score of disease activity 
based on bowel wall contrast enhancement, bowel wall thickness, presence of perifocal 
lymph nodes and loss of haustral folds (table 14) In comparison to endoscopic biopsies 
MRC achieved sensitivity of 87% and specificity of 100% for detecting inflammation. 
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Contrast uptake Wall thickness Haustral Folds Peri focal LN 
0- no uptake 0= no thickening 0= no loss of folds 0= no LN 
1= < 25% 1=<25% increase 1=<25% loss 1=1-4 LN 
2=25-50% 2=25-50% increase 2= 25-50% loss 2= 5-10 LN 
3=>50% 3=>50% increase 3= > 50% loss 3= >10 LN 
Slight inflammation = 
< 4 points  
Moderate 
inflammation=  
5-8 points 
Severe inflammation= 
>8points 
 
Table 14: MRC Inflammation score by Ajaj et al (15) 
The ability of MRC to accurately detect extra-luminal complications has also been 
reported, often leading to a change in therapeutic strategy (125). 
As with any MR technique some patients are unable to undergo the test due 
claustrophobia and as will be explored later in this thesis, for some holding water and 
breath holds are difficult parts (173, 174). 
1.3.3.6.1 MRC without bowel preparation  
Although MRC is often performed after full laxation, it is known bowel preparation is 
often poorly tolerated: 75% of patient under going bowel preparation express symptoms 
ranging from “feeling unwell” to “inability to sleep” (175). 
“Fecal tagging” is a concept introduced to avoid bowel cleansing prior to radiological 
colonic imaging. It involves ingestion of contrast compounds such as barium sulfate, 
ferumoxil solution containing 5% gastrograffin, 1% barium and 0.2% locust bean gum 
added to regular meals 36 hours prior to examination in order to modify the signal 
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intensity of colonic content to match that of the rectal enema. In affect, the fecal 
material becomes “virtually invisible”(176). 
Most of the literature pertaining to non-laxative MRC pertains to the use of the 
technique in detecting colorectal neoplasia. 
Lauenstein and colleagues (177) applied a dark lumen technique after fecal tagging with 
barium sulfate in patients with colonic symptoms and used colonoscopy as reference 
standard. Reported sensitivity was 89.3% for detection of polyps and carcinoma. In 
another study, Goehde et al found poorly tagged stool signal in 18% of patients. 
Although, overall sensitivity of 100% for detection of polyps larger than 2 cm while it 
was 40% for polyps between 10-19mm in comparison to conventional CC. Interestingly 
however, patients rated the ingestion of large amount of barium sulfate (150 ml at each 
6 meals before procedure) as worse than bowel preparation (178). 
Florie and colleagues (179) used limited bowel preparation with lactulose and fecal 
tagging with gadolinium and compared patient experience and preference with 
conventional CC. Patients found MRC with limited bowel preparation less burdensome 
(p <0.001) and less painful (p<0.001) than CC. Overall patient preference was higher 
for MRC immediately and even after 5 weeks. Similar higher acceptance for MRC with 
fecal tagging is found in other studies (124, 180).    
The role of MRC with fecal tagging in detection of inflammatory bowel disease activity 
has been evaluated but with disappointing results. One study reported just 32% 
sensitivity and 88% specificity for detection of inflamed segment in comparison to 
conventional CC (181). Difficulty in identification of inflammatory changes, 
particularly in establishing precise measurements of wall thickness and obscuration of 
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the presence of ulceration perhaps make the technique less suitable method for adequate 
assessment of IBD. 
An alternative approach is to reduce stool signal by increasing its water content (so 
called “fecal cracking”) Ajaj et al (182) used the oral stool softener lactulose and rectal 
stool softener docusate sodium (DS) for this purpose. Stool signal intensity was 
compared in patients without any stool softeners, after use of oral lactulose only, after 
rectal ducosate sodium only and the combination of oral lactulose and rectal DS. The 
lowest stool signal intensity was seen after combination of oral and rectal softeners but 
clinical usefulness of this method still needs to be assessed.  
As discussed above basic T1 and T2 weighted sequences are the mainstay of enteric 
imaging using MRI. There has however been some work investigating the use of novel 
sequences such as diffusion weighted imaging. The signal from diffusion weighted 
images is dependent on the movement of water in the extra-cellular tissues. It was seen 
intuitive that the inflammatory component of IBD would affect the signal in diffusion 
weighted images (either restricting diffusion due to increased inflammatory cells, or 
facilitating water movement due to tissue edema). Oussalah et al (183) performed 
diffusion weighed imaging (DWI) during MRC without bowel cleansing in patients 
with known IBD. Disease activity was assessed using an MR score based on DWI 
hyperintensity, Gadolinium enhancement pattern after IV administration, bowel wall 
thickening, parietal edema and presence of ulcers. The MR score achieved better 
accuracy for detection of inflammation in UC than CD, and demonstrated significant 
correlation with diagnostic scores such as the modified Baron score and Walmsley 
index. Continuous and diffuse colonic inflammation in UC was better detected using 
diffusion – weighted MR as compared to the segmental involvement of CD. Bowel wall 
thickness was the best marker of CD, likely reflecting trans mural inflammation. The 
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lack of bowel preparation and relative short acquisition time of the procedure improved 
patient compliance (Figure 6).  
 
    Figure 6: Diffusion weighted imaging during MRC  
1.3.4 COMBINED ASSESSMENT OF SMALL AND LARGE BOWEL 
Given the potential of CD to affect anywhere in the GI tract, an MRI techniques that can 
assess both the small bowel and large bowel at the same time would be intuitively of 
interest. Simplistically it is possible to perform both MRE and MRC at the same time. 
This technique has been used with some promising results. For example Low and 
colleagues (184) used 2% barium orally and rectal water in patients with known IBD. 
They compared T2 weighted breath- hold single- shot fast spin –echo (SE) and 
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gadolinium enhanced spoiled gradient- echo (GRE) MR imaging with endoscopy, 
barium study and surgery. GRE MR imaging was better in depicting disease extent and 
severity in comparison to SE MR imaging with per patient sensitivity of 100% vs. 60%, 
per segment sensitivity of 89% vs. 52% with overall disease detection in 93% patients 
in comparison of 43% patients respectively. 
    
Ajaj et al (185) compared MRI findings in two groups of patients. One group had MRE 
with 0.2% locust bean gum and 2.5% mannitol while the other group had an additional 
rectal water enema. They found better diagnostic accuracy in terminal ileum and colon 
in those receiving the enema due to better distension of bowel, although noted the 
induced discomfort of the combined technique to patients. Similarly Scheryer et al also 
found improved diagnostic value with combined MR Enteroclysis and MRC approach 
(186). They used T2 weighted and contrast enhanced T1 weighted sequences as an 
integrative protocol and colonoscopy as reference standard.   
 
 Rimola and colleagues in two consecutive studies use the combine technique to derive 
and validate an MRI index of disease activity. In first study (16), they applied the 
combined technique by using 1500 ml of iso-somatic PEG and electrolyte solution for 
distention of the small bowel and a water enema  (1-2L) via a rectal catheter to fill the 
colon. Intravenous gadolinium was administered. 50 known IBD patients had 
ileocolonoscopy and MRI. The CDEIS was used to assess endoscopic activity and they 
proposed a magnetic resonance index of activity (MRIA) based on wall thickness, post 
contrast wall signal intensity, relative contrast enhancement, presence of mural edema, 
ulcers, pseudopolyps and lymph node enlargement. 
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MRIA index= 1.5xwall thickness +0.02xRCE+5xoedema+10xulcers 
 
There was significant correlation between CDEIS and MRIA (r=0.82, p<0.001) and the 
authors reported high accuracy of MRIA for detection of disease activity (ROC 
0.891,sensitivity 0.81 and specificity 0.89), and detection of ulcerated lesions (ROC 
0.978, sensitivity 0.95, specificity 0.91) in colon and terminal ileum. The global MRAI 
also showed significant correlation with CDEIS (r= 0.78, p <0.001), Harvey – 
Bradshaw index (r=0.56, p<0.001) and CRP (r=0.53, p<0.001).  
 
In second study from the group (187), same quantitative Magnetic Resonance index 
(MaRIA=1.5 wall thickness + 0.02RCE + 5edema + 10ulceration) was compared with 
CDEIS while endoscopy disease activity was also classified as absent, mild 
(inflammation without ulcers) and severe (presence of ulceration). Wall thickness, 
relative contrast enhancement (RCE), presence of edema and ulcers were validated as 
independent predictors of disease severity as in the previous study. MaRIA correlated 
with CDEIS (r= 0.798,p<0.001 per segment and r= 0.87, p<0.001 per patient). 
Therefore, the authors proposed the use of this index to categorize disease severity and 
to monitor response to therapeutic interventions.  
 
Hyun et al (188) also reported comparable results between endoscopy (ileocolonoscopy 
& double-balloon endoscopy) and magnetic resonance enterocolonography (MREC). 
Sensitivity of MREC for detection of deep mucosal lesions was 88.2 %, for all CD 
lesions was 61.8% and for stenosis was 71.4% for colon and 100, 85.7 & 100% for 
small bowel respectively. 
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1.3.5 REVIEW OF LITERATURE – REGARDING USE OF MRI FOR 
DISEASE ASSESSMENT OF IBD  
Different MRI parameters have been used as criteria for disease detection and 
evaluation such as wall thickness, contrast enhancement, lymphadenopathy, comb sign, 
loss of haustrations and detection of stenosis and the summary of some of the studies 
and criteria used is described in Table 15. 
 
 
Study 
Year  
Magnetic 
field 
Luminal 
contrast  
IV contrast  Coil   Criteria  
Low et 
al(157) 
2000 
1.5 T 1350 mL 2% 
barium-oral, 
0.5-1 L water -
rectal 
0.1 mmol/kg 
Gadopentetate 
dimeglumine 
Body Wall thickness 
Enhancement  
Rieber et al 
(161) 
2000 
1.5 T Enteroclysis 0.1 mmol/kg 
Gadopentetate 
dimeglumine 
Surface  Wall thickness 
Stenosis 
Schunk et al 
(149) 
2000 
1.0T 2.5% mannitol 0.1 mmol/kg 
Gadopentetate 
dimeglumine 
Body Enhancement 
Koh et al 
(158) 
2001 
1.0 T 600 mL water 
– oral 
0.1 mmol/kg 
Gadopentetate 
dimeglumine 
NA Enhancement  
Wall thickness 
lymph -
adenopathy 
 Comb sign 
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Miao et al 
(150) 
2002 
1.0T 600 mL water- 
oral 
0.1 mmol/kg 
Gadopentetate 
dimeglumine 
NA Enhancement  
Wall thickness 
Lymph -
adenopathy 
 Comb sign 
Laghi et al 
(151) 
2003 
1.5T 10mL/kg 
polyethylene 
glycol – oral 
0.1 mmol/kg 
Gadopentetate 
dimeglumine 
Surface Enhancement  
Wall thickness 
Ochsenkuhn 
et al (163) 
2004 
1.5T 400mL 
barium, 1.5-2L 
ferristerne 
(enteroclysis) 
0.1 mmol/kg 
Gadopentetate 
dimeglumine 
NA Enhancement  
Wall thickness 
Stenosis 
Ajaj et al 
(185) 
2005 
1.5T 3L 
polyethylene 
glycol –oral 
1.5-2L water – 
rectal 
0.2 mmol/kg 
Gadopentetate 
dimeglumine 
Surface Enhancement 
Wall thickness 
Haustration 
Lymph -
adenopathy 
Schreyer et 
al (189) 
2005 
1.5T Polyethylene 
glycol –oral 
1.5 L 
Gadopentetate 
dimeglumine 
in water  
(5mmol/L) 
0.1 mmol/kg 
Gadopentetate 
dimeglumine 
Surface Enhancement  
Wall thickness 
Comb sign 
Lymph -
adenopathy 
 96 
Schreyer et 
al (186) 
2005 
1.5T 2L water-oral 
700mL 0.9% 
NaCl rectal 
0.2mmol/kg 
Gadopentetate 
dimeglumine 
Surface Enhancement  
Wall thickness 
Comb sign 
Lymph -
adenopathy  
Stenosis  
Table 15: MRI imaging features in inflammatory bowel disease (190) 
 
 
1.3.5.1 Accuracy of MRI in diagnosis of IBD 
Studies have reported over all sensitivity of 78% (95% CI 67-84%) and specificity of 
85% (95% CI 76-90%) on per patient basis for diagnosis in patients with suspected CD 
in comparison to clinical, endoscopic and SBE findings as summarized in Table 16 
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Study Patients 
* 
 
Population Reference 
standard 
Location 
evaluated  
Sensitivity  
(%) 
Specificity  
(%) 
Albert et 
al 
(164) 
25/14 Adults Ileo- 
Colonoscopy 
SBCE 
Small 
bowel 
77 80 
Pilleul et 
al 
(152)  
15/6 Children Ileo- 
Colonoscopy 
Small & 
large 
bowel 
83 100 
Borthne et 
al 
(143)  
20/NA Children Colonoscopy Small & 
large 
bowel 
82 100 
Horsthuis 
et al (159) 
33/15 Children Endoscopy 
(ileo-
colonoscopy 
gastroscopy) 
Enteroclysis, 
Clinic 
Small & 
large 
bowel 
61-91 
(2 
observers) 
60-90 
(2 
observers) 
*No of patients included / No of patients confirmed 
Table 16: Accuracy of MRI in diagnosis of IBD on a per patient basis (191)  
 
1.3.5.1 Assessment of disease extent 
Studies have reported that MRI has sensitivity of 74%  (95% CI 68-80%) and 
specificity of 91% (95% CI 86-95%) for small bowel extent (table 17). 
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Study Patient 
with 
CD 
total 
/active 
Population Reference 
standard 
Location 
evaluated  
Sensitivity  
% 
Specificity  
% 
Low et 
al  
(184) 
28/25 Adults Barium studies, 
High resolution 
endoscopy 
Surgery 
Small & 
large 
bowel 
86 NA 
Pascu 
et al 
(110) 
37/NA Adults Ileocolonoscopy TI & 
colon 
38 90 
Albert 
et al 
(164) 
52/30 Adults Capsule 
endoscopy 
Small 
bowel 
85 100 
Tillack 
et al 
(145)  
19/18 Adults Capsule 
endoscopy 
Small 
bowel 
78 91 
Fiorino 
et al 
(148)  
44/28 Adults  Ileocolonoscopy 
Surgery 
Small 
bowel 
and 
colon 
88 88 
Table 17: Accuracy of MRI in the assessment of disease extent in IBD (191) 
 
1.3.5.1 Assessment of disease activity  
Overall sensitivity of MRI for the assessment of disease activity on per patient is 80% 
(95% CI 77-83%) and specificity 82% (95% CI 78-85%) whereas on per segment basis 
it is 70% (95% CI 67-73%) and 89% (95% CI 93-96%) respectively. Below is the 
summary of some of these studies using different reference standard.  
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Study Patients   
total 
/active 
Reference 
standard 
Location  Sensitivity 
% 
Specificity 
% 
Low et al 
(157) 
26/NA 
segment
193/65 
Endoscopy 
Enteroclysis 
Barium 
enema 
Surgery 
Small 
and large 
bowel 
80-85 91 
Koh et al 
(158) 
30/7 
segment 
124/30 
Ileo-
colonoscopy 
TI and 
colon 
59 
91 
93 
71 
Miao et al 
(150) 
30/23 Ileo-
colonoscopy 
TI and 
colon 
87 71 
Neurath et al 
(192) 
51/51 
segment 
139/42 
Ileo-
colonoscopy 
TI and 
colon 
67 93 
Ochsenkuhn 
et al (163) 
25/18 Ileo-
colonoscopy 
TI 88 85 
Pilleul et al 
(152) 
62/23 Ileo-
colonoscopy 
TI and 
colon 
78 46 
Schreyer et 
al (186) 
30/29 
segment 
161/49 
Ileo-
colonoscopy 
TI and 
colon 
55 98 
Florie et al 
(141) 
31/21 Ileo-
colonoscopy 
TI and 
colon 
93 55 
Horsthuis et 
al (142) 
20/16 Ileo-
colonoscopy 
TI and 
colon 
100 100 
 100 
Lee et al 
(165) 
30/18 Ileo-
colonoscopy 
TI 83 100 
Rimola et al 
(16) 
50/3 
segment 
218/83 
Ileo-
colonoscopy 
TI and 
colon 
81 89 
Siddiki et al 
(147) 
30/21 Ileo-
colonoscopy  
TI 91 67 
Fiorino et al 
(148) 
44/28 Ileo-
colonoscopy 
Surgery 
Small 
bowel  
Colon 
81-90 91-95 
Oussalah et 
al (183) 
61/NA 
segment 
221/NA 
Ileo-
colonoscopy 
TI and 
colon 
58 84 
Hyun et al 
(188) 
30/20 
230/64 
Ileo-
colonoscopy 
Cap 
endoscopy 
Small 
bowel  
Colon 
86 
 
62 
93 
 
95 
Rimola et al 
(187) 
48/29 
258/115 
Ileo-
colonoscopy 
Small 
bowel  
Colon 
87 87 
Table 18: Accuracy of MRI in the assessment of disease activity in IBD (191)  
1.1.1.1 Assessment of disease severity  
For the purpose of assessment of disease severity different MRI parameters and indices 
have been compared with endoscopy (ileocolonoscopy, Capsule endoscopy and double 
balloon enteroscopy) (table 19).  
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Study Patient 
with CD 
total 
/active 
Population Reference 
standard 
Location 
evaluated  
Results   
Pascu et 
al (110) 
37/NA Adults  Ileocolonoscopy TI  
Colon 
Correlation between 
MRI index and 
endoscopy activity 
index  
r=0.344,p=0.007 
Florie et 
al (141) 
31/21 
segments  
141/NA 
Adults  Ileocolonoscopy TI  
Colon  
Correlation between 
MRI and endoscopy 
severity 0.59  
(observer 1)- 0.53 
(observer 2) p<0.001 
Schreyer 
et al 
(186) 
30/29 Adults  Ileocolonoscopy TI  
Colon 
Distinction between 
mild, moderate and 
severe disease.  
Sensitivity 69%, 
Specificity 99% 
Horsthuis 
et al 
(142) 
20/15 Adults Ileocolonoscopy TI  
Colon 
Lack of correlation 
between MRI 
severity and 
endoscopic severity 
r=0.4,p=0.09  
Tillack et 
al (145) 
19/18 
segments 
40/NA 
Adults Capsule 
endoscopy 
Small 
bowel 
Distinction between 
mild, moderate and 
severe  
Sensitivity 58%, 
Specificity 77% 
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Rimola 
et al (16) 
29/48 
segments 
115/258 
Adults Ileocolonoscopy TI  
Colon 
Distinction between 
mild, moderate and 
severe  
Sensitivity 91%, 
Specificity 95% 
Oussalah 
et al 
(183) 
61/NA 
segments 
211/NA 
Adults  Ileocolonoscopy TI  
Colon 
Correlation between 
MRI index and 
endoscopic severity 
index r= 
0.659,p<0.001 
Rimola 
et al 
(187)  
48/NA 
segments 
158/115 
Adults  Ileocolonoscopy TI  
Colon 
Distinction between 
mild, moderate and 
severe  
Sensitivity 92%, 
Specificity 92% 
Correlation between 
MRI index and 
endoscopic severity 
index 
r=0.84,p<0.001 
Hyun et 
al (188) 
30/20 Adults  Ileocolonoscopy 
Double balloon 
enteroscopy 
Small 
bowel  
Colon 
Correlation between 
MRI index and 
endoscopy severity 
index 
r=0.85,p<0.001 
Table 19: Efficacy of MRI in the assessment of disease severity in IBD (191)  
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1.3.5.2 Assessment of complications in IBD 
In comparison to endoscopy, barium radiology, US, CT and surgery, MRI has shown 
sensitivity of 40 -100% for detection of intra abdominal fistulae and sensitivity of 86% 
(95% CI 79-91%) specificity of 93% (95% CI 88-97%) for the detection of abscesses 
(table 20). 
Study Patients 
with CD 
Reference 
standard 
Complications  
(n) 
Sensitivity  
(%) 
Specificity  
(%) 
Magnano et 
al (140) 
22 Endoscopy Stenosis (8) 
Abscess (1) 
87 
NA 
92 
NA 
Horsthuis et 
al (142) 
47 Endoscopy Stenosis (7) 86 85 
Pilleul et al 
(152) 
47 US 
Surgery 
Stenosis (8) 
Fistula (9) 
100 
100 
100 
100 
Florie et al 
(141) 
31 Endoscopy Stenosis, 
fistula, 
abscess (8) 
75 91 
Maccioni et 
al (139) 
59 Endoscopy 
CT, US 
Barium 
radiology  
Surgery 
Stenosis (22) 
Fistula (9) 
Abscess (4) 
91 
78 
86 
100 
100 
93 
Negaard et al 
(160) 
35 Endoscopy Stenosis (9) 86 93 
Tillack et al 
(145) 
19 (52 
segments) 
Capsule 
endoscopy 
Endoscopy 
Stenosis (22) 82 93 
Martinez et 
al (155)  
30 Endoscopy 
Barium 
radiology  
Fistula (17) 71 92 
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Surgery 
Lee et al 
(165)  
30 Endoscopy  
Barium 
radiology  
Surgery 
Fistula (11) 
Abscess (5) 
100 
100 
100 
100 
Fiorino et al 
(148) 
44 Endoscopy 
Surgery 
Stenosis (14) 
Fistula (5) 
92 
40 
90 
94 
Table 20: Accuracy of MRI in the assessment of complications in IBD (191). 
 
In summary, MRC appears to be a useful examination that is complementary to 
colonoscopy in assessing the colon. Indeed use is increasing where the whole colon 
cannot be explored using colonoscopy for technical reasons, patient intolerance, 
stenosis, or due to a perceived higher risk of perforation. The ability of MRC to detect 
colonic inflammation is one of the central themes of this thesis, along side its ability to 
monitor therapeutic responses and prognosticate in severe colitis. 
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2 SECTION TWO: CURRENT USE AND 
DIAGNOSTIC IMPACT OF ENTERIC MRI  
 
2.1 USE OF SMALL BOWEL IMAGING FOR THE 
DIAGNOSIS AND STAGING OF CROHN’S 
DISEASE – A SURVEY OF CURRENT UK 
PRACTICE 
 
2.1.1 INTRODUCTION 
As discussed in Chapter 1, despite advances in technology, the small bowel remains 
relatively inaccessible to conventional endoscopic techniques and radiological imaging 
plays a major role in the assessment and diagnosis of both luminal small bowel disease, 
and extra-enteric complications. 
Although barium fluoroscopy and CT remain the conventional tests, both impart a 
significant radiation dose to patients (193, 194), which is of major importance given the 
relatively younger patient population afflicted by Crohn’s disease (195). The recently 
published European evidenced based consensus on the diagnosis and management of 
Crohn’s disease (196) states “the radiation burden from fluoroscopy and CT is 
considerable so alternatives such as ultrasound and MRI should be considered when 
possible.”  Although advocates of ultrasound and particularly MRI suggest they may be 
the ideal “one stop shop” in Crohn’s imaging, evaluating luminal, mural and extra-
mural disease, there is a relatively small evidence base upon which to rationalise the 
implementation of new imaging technologies within the NHS and it is unclear to what 
extent they have disseminated into routine UK clinical practice. The purpose of the 
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survey was therefore to assess the current utilisation of individual small bowel imaging 
investigations for Crohn’s disease within NHS radiological practice, and to gauge 
current gastroenterological referral patterns 
 
2.1.2 MATERIALS AND METHODS 
Two similar questionnaires were devised for distribution to UK NHS departments of 
Radiology and Gastroenterology (appendix A and B). The questionnaires included 
various clinical scenarios relevant to the imaging diagnosis and management of Crohn’s 
disease, including first diagnosis of small bowel disease, small bowel staging in known 
disease, assessment of suspected extra luminal complications and possible obstruction, 
and imaging of suspect disease flare. The questionnaires were devised in collaboration 
with local gastroenterologists (Stuart Bloom and Sara McCartney) and they approved 
clinical definitions used.  
Additional information captured by the radiological questionnaire included the type of 
hospital (teaching, district general or other) and the specific use of oral contrast agent if 
small bowel MRI was being performed. Space for additional comment was included on 
the questionnaires. The gastroenterological questionnaire also included colonoscopy as 
an investigatory option given conventional endoscopic technique is in the main at the 
disposal of clinicians rather than radiologists. The imaging options available to 
gastroentologist were also simplified (e.g. MRI techniques not subdivided into 
enterography and enteroclysis) to improve particularly respondent compliance and 
reduce any potential confusion with imaging terminology. 
For each question, it was permissible to tick more than one imaging test option if more 
than one test was routinely concurrently performed. Importantly, in each clinical 
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scenario, patients were sub stratified according to age to capture data on any perceived 
barrier to use of those tests utilising ionising radiation in younger cohorts. 
2.1.2.1 Questionnaire Distribution  
A list of UK departments of Radiology was obtained from the Royal College of 
Radiologists with approval from the Audit Committee.  A list of Gastroenterology 
departments was obtained from the British Society of Gastroenterologists.  In January 
2008, 240 questionnaires were sent out by Rehana Hafeez, Rebecca Greenhalgh and 
Janaki Rajan to the Clinical directors of the departments of Radiology and 254 
questionnaires were sent to Clinical directors of the departments of Gastroenterology 
with a covering letter asking the questionnaire be given to the most appropriate clinician 
in the department to fill out.  A stamped addressed envelope was included for return of 
the questionnaires. The questionnaires were sent out a second time 2 months later to 
departments that had not replied. A copy of the questionnaire was also posted on the 
British Society of Gastrointestinal and Abdominal Radiologists website 
(www.bsgar.org) and members invited to participate if their hospital had not done so 
already. 
2.1.3 RESULTS 
The final return rates for Radiology departments were 27% (63 replies from 20 teaching 
hospital and 43 DGHs) and 29%  (73 replies) for departments of Gastroenterology. 17 
replies were from radiology and gastroenterology departments from the same hospital. 
2.1.3.1 Tests offered and overall frequency of use 
55 (90%) of 63 radiology departments routinely performed Barium studies.  Barium 
follow through (BaFT) was the most commonly performed procedure with an average 
of 15.4 examinations per department per month (range 1-50), of which 67% were for 
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suspected diagnosis and 33% for disease follow-up. Twenty two (35%) radiology 
departments offered barium enteroclysis (BE) (59% for suspected disease).  
Forty four (72%) departments performed CT with oral contrast (CTO) with on average 
5.1 scans per department per month (range 1- 20), among these 51% for suspected 
disease while 49% for disease follow-up. CT enteroclysis (CTE) was performed in 7 
(11% of total departments) centres (5 of which were teaching hospitals). 
 
46% (29) of radiology departments offered small bowel ultrasound (SbUS), on average 
7.5 per department per month (range 1-30), 61% of these for suspected disease and 39% 
for follow up. 13 out of these 29 were teaching hospitals  
Just 38% (24) of departments who replied, offered any small bowel MRI service 
(MRIO), on average 5.04 per department per month (range 1 – 20), of which 60% were 
performed for disease follow-up. Of those stating their preference of oral contrast, 
Kleen prep and mannitol were preferred equally (21% each), locust bean gum/mannitol 
solution by 12.5% and Gastrograffin by 9 %. Seven centres (6 of which were teaching 
hospitals) offered MR Enteroclysis (MRIE), performing on average 78 per month 
between them, the majority (62%) for disease follow-up.   
11 (6 teaching hospitals) performed between them on average 83 Capsule endoscopies 
(Cap E) per month, 64% for suspected disease. 
 
2.1.3.2 Use of tests according to indications- Radiologists 
For imaging of the small bowel in newly diagnosed Crohn’s disease, barium follow 
through was the most commonly used investigation across all age groups (Figure 7), for 
example 34 (54%) radiology departments used it in those aged <20 years and 43 (68%) 
for patients above the age of 61.  Small bowel ultrasound (SbUS) and MR were used 
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more frequently in patients <40 years old, but only then by 18 (29%) and 17 (27%) of 
departments respectively.  CT was infrequently used in patients below 40 and only by 
10 (16%) of departments even in those over 60 for this indication. Sixty percent of 
departments use a single imaging modality only, but 40% suggest they offer more than 
one test in combination. 
 
Figure 7: First line investigation performed by Radiologists in newly diagnosed Crohn's 
disease patients. Barium follow through (BaFT) is most commonly used while 
small bowel USS (SbUS) and MRIO relatively more frequently used in younger 
patients. 
 
Similarly, in patients with a suspected but unknown diagnosis of small bowel Crohn’s 
disease, barium follow through was also the most commonly used investigation 
regardless of whether there is high or low clinical suspicion of disease (42 [67%] of 
departments averaged across the age groups) (Figure 8). 
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Figure 8: Investigations used in patients with high clinical suspicion of Crohn’s disease. 
Standard barium tests are performed more frequently than cross sectional imaging.  
 
 
Interestingly however, in those with a low clinical suspicion, SbUS was used relatively 
commonly, particularly in those aged below 20 (28 [44%] of departments) (Figure 9).   
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Figure 9: Investigations in patients with a low clinical suspicion of Crohn's disease. 
BaFT is most commonly used investigation in all age groups while SbUS is used 
relatively commonly in patients younger than 20 years.  
 
 
Once again CT was infrequently used (by a maximum of 12 (19%) of departments in 
those aged over 61 years and with a high clinic suspicion of disease, and MRI was most 
frequently used in those age less than 20 with a high clinical suspicion (14 [22%] of 
departments).   
 
Conversely when extra-luminal complications (such as fistula or abscess) were 
suspected, CT became the most commonly performed (for example by 34 [54%] and 46 
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[73%] departments for those aged less than 20 and > 60 years respectively). SbUS and 
MR studies were most commonly used in younger patients, but even then less than CT 
(Figure 10). 
 
 
Figure 10: Investigations used for patient with suspected extra luminal complications. 
CT is the preferred investigation in all age groups followed by BaFT although 
SbUS and MR are used with increased frequency in younger patients. 
In outpatients with suspected obstruction, BaFT and CTO were most frequently used 
(36 [57%] and 29 [46%] of departments averaged across the age groups (Figure 11). 
 
0
10
20
30
40
50
60
70
80
BaFT BE SbUS MRIO MRIE CTO CTE Cap E Nil
P
er
ce
nt
 o
f 
D
ep
ar
tm
en
ts  <20 years 
 21 - 40 years 
41 - 60 years
>61 years
 113 
 
Figure 11: Investigations for patients with suspected small bowel obstruction. BaFT and 
CT are commonly performed, often concurrently and MR is performed with 
relative increased frequency in younger patients. 
However, once again, when MRI was offered, it was mainly for younger patients 
instead of CT (18 [29%] of departments in those aged less than 20 years). Many 
departments suggested they would employ different tests concurrently (for example 
20% would perform both BaFT and CTO). 
Finally, for those with a clinically suspected flair in need of re-evaluation of the small 
bowel, whilst BaFT was the investigation of choice (35 [56%] of departments averaged 
across the age groups) CTO was used more frequently (21 [33%] of departments 
averaged across the age groups) compared to in those with newly diagnosed or 
suspected disease   Small bowel ultrasound and MR were used more frequently in 
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patients of  <20 years old, and then by 20 (32%) and 13 (21%) of departments 
respectively (Figure 12). 
 
 
Figure 12: investigations performed in patients with clinical or biochemical disease flare 
up 
2.1.3.3 Requesting of tests according to indications – Gastroenterologists 
 
To assess disease extent in newly diagnosed Crohn’s disease, BaFT was most requested 
modality (out of total 73 Gastroenterology departments 53 (73%) request it for patients 
> 41and 45 (62%) for patients < 40). In 50% departments this was the only imaging 
requested. MRI was requested in 15 (21 %) departments for patients under 20 and SbUS 
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requested by at most 6 (8%) of departments but almost always in combination with a 
radiological test.  70% of gastroenterologists requested a single investigation only in all 
age groups while up to 7 (10%) would not perform any investigation. 
In patients with a high index of clinical suspicion for Crohn’s disease, 59 (81%) of 
gastroenterologists would perform endoscopy and biopsy essentially regardless of age, 
of which around one third would also perform BaFT on the same patients. SbUS was 
the least frequently used imaging modality being requested by less than 10% of 
gastroenterologist across all age groups. MRI was most frequently requested in those 
less than 40 years and then by just 11 (15%) departments (Figure 13). 
 
                        BaFT    SbUS       MRI      CT      Cap E     Endo & Bx   Nil 
Figure 13: Investigations performed and/or requested by gastroenterologists in patients 
with high suspicion of CD.  Endoscopy and biopsy with concurrent BaFT is 
preferred.  
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to those with high clinical suspicion, although SbUS was a little more frequently 
requested by 9 [12%] of departments in those aged below 40) (Figure 14). 
 
                         BaFT      SbUS      MRI         CT         Cap E     Endo & Bx    Nil 
 
Figure 14: Investigations requested by Gastroenterologists in patients with low clinical 
suspicion of Crohn’s disease 
CT was requested by 41 (57%) of gastroenterologists when assessing suspected 
extraluminal disease regardless of age. BaFT was used by 29 (40 %) departments, while 
SbUS by at most 13 (17%) [In those aged less than 20]. However MRI was more 
popular, being requested by 22 (30%) in patients below the age of 20. Barium follow 
through was the investigation of choice for assessing obstruction requested by 50 (68) 
% of departments across all age groups (Figure 15). 
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                      BaFT          SbUS              MRI             CT                Cap E               Nil 
 
Figure 15:Investigations requested by Gastroenterologists in patients with suspected 
extra luminal complications in patients with Crohn’s disease  
 
When there was clinical evidence of a flare 17 (23 %) of gastroenterologists would not 
request further imaging.  Across all age groups an average of 30 (41%), 4 (6%), 8 (10%) 
and 12 (16%) would however request BaFT, SbUS, MRI and CT respectively (Figure 
16). 
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               BaFT       SbUS          MRI     CT     Cap E          Nil  
 
Figure 16: Investigations performed and/or requested by gastroenterologists in patients 
with suspected clinical flare. BaFT is the most frequently request examination 
 
2.1.3.4 Comparison summary between radiologists and gastroenterologists 
Barium follow remains the preferred small bowel imaging technique in all patient 
groups and use was similar between gastroenterologists and radiologists. There was also 
agreement in the use of CT as the primary modality in the assessment of extra luminal 
complications, although for assessment of obstruction radiologist were more likely to 
recommended CT than gastroenterologists request it. 
 
However, radiologists were more likely to use SbUS and MRI when assessing patients 
both with suspected and proven disease, especially in patients <40 years (Figure 9 and 
13).  
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2.1.4 DISCUSSION 
 
For many years, barium follow through has been the routine radiological investigation 
for assessing known or suspected Crohn’s disease of the small bowel.  However, more 
recently there has been an increasing literature regarding the alternative use of cross 
sectional imaging techniques, notably SbUS, CT and MRI (section 1.2.3 and section 
1.3.2.6). Potential advantages include the ability to better assess extramural 
complications, grade disease activity and in the case of ultrasound and MRI eliminate 
the radiation burden in this generally young patient cohort (162, 197, 198).  Whilst 
European guidelines increasingly advocate the use of cross sectional techniques 
(particularly MRI and SbUS) anecdotally dissemination in the UK has been patchy and 
ad hoc. 
Based on this survey data I have confirmed that barium studies remain the imaging 
investigation most commonly performed in both diagnosis and assessment of Crohn’s 
disease in all ages. This is perhaps not surprising given their availability, relative 
simplicity and familiarity to both radiologists and gastroenterologists alike. 
Furthermore, the examination remains very much part of the core curriculum training of 
UK radiologists, unlike more specialist investigations such as ultrasound and MRI, 
which as this survey shows are limited to less than 50% of UK departments. When 
performed well, it provides detailed analysis of the extent of diseased mucosal surfaces. 
It also has reasonable documented diagnostic performance, sensitivity and specificity of 
85%-95% and 89%-94% respectively in the diagnosis of Crohn’s disease (199). There is 
evidence that the level of interpretive performance for barium enema may be 
suboptimal in the UK (200). It is unclear whether small bowel fluoroscopy is suffering 
the same fate as the popularity of new cross sectional techniques increases. Although 
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the majority of UK Radiology departments now have access to MRI technology, in this 
survey only 38% offered MRI of the small bowel, mainly for those with known Crohn’s 
or a high clinical suspicion. The aim of my survey was to assess current practice and as 
such, I did not complicate the questionnaire by collecting data on why one test was 
preferred over another. Although as discussed in third chapter of section none (1.3) 
recent Meta analysis data suggests MRI has high performance characteristics (190), it is 
important to state that although it is a theoretically attractive option in imaging Crohn’s, 
there is no randomized trial data confirming its superiority over, or even equivalence to 
conventional barium investigations. Without this data it is likely that MRI small bowel 
provision will remain ad hoc, but certainly lack of interpretative expertise and scanner 
capacity likely contribute to the low level of dissemination.  It is however interesting to 
note that radiologists were more likely to use MRI than gastroenterologists request it. 
Although knowledge of the technique and the supporting data is slowly increasing 
amongst UK radiologists, inevitably there will be a lag period as such information 
permeates through to the gastroenterological community. It is also interesting to note 
that although MR Enteroclysis likely has higher sensitivity than MR Enterography (190) 
the latter is significantly more widely utilized likely due to its greater simplicity and 
reduced invasiveness. Different oral contrast media has been used for the procedure 
such as bulk fiber laxatives mannitol, locust bean gum or a combination of both. 
 Forty-six percent of departments performed SbUS. Although ultrasound use for small 
bowel disease has been advocated for many years, it is clear the level of dissemination 
in the UK remains relatively low. The known reliance on expertise and associated steep 
learning curve (198) together with technical difficulties in obese or “gassy” abdomens 
have always limited uptake, as has the general reluctance of clinicians to request the 
examination (confirmed in this survey). However as noted in section 1.3.2.6, studies 
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investigating the diagnostic accuracy of US have shown reasonable results: sensitivity 
ranging between 84% and 90% and specificity between 98%-100 % (108, 113, 201-
203). The rapidity and safety of ultrasound together with the relative accessibility of the 
terminal ileum in most patients likely explains the relatively frequent use by radiologists 
in excluding disease particularly in younger patients with a low underlying clinical 
suspicion. Its ability to assess disease activity and response to treatment by using colour 
flow Doppler and US contrast agents is also an advantage (204). Both MRI and SbUS 
tended to be offered more frequently in teaching hospitals. 
CT was used infrequently in staging those either without a proven diagnosis of Crohn’s 
or for assessing those with a new diagnosis. Similar to MRI, there is no hard data 
supporting the superiority of CT over other tests in this context, and of course the 
examination imparts a reasonable radiation burden in this generally younger patient 
cohort (194, 195). However, CT is currently preferred for detecting extraluminal 
complications (such as abscesses) by most radiologists and gastroenterologists despite 
the radiation dose. Extramural complications are well shown on CT, and it likely is the 
reference standard test for the detection of intra abdominal sepsis (205-208).  
There was however evidence throughout the survey that radiation dose was a 
consideration by participants, as MRI and SbUS tend to be used more frequently in 
younger patient groups. However even in patients <20 years of age, tests using ionising 
radiation (especially barium follow through) were more frequently used for every 
indication listed. 
 
It is of note that the use of capsule endoscopy was relatively infrequent even amongst 
gastroenterologists, confirming its role a very much a second line test in Crohn’s 
disease. 
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The survey does have limitations. At best it can only be a snap shot of UK practice, and 
cannot detect changing trends in uptake of new imaging technologies-to do so will 
require a repeat survey in the future. The questionnaire return rate was relatively low 
but perhaps, not unexpected given the relatively detailed nature of the survey. I cannot 
however exclude the possibility that my sample is biased. Departments with an interest 
in small bowel imaging may for example have been more willing to reply. If anything, 
however such bias would perhaps tend to overestimate the use of new imaging 
technologies. In addition, this to my knowledge is the only such survey of UK small 
bowel imaging to date. Whilst I sampled radiology and gastroenterology departments 
separately, there was unavoidable overlap in the centers that responded but was only in 
17 departments. Of course another limitation is that gastroenterologists were likely to 
have responded based on the knowledge which tests are available at their institution and 
which tests they “could get”. The survey may therefore underestimate their interest in 
new cross sectional imaging techniques such as MRI and USS and willingness to 
request them were they available. It would have been useful to ask gastroenterologists 
of their actual preferences for imaging and their knowledge of guidelines 
recommending the use of newer technologies. Finally as noted above, although 
responder was allowed free text space, I did not specially enquire as to reasons why one 
imaging test was preferred over another and what if any were perceived barriers to the 
introduction of new tests. However, it is relatively difficult to capture this data without 
introducing bias with the phraseology of questions, and my main aim was to produce a 
simple snap shot of the use of small bowel tests in the UK for various clinical 
indications. 
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In summary, based on my survey of UK radiology and gastroenterology departments, 
barium follow though remains the most frequently performed and requested 
examination for known or suspect luminal small bowel Crohn’s disease, with CT being 
most frequently performed in those with suspected extra luminal complications. There 
has been only moderate dissemination of new small bowel technologies- MRI and small 
bowel USS are at present performed by a minority of UK imaging departments, 
particularly for patients aged less than 40 years. In general, radiologists are more likely 
to recommend MRI or USS than gastroenterologists are to request them. In the absence 
of hard trial data on which to base national guidelines, it is likely that uptake of MRI 
will remain rather patchy and ad hoc. The onus is on the radiological and 
gastroenterological communities to produce this evidence base to guide appropriate 
dissemination of new technologies such as small bowel MRI into standard clinic 
practice. 
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3 SECTION THREE: MRI IN IBD RELATED 
COLITIS  
 
As discussed in chapter 1.3, magnetic resonance imaging (MRI) has shown considerable 
promise in quantifying inflammatory activity in Crohn’s disease and ulcerative colitis 
involving small and large bowel (15, 212, 227). In section 2 the work covered the 
current use and impact of MRI in small bowel disease, a more established clinical 
indication. This section concentrates on use of MRI in the colon, for which clinical 
utility is less clear but impact could be as great as in the small bowel.  
 
 
3.1 QUANTITATIVE MAGNETIC RESONANCE 
IMAGING OF COLONIC MURAL 
ENHANCEMENT: SEGMENTAL DIFFERENCES 
EXIST IN ENDOSCOPICALY PROVEN 
NORMAL COLON 
3.1.1 INTRODUCTION 
When applied to the colon, most workers have used the technique of MR colonography 
(MRC) and as already described in section 1.3.3 various MRI parameters have been 
shown to correlate with disease activity, notably bowel wall thickness, T2 signal and 
contrast enhancement pattern. Absolute post gadolinium enhancement remains more 
controversial, with some workers finding high correlation (16), while others finding no 
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relationship (154). The reason for this variability likely includes differences in studied 
patient cohorts, applied standards of reference for disease activity (histological, 
biochemical, endoscopic or clinical) and methods of enhancement measurement (simple 
relative change in signal intensity at one time point or more complex quantitative 
dynamic contrast enhancement techniques). However, the baseline post contrast 
enhancement of normal (i.e. non inflamed colon) has received little attention. There are 
good reasons why enhancement may differ between bowel segments. Anatomical 
differences exist in segmental blood supply, the right colon is supplied via the superior 
mesenteric artery the left predominantly by the inferior mesenteric artery and the lower 
rectum via the iliac vessels (228). Colonic function also differs with proximal colon 
providing much of the water absorptive capability of the colon (229). 
In 15 normal volunteers, Ajaj et al have shown that at a single time point post contrast 
(75 seconds), relative enhancement differs according to colonic segment (being highest 
in the rectum and sigmoid and lowest in the right colon and descending) (15). 
Clearly inter- segmental differences of normal colon enhancement will influence the 
interpretation of MRI in inflammatory bowel disease, in particular when assessing 
potentially inflamed bowel. The purpose of this study was to present and discuss the 
quantitative MRI changes that occur following enhancement of endoscopicaly proven 
normal colon and to assess inter- segmental differences.   
3.1.2 MATERIALS AND METHODS 
8 patients (4 females, mean age 45, range 25 to 57) with no known history of 
inflammatory bowel disease and undergoing conventional colonoscopy were recruited 
to undergo additional MRC on the day of their conventional examination. 
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3.1.2.1 Patient preparation 
All patients underwent solid food restriction from lunchtime the day before colonoscopy 
followed by full bowel purgation- 10 Senna tablets and two sachets of magnesium 
citrate (Citramag- Sanochemia Diagnostics, UK) dissolved in one litre of water. MRC 
was performed by the thesis research fellow (Rehana Hafeez) 2 hours before 
colonoscopy in all patients. Following rectal introduction of 16F Foley catheter, the 
colon was gently filled with 1.5l of warm tap water from an enema bag held at shoulder 
height (i.e. filling by gravity). Bowel motility was abolished by intravenous spasmolytic 
(Buscopan, Boehringer Ingelheim, Germany) 0.3mg/kg (maximum 20 mg) immediately 
prior to abdominal imaging. 
3.1.2.2 MRI protocol  
Images were acquired in the prone position with a 1.5T Siemens Avanto (Avanto; 
Siemens, Erlangen, Germany) magnet using the body and spine array coils.  
The pre – contrast T1 relaxation time of colon was measured by using three breath-hold 
coronal fat saturated 3D Fast Low Angle Shot (FLASH) images of the abdomen and 
pelvis with different excitation flip angles (flip angles 5°, 10°, and 35°) (table 24) (230)  
Prior to intravenous contrast administration, three 3D FLASH baseline sets of coronal 
images were acquired during suspended inspiration (table 21). A single dose of (0.2 
mg/Kg) IV gadoterate meglumine (Dotarem; Guerbet Roissy, France) was then injected 
into an arm vein at 3 mL/sec, followed by a saline chaser (10 mL). At injection the 
patient was asked to hold his/her breath for 20 seconds (during which a single 3D 
FLASH volume dataset was acquired), followed by 10 seconds of gentle breathing, 
immediately followed by another 20 seconds breath hold acquisition and 10 seconds of 
gentle breathing. The acquisition protocol was repeated to generate a total of 8 post 
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contrast 3D FLASH datasets.  
 
 *FLASH 3D 
(T1 calculation) 
*FLASH 3D 
(Pre-contrast) 
*FLASH 3D 
(Post-contrast) 
TE (ms) 2.4 2.4 2.4 
TR (ms) 5.15 5.15 5.15 
FA (degrees) 5°, 10°, 35° 35° 35° 
NEX 1 1 1 
iPAT 2 2 2 
FOV (mm) 500x500 500x500 500x500 
STH 3 3 3 
No. slices 48-60 48-60 48-60 
BW (Hz) 300 300 300 
Acq. Matrix 256x154 256x154 256x154 
Recon. Matrix 512x512 512x512 512x512 
TA (s) 17 17 17 
No. Acq. **1 3 8 
Table 21: MR Acquisition Parameters 
*Breath held fat saturated coronal T1 weighed 3D Fast Low Angle Shot  
**Single acquisition at each flip angle 
TR- repetition time, TE- echo time, FA- flip angle, NEX- number of signal 
Averages, iPAT- parallel imaging factor, FOV- field of view,  
STH- slice thickness 
BW- pixel bandwidth, TA- Time for single 3D FLASH acquisition. 
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3.1.2.3 Colonoscopy 
Indications for colonoscopy for recruited patients were change in bowel habits (n=3), 
previous history of colonic polyps (n=3) and PR bleeding (n=2). 
Patients remained nit by mouth following MRC for a further 1 to 2 hours while awaiting 
colonoscopy performed by experienced (2-10 years) operators. Intravenous sedatives 
(Midazolam 50 microgram/kg, max 10 mg and Fentanyl 100 mcg) were administered, 
together with nasal oxygen. All patients had multiple ileo- colonic biopsies taken to 
exclude microscopic colitis. None of the patients had any complication and all were 
discharged within few hours. None of the biopsies showed features of inflammation. 
3.1.2.4 MRI data analysis 
Region of Interest (ROI) analysis was performed on 3D FLASH MR Images using the 
open source OsiriX medical imaging platform (http://www.osirix-viewer.com). Single 
freehand linear ROIs (mean size, 5.4 cm; range 2.3 to 9.8cm) were located in the 
colonic wall of the ascending colon, descending colon and lower rectum by a radiologist 
(Shonit Punwani) and thesis author in consensus (Figure 24). These segments were 
chosen as representative of the known differing vascular supply and functional 
properties of the colon over its length. To guide ROI placement, the observers first 
reviewed the whole MR contrast dataset and chose those parts of the bowel wall reliably 
identifiable throughout the time series. In order to maintain the ROI within the colonic 
wall between successive acquisitions, the shape of the linear ROI was altered (with the 
length [±0.01 cm] and anatomical position kept constant) to account for any colonic 
deformations.  
The mean ROI signal intensity was recorded for each segment. The signal from the 
three pre-contrast baseline acquisitions for a given ROI was averaged, provided a single 
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pre –contrast ROI signal intensity for colonic each segment. T1 was calculated for each 
segment in Microsoft Excel for Mac (2011) using the expression for the evolution of 
signal intensity in spoiled gradient echo and solving for T1 (230). The T1 relaxation rate 
(R1) was derived by 1/T1. 
3.1.2.1 Statistical Analysis 
The mean R1 (n=8 patients) prior to contrast and at each of the 8 post-contrast time 
points was used to generate an enhancement (R1-time) curve for the three colonic 
segments.  
The initial change in R1 (ΔR1) was calculated between the 10 (1st post-contrast) and 40 
seconds (2nd post-contrast) time points. 
Early ‘plateau phase’ post-contrast R1 was derived as the average of the 40, 70 and 
100s measurements for each segment. Late ‘plateau phase’ post-contrast R1 was 
calculated as the average of the 130,160,190 and 210 measurements.  
The area under the R1- time curve (AUC-R1) was determined using Prism (GraphPad 
Prism version 4.00 for Mac, GraphPad Software, Sam Diego California USA, 
www.graphpad.com) 
The Shapiro- Wilks test was applied to the data and a normal distribution confirmed. A 
student’s paired t-test was therefore used to compare R1 at pre-contrast, ΔR1, early and 
late post-contrast plateau phase R1, and the AUC-R1 between the individual colonic 
segments.  
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Figure 17 (a): Region of interest placement was performed using OsiriX. 
Pre-contrast coronal T1 weighted VIBE image of a rectum with a linear 
region of interest placed within the rectal wall. 
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Figure 17(b): Matched post-contrast 10, 40, 70, 100, 130, 160, 190, 220 second (1 to 8 
respectively) images demonstrating the linear region of interest on successive 
acquisitions. 
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3.1.3 RESULTS 
 
All colonoscopies were complete to the terminal ileum and normal, with no evidence of 
inflammatory bowel disease on direct inspection or biopsy. 
The mean pre-contrast T1 of ascending colon, descending colon and rectum were 
606±264, 661±264 and 680±300 ms respectively. 
R1-time curve for ascending colon, descending colon and rectum are illustrated in 
figure 25. Pre-contrast there was no significant difference of R1 values between 
individual segments (table 22). ΔR1 was greater for the ascending than descending 
colon (table17, p=0.03). There was no significant difference in ΔR1 for other colonic 
segments (table 22).  
Early and late post-contrast plateau phase R1 values were not significantly different 
between bowel segments (table 22). 
 
The AUC-R1 of the ascending colon was significantly greater than the descending 
colon (table 16, p=0.03). There was significant difference of AUC-R1 between the 
rectum and other colonic segments (table 22). 
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 Ascending  Colon 
Descending  
Colon 
Rectum 
Pre – contrast T1 (ms-
1) 
606±244 661±264 680±300 
Pre-contrast R1(ms-1) 0.0019±0.0007 0.0023±0.0021 0.0018±0.0004 
ΔR1 (ms-1) 0.0042±0.0010 0.0033±0.0015 0.0048±0.0025 
Early post-contrast 
R1 (ms-1) 
0.0042±0.0010 0.0033±0.0015 0.0048±0.0025 
Late post-contrast R1 
(ms-1) 
0.0049±0.0021 0.0036±0.0015 0.0049±0.0024 
AUC-R1 0.54±0.19 0.30±0.14 0.60±0.46 
    
Table 22 (a): Quantitative MR colonic segmental parameters  
 
 Ascending vs. 
Descending t-test  
(p-value) 
Ascending vs. 
Rectum t-test 
(p-value) 
Descending 
vs. 
Rectum t-test 
(p-value) 
Pre-contrast R1 (ms -
1) 
0.50 0.62 0.49 
ΔR1 (ms-1) 0.03* 0.48 0.07 
Early post-contrast 
R1 (ms-1) 
0.21 0.60 0.24 
Late post-contrast R1 
(ms-1) 
0.08 1.0 0.30 
AUC-R1 0.03* 0.14 0.75 
 
Table 22(b): Comparison of colonic segments  
*Significant difference at the p<0.05 level. 
ΔR1 is the change in R1 between the 10 (1st post-contrast) and 40 seconds (2nd post-
contrast) Acquisitions. 
AUC-R1 is the area under the R1-time curve. 
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                     Figure 18 a: R1- time curve for ascending colon 
 
             Figure 18 b: R1-time curve for Descending colon 
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                        Figure 18 c: R1-time curve for Rectum 
 
3.1.4 DISCUSSION 
T1 relaxation is a consequence of fluctuations in the magnetic field experienced by 
individual hydrogen nuclei, which in the body are predominantly bound within water 
molecules. As each hydrogen nucleus has magnetic properties, the rotational and 
tumbling movements of water molecules themselves act as the main source of magnetic 
field fluctuations. For effective T1 relaxation, the oscillations in magnetic field have to 
occur at a specific frequency called the Larmor frequency. The greater the number of 
hydrogen nuclei experiencing fluctuations at the Larmor frequency the shorter the T 
relaxation time and the brighter the signal. The number of oscillations at the Larmor 
frequency is greater for water contained within soft tissues as compare to pure water or 
solid structure. The study found that mean pre-contrast T1 of normal colonic segments 
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was 606 to 680 ms with a narrow range and that there was no significant inter-
segmental difference between R1 (1/R1), reflecting the nature of the T1 relaxation 
mechanism. 
 
Gadolinium based contrast agents work by producing additional magnetic field 
oscillations at the Larmor frequency thereby further shortening the T1 relaxation time 
and increasing signal within the image. For the effects of contrast agents to be realized, 
they must be in close proximity of water molecules. When confined within the 
vasculature, the number of water molecules affected is limited. With free leakage into 
the interstitium, more tissue water is exposed to the T1 shortening effects.  
 
The study found significant difference between colonic segments in their behavior 
following gadolinium administration. Notably ΔR1 and AUC-R1 were greater for the 
ascending than descending colon. By way of explanation, Skinner et al using vascular 
casts of normal colon showed a higher micro vascular volume (13.4±3% and 7.7±2.2% 
respectively) and micro vascular surface area (22.4±5% and 17.5±6.9% respectively) in 
the proximal colon compared with the distal colon (231). A higher percentage vascular 
volume in the proximal colon would mean that there is proportionally more 
intravascular water upon which intravascular gadolinium can act. Furthermore, 
considering dynamic contrast enhanced models the volume transfer coefficient (Ktrans) is 
the product of capillary permeability and surface area where blood flow is not limited 
(232). As the micro vascular surface area of the proximal colon is greater than distal 
colon (231) it follows that Ktrans  should be higher (assuming the vascular permeability is 
equal or higher). A larger Ktrans   signifies, that intravenous contrast will pass more freely 
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into the interstitial space exposing more tissue water to the gadolinium induced T1 
relaxation effects likely accounting for the greater increase in R1 (larger ΔR1) of 
ascending colon compared with descending colon. 
 
Ajaj et al found that prior to IV contrast there was no difference between the contrast to 
noise ratio of different colonic segments, and at 75 seconds following IV contrast 
enhancement was highest in the rectum and sigmoid, and lowest in the ascending and 
descending colon (15). This study partially supports their findings, as no difference was 
found in R1 between segments prior to contrast and a relative lower enhancement 
within the descending colon. However discrepant to Ajaj et al, no significant difference 
was found between rectum and ascending colonic R1 changes, and R1 change within 
the ascending colon was higher than descending colon. By way of explanation, it is 
possible results were influenced by the differences in acquisition and analysis of the MR 
data between the two studies. In contrast to Ajaj et al, enhancement differences 
evaluation was done between segments based on quantitative R1 change in order to 
avoid the effect of spatial signal intensity variation that can occur across images; and 
the potential difficulties with noise assessment within images where parallel imaging or 
image filters have been used (233). 
 
The purpose of the study was to assess whether segmental variations are present in the 
enhancement of normal colon. Whilst these results present quantitative measurements 
performed on a total of eight normal patients at a single center (UCLH), they 
nevertheless illustrate statistically significant difference between colonic segments that 
support the anatomical and functional differences within the colon. Furthermore, a 
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robust selection standard was used, ensuring all these patients had confirmed normal 
(non-inflamed) colonic appearances at endoscopy. The study also intentionally limited 
analysis to segments with clearly defined regional blood supplies and functional 
specializations. I acknowledge that further recruitment is necessary to investigate the 
segmental differences that are “near statistical significance” in these results. Indeed the 
small sample size and large standard deviation between measurements means we must 
treat the data with some caution-it is possible difference in significance between 
ascending and descending colon be a reflection of the differences in standard deviation 
of the baseline data. However there was no significant difference between pre-contrast 
segmental RI values, despite the relatively large standard deviations of the data. Such 
changes only became apparent following contrast administration.  
In conclusion my results highlight that inter-segmental differences in colonic 
enhancement are present. These should be considered when using enhancement as a 
biomarker for colonic inflammation as not all differential segmental enhancement is a 
result of inflammation. 
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3.2 ASSESSMENT OF COLONIC DISEASE 
ACTIVITY IN INFLAMMATORY BOWEL 
DISEASE USING MRI COLONOGRAPHY 
 
3.2.1 INTRODUCTION 
Rational use of immunosuppressive therapies in IBD disease relies on accurate 
identification of those patients with acute inflammation –so called “active disease” who 
are most likely to respond to the treatment, together with assessment of the disease 
extent. The management of colonic IBD and assessment of response to medication 
largely depends on accurately documenting the location, extent, and the severity of the 
inflammation.  
As discussed in section 1.2.3, unfortunately there is no reliable, non-invasive method to 
identify such patients. Clinical assessments based on patient symptomatology (e.g. 
CDAI), biomarkers and endoscopy. As already described in section 1.3.3, MR 
Colonography has been advocated as a potentially useful investigation for this purpose.  
Several qualitative MRI scoring systems for assessing inflammatory activity in IBD are 
beginning to appear in literature. 
For example Steward et al have described a simple and rapid qualitative scoring system 
which has been developed and validated in patients with small bowel CD by using a 
robust transmural histological reference standard of inflammation (234). In this study 
data from 16 patients was used to derive the MRI score. All these patients had gone 
elective surgery for CD and had pre operative MRE. An MRI was performed of the 
resected specimen and used to accurately co- locate sites of full transmural histological 
sampling with regions of interest placed within the bowel on the pre –operative MRI. 
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The pathological reference standard of inflammation was based on ulceration and the 
extent and depth of neutrophilic infiltration and a transmural histopathological acute 
inflammation score (AIS) was assigned. 
Qualitative measurement were taken on pre operative MR images according to a 
qualitative scoring system which included mural thickness, mural T2 signal intensity, 
perimural oedema (Fat saturated half- Fourier RARE images), bowel wall enhancement 
(VIBE images 70 seconds post contrast) using adjacent normal bowel wall as reference.  
Using a regression analysis with backward selection, the authors proposed the final 
index which best predicted histological AIS was  
 = 1.79 + 1.34 Mural Thickness (in mm) + 0.94 mural T2 score 
(R squared = 0.52) 
This score was then validated in a sample of 26 patients who had MRE and endoscopy 
with terminal ileum biopsy within four weeks. The MRI score was calculated for 
terminal ileum of each patient. In all patients endoscopic biopsy was taken from the 
terminal ileum and acute inflammatory score assigned (eAIS) (again mainly based on 
ulceration and extent of neutrophilic infiltration see table 28 below). There was a 
significant correlation between MRI index and histopathological eAIS (Kendall's tau b 
= 0.4, 95% CI = 0.11 to 0.64, p=0.02). 
This score has recently been modified by the authors to take into account the length of 
affected bowel in each segment (as apposed to a single point estimate) as well as extra 
enteric complications (235). This “MRI activity score” is further detailed in the methods 
of this chapter below.  
An alternative system has been proposed by Rimola et al (16, 187) and already 
described in section 1.3.4. Rimola used the CDEIS as reference for disease severity to 
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derive and validate their qualitative MRI score (MaRIA) based on wall thickness, 
relative contrast enhancement (RCE) and presence of oedema.  
 MaRIAS= 1.5 wall thickness + 0.02 RCE+ 5 oedema+10ulceration  
This index showed correlated with CDEIS (r=0.82, p<0.001)) and in second study they 
validated the same score in a new patient cohort [MaRIA correlated with CDEIS (r= 
0.798,p<0.001 per segment and r=0.87, p<0.001 per patient) Harvey – Bradshaw index 
(r=0.56, p<0.001) and CRP (r=0.53, p<0.001)].  
The utility of these scoring systems is yet to be fully tested. For example the scoring 
system described by Steward was based on small bowel disease and its applicability to 
the colon is unknown. Although Rimola et al have validated their score in a new patient 
cohort, these were recruited from the same center and the data was analyzed by the 
same clinical and radiological teams. A true test of any scoring system is if it can be re-
produced in a completely new patient population by a different clinical group. 
Therefore, the purpose of this study was to apply these proposed MRI scores of small 
bowel Crohn’s disease activity in a new patient cohort recruited at UCLH and evaluate 
their ability to predict colonic disease activity against a reference standard of 
Endoscopy (CDEIS), Histology grading and eAIS.  
 
3.2.2 MATERIALS AND METHODS 
Twenty one patients with colonic inflammatory bowel disease undergoing endoscopy as 
part of normal clinical care were recruited to undergo prior MRC. One patient was 
incontinent of the water enema and excluded. Among 20 patients 10 females (mean age 
35 range 16-50) and 10 male patients (mean age 42 range 29-63) took part in the study. 
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 New suspected cases Follow up  
Total 5 15 
Males  02 07 
Females 03 08 
UC 02 08 
CD 03 07 
Table 23: Patients for MRC 
3.2.2.1 Eligibility criteria  
Patients undergoing endoscopy for IBD related indications, notably 
a) Known previous histopathological diagnosis of CD or UC undergoing investigation 
for restaging of disease, disease extent or assessment of response to therapy 
b) High clinical suspicion of IBD based on clinical examination and current 
investigations (biochemical or radiology [CT, MRI, Barium studies, ultrasound]) 
e) Age 16 or over 
3.2.2.2 Exclusion criteria 
 
a) Pregnancy 
b) Contraindication to MRI (pacemaker, metallic implant, severe claustrophobia etc.) 
c) Patients with history of renal impairment (theoretical risk of nephrogenic systemic 
fibrosis with gadolinium), active ischemic heart disease and acute glaucoma.  
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3.2.2.3 MRI protocol 
Patients had undergone bowel preparation deemed necessary for their conventional 
endoscopy, and this was not altered. All the patients underwent MRColonography 2 
hours before colonoscopy according to standard MRC protocol (Appendix C). 
3.2.2.4 Endoscopy and reference 
Endoscopy was performed as per usual practice, in the endoscopy unit by the 
experience operators (2-10 years experience). All the patients remained nil by mouth for 
1-2 hours after MRC while waiting for CC. Intravenous sedatives (Midazolam 50 
microgram/kg, max 10 mg and Fentanyl 100 mcg) was administered, together with 
nasal oxygen. The operators completed a validated Crohn’s Disease Endoscopic Index 
of Severity (CDEIS) study proforma, documenting the endoscopic severity of the 
colonic disease. The endoscopic scoring system utilized is based on variables such as 
ulceration, area of surface involved by disease and ulceration and presence of stenosis 
(ulcerated or non ulcerated) (see section 1.2.3.3.1 for full definition of the CDEIS). 
Three patients had flexible sigmoidoscopy as a planned procedure and 17 had complete 
CC. 
3.2.2.5 Histopathology and reference  
The biopsies taken during the endoscopy were sent for histological assessment. An 
experienced histopathologist (M Justo Rodriguez) scored the biopsies for inflammation 
using standard five grade classification system for inflammation (defining the degree of 
inflammation according to the presence of inflammatory cells in lamina propria and 
epithelium and crypt destruction, ulceration and abscess formation) (236) (Table 24).  
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Grade Definition  Features 
Grade 1 Minimal active Increase in inflammatory cells in the lamina 
propria (lymphoplasmacytic). 
Grade 2 Mildly active Presence of neutrophils/eosinophil but 
confined to the lamina propria 
Grade 3 Moderately active Neutrophils within epithelium (crypt or 
surface) but no crypt abscess formation 
Grade 4 Markedly active As in 3 but with crypt destruction and 
abscesses 
Grade 5 Severely active As in 4 with erosions/ulcerations 
 
Table 24: Histopathological Inflammatory grading system 
In addition an alternate grading system of histopathological inflammation (eAIS) 
previously devised by the pathologist and used in the work by Steward et at was 
assigned to each biopsy (234) (Table 25). 
Histological variable Grade 
Erosion or ulceration 0= No, 1= yes 
Polymorphs in lamina propria  0= No, 1= yes 
Cryptitis  0= No, 1= yes 
Crypt abscess formation  0= No, 1= yes 
Inflammatory exudates 0= No, 1= yes 
Granulomas 0= No, 1= yes 
Table 25: eAIS 
 145 
3.2.2.6 Data analysis 
Data analysis was performed on Images using the open source OsiriX medical imaging 
platform (http://www.osirix-viewer.com) as in section 3.1.2.3, in consensus by a GI 
Radiology research fellow (Jessica Makanyanga) and the thesis author (Rehana Hafeez). 
Example images of the various scoring categories were made available to the observers 
from the original publications of Steward (234) and Rimola (16, 187) to help 
standardize the grading of the datasets. A consultant radiologist Prof Stuart Taylor (10 
years of abdominal MRI experience) closely supervised the scoring process by the 
observers, although a formal inter-reader agreement analysis was not performed.  
In all 20 patients the colon was divided into six segments (caecum, Ascending colon, 
transverse colon, descending colon, sigmoid and rectum) using standard anatomical 
definitions for the purpose of data analysis.  
3.2.2.6.1 Steward Score 
The two observers scored qualitative observations in all six segments according to the 
previously derived and validated scoring system for CD described by Steward et al and 
based on wall thickness and T2 signal (Table 29) (Figure 19 a & b). 
MRI index was calculated for each segment as: 
1.79+1.34mural thickness+0.94 mural T2 score  
The individual segmental scores were added to get the final score for each patient. 
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Figure 19 a: Mural thickness – Transverse colon  
Figure 19 b: Increase mural T2 signals   
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Score 0 1 2 3 
Mural 
thickness 
1-3 mm >3-5 mm >5-7 mm >7mm 
Mural T2 
signal  
Equivalent to 
normal bowel 
wall 
Minor increase 
in signal –
bowel wall 
appears dark 
grey on fat 
saturated 
images  
Moderate increase 
in signal- bowel 
wall appears light 
grey on fat 
saturated images 
Marked increase 
in signal- bowel 
wall contains 
areas of white 
high signal 
approaching that 
of luminal 
contents 
Table 26: Qualitative parameters used to calculate Steward score  
 
3.2.2.6.2  MRI activity score 
The MRI activity score was assigned to each of the 6 colonic segments by the observers 
in consensus according to following definitions (Table 27) (Figure 20). 
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Figure 20 a: T1 weighted imaging – Dark lumen MRC 
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Figure 20 b: Mural thickness score 2  
 
Figure 20c: Mesenteric edema score 2 (small pool) 
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Figure 20 d: Moderate T1 enhancement of sigmoid colon with layer pattern  
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Score 0 1 2 3 
Mural 
Thickness* 
Colon 
<3mm >3 - 5 mm >5 - 8 mm >8mm 
Mural T2 
signal** 
 
Equivalent to 
normal bowel 
wall 
 
Minor increase 
in signal-bowel 
wall appears 
dark grey on fat 
saturated 
images 
 
Moderate 
increase in 
signal-bowel wall 
appears light grey 
on fat saturated 
images 
 
Marked increase 
in signal-bowel 
wall contains areas 
of white high 
signal approaching 
that of luminal 
content 
Mesenteric 
edema 
 
None 
 
Thin rim <2mm Small pool <3 cm Large pool >3 cm  
T1 
Enhancement** 
 
Equivalent to 
normal bowel 
wall 
 
 
Minor 
enhancement-
bowel wall 
signal greater 
than normal 
small bowel but 
significantly 
less than nearby 
vascular 
structures  
Moderate 
enhancement-
bowel wall signal 
increased but 
somewhat less 
than nearby 
vascular 
structures 
 
Marked 
enhancement-
bowel wall signal 
approaches that of 
nearby vascular 
structures 
 
Mural 
enhancement 
pattern 
N/A or 
homogenous 
 
Mucosal Layered  
 
 
 152 
Multiplication factor per length of segment involved by disease 
Length of disease 
segment 
0cm 0-5cm x 1 5-15cm x 1.5 >15cm x 2 
 
 
 
 
 
Table 27: Qualitative measurements for Qualitative MRI activity index 
*measured using electronic calipers 
**compared to normal small bowel 
***compared to nearest vessel 
MRI activity score=(Caecum score x multiplication factor for involved caecum length) 
+ (ascending score x multiplication factor for involved ascending length) + (transverse 
score x multiplication factor for involved transverse length) + (descending score x 
multiplication factor for involved descending length) + (sigmoid score x multiplication 
factor for involved sigmoid length) + (rectum score x multiplication factor for involved 
rectum length) + score for adenopathy + score for comb sign   
                                    (Total possible score 178) 
 
 
 
Score 0 5 
Lymph nodes Absent Present 
Comb Sign Absent Present 
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3.2.2.6.3 MaRIA index 
Similarly, observations were made in six segments of colon to derive the MaRIA index 
using definitions proposed by Rimola et al (16, 187). The index included bowel wall 
thickness, mural edema (hyper intensity on T2 weighted sequence of the bowel wall 
relative to the signal of psoas muscle), Ulceration (deep depression in the mucosal 
surface of a thickened segment) and enlarged regional mesenteric lymph nodes (>1cm). 
Region of interest (ROI) were placed in all six segments pre contrast and post contrast 
(70 seconds) in the same location (Table 28) (Figure 21). 
Wall thickness  
ROI pre-contrast wall signal intensity  
ROI post-contrast wall signal intensity  
Edema Y/N 
Ulcers Y/N 
  Table 28: MRC parameters for MaRIA index  
MaRIA index = 1.5 wall thickness + 0.02 RCE+ 5 edema+ 10 ulcer 
Relative contrast enhancement (RCE) was calculated as:  
¼ [(WSI post gadolinium- WSI pregadolinium)/(WSI pregadolinium )] x 100x (SD 
noise pregadolinium/SD noise post gadolinium) 
Whereas SD noise was calculated as average of three SDs of the signal intensity 
measured outside of the body before and after gadolinium injection. 
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Figure 21 a: ROI – pre contrast Ascending colon  
Figure 21 b: ROI post contrast – Ascending colon  
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3.2.2.7 Statistical analysis 
Spearman correlation was used to evaluate relation between all three MRI index, 
CDEIS, histology grading and eAIS. This was done on a per patient basis (i.e. using 
total MRI, CDEIS and histology scores), and then repeated on a per segment basis (split 
into the 6 segments). For the MRI activity index, the scores for lymph nodes and comb 
sign were excluded from the individual segmental scores given the reference standard 
was based on luminal evaluation only. 
3.2.3 RESULTS  
The mean MRI index using the method of Steward was 37.53 (range 28.51 – 55.01 and 
SD 8.9)  
The mean MRI activity score was 10.30 (range 0- 48 and SD 15.3) 
The mean total MaRIA index was 6.37 (range 0- 21.81and SD 4.0) 
3.2.3.1 CDEIS 
Mean total CDEIS was 5.58 with range of 0-63.6 and SD 14.64. 
3.2.3.2 Histology grading and eAIS 
All the biopsies taken during endoscopy were graded according to inflammation grading 
(1-5) in each segment with possible maximum grading of 30 in any one individual 
patient. The mean total histological grade was 3.7 with range of 0-12 and SD 4.092. 
The mean eAIS was 3 with range of 0-12 and SD 3.569.    
3.2.3.2.1 Steward score vs. CDEIS and histology scores 
On per patient basis and using the total Steward score and CDEIS, there was significant 
correlation between the Steward score and CDEIS r=0.559 & p =0.01 but no correlation 
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was present with either the standard histology grading (r=0.08 & p=0.71) or eAIS 
(r=0.097& p=0.68) (Figure 22). 
 
 
 
     Figure 22:  Scattered graph showing correlation between the Steward score and 
CDEIS – less than 20 points are illustrated due to overlapping of individual data points.  
3.2.3.2.1.1 Per segment Data 
The per segment basis mean Steward score was 8.87 and CDEIS 0.35, standard 
histology grading 0.62 and eAIS was 0.51. Again there was significant correlation seen 
between the MRI score and CDEIS (r= 0.4, p=<0.01) but no correlation was found with 
standard histology grading(r= 0.098, p= 0.28) or eAIS (r= 0.11, p=0.198).  
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3.2.3.2.2 MRI activity score vs. CDEIS and histology scores 
The MRI activity score also showed a significant correlation with CDEIS (r= 0.55, 
p=0.01)  on per patient basis, but not with histological grading (r= 0.13 & p=0.56) or 
eAIS  (r= 0.19 & p= 0.4) (Figure 23). 
 
 
Figure 23: Scatter graph between Qualitative MRI severity index and CDEIS- less than 
20 points are illustrated due to overlapping of individual data points.  
3.2.3.2.2.1 Per segment data 
On per segment basis the MRI activity score showed a significant correlation with 
CDEIS (r=0.49,p=<0.01), and also histology grading (r=0.2,p=0.035) and eAIS 
(r=0.22,p=0.02) as well. 
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3.2.3.2.3 MaRIA index vs. CDEIS and histology scores 
The MaRIA index showed positive correlation with CDEIS (r=0.61 & p=0.005) on per 
patient basis, but not with histology grading (r=0.02 & p=0.93) or eAIS (r=0.96 & 
p=0.69) (Figure 24). 
 
 
Figure 24: Scattered graph between MaRIA index and CDEIS - less than 20 points are 
illustrated due to overlapping of individual data points.  
3.2.3.2.3.1 Per segment data 
The MaRIA index also correlated with CDEIS on per segment basis (r=0.45, p=<0.01) 
but there was no correlation found with histology grading (r=0.16,p=0.1) or with eAIS 
(r=0.18,p=0.05). 
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3.2.4 DISCUSSION 
 
As discussed in session 1.3.3.6, MRC has emerged as a potentially useful investigation 
for assessment IBD related colitis but there are inconsistencies in current literature 
regarding techniques, MRI parameters and reference standard applied (symptoms 
scoring, biochemical markers, endoscopic, histological and surgical).  
The study attempted to test 3 proposed MRI scores of activity against endoscopic and 
histological standard of reference. 
The data showed that all 3 scores (Steward score, MRI activity index and MaRIA index 
correlated significantly with CDEIS on a per patient and per segment basis, providing 
some validity to their use in clinical practice.  
The Steward score was based mainly on small bowel work using surgical resection 
specimens and (234) found wall thickness and T2 mural signal were the best predictors 
of inflammation : a combined score of these parameters showed a sensitivity of 81% for 
detection of histological inflammation. In this study I correlated the same combined 
score with histological sampling from the colon and failed to re-produce this positive 
correlation. That in general MRI scores did not correlate well with colonic histology 
(excepting the MRI activity index on a per segment basis) is perhaps to be expected. 
Histological biopsies are prone to sampling error, and grading is subjective. 
Furthermore although the study attempted to match sites of MRI and histological 
sampling on a segmental basis, in reality the actual anatomical matching would likely 
have been poor. It is easier to match MRI with histology in the terminal ileum given the 
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landmark of the ileocaecal valve, then in the colon where even segmental demarcation 
is subjective.  
The MRI activity score is a modification of Steward score, and previous work has 
shown significant correlation with faecal calprotectin level (Kendall's tau b=0.42, 
p=0.0009). Contrary to Steward score, this score was significantly correlated with both 
histology grades on per segment basis. It is of interest that the MRI activity index 
seemed to best correlated with the reference standard overall (i.e. CDEIS and 
histology). The score is takes into account many more parameters than the Steward 
score and MaRIA index, including the length of the bowel affected in each segment. 
This presumably added to its ability to assess colonic inflammatory activity. However it 
is clearly more complex than the others scores to collate and how useful it is in time 
pressured day to day clinical practice is debatable. 
The Rimola score (including wall thickness, contrast signal intensity and RCE) has been 
shown to correlate well with endoscopic inflammation severity. The present study was 
able to reproduce this work:  MaRIA showed positive correlation with CDEIS, although 
again no such association was found against histological features of inflammation.  
The MRI parameters, which make up the scores, are of interest. An assessment of wall 
thickness and T2 signal was common to all 3 systems, with inclusion of contrast 
enhancement in the MRI activity score and MaRIA. The strength of correlation with 
CDEIS (on a per patient basis) was not overtly less with the simple Steward score in 
comparison to the more complex MRI activity score and MaRIA score. This perhaps 
suggests grading contrast enhancement may not be crucial in predicting disease activity. 
In chapter 3.1 I have already shown that there are segmental differences in contrast 
uptake in normal colon, and the work of Taylor et al (154) has shown contrast uptake is 
related to disease chronicity and microvessel density and not just inflammatory activity. 
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However other workers have previously included contrast uptake in their score. Notably 
Ajaj et al (15) used an MRC score based on (contrast uptake, wall thickness, haustral 
folds and peri focal lymphnodes) and in comparison with endoscopic biopsies found 
positive results for detection of IBD (sensitivity of 87% and specificity of 100). Like the 
present study, they used a dark lumen technique. 
Furthermore, as I present in later chapters (3.4), quantitative measurement of contrast 
enhancement does correlate with disease severity in acute severe colitis, so overall it I 
think we can conclude that it is of value. It does seem however that wall thickness and 
T2 signal (likely reflecting mural edema) are the best predictors of disease activity. 
The present study utilized a full bowel preparation and dark lumen technique Scheryer 
et al (189) used a bright lumen technique while Langhorst et al (181) made use of fecal 
tagging. However neither found such positive results for detection of inflammatory 
changes. The present study does therefore also support the concept that a dark lumen 
technique after bowel purgation is “state of the art” for MRC.  
Other MRI sequences are also now under investigation. Ossalah et al (183) have  
assessed disease activity with help of diffusion weighted imaging using a score based on 
DWI hypersensitivity, contrast enhancement pattern, bowel thickening, parietal edema 
and presence of ulcers. They found good correlation with an endoscopic reference 
standard. The present study did not utilize diffusion weighted imaging. However I 
consider this technique in the assessment of acute severe colitis (Chapter 3.4). 
The findings of this study should be interpreted with some caution. The cohort included 
a mixture of patients with UC and CD. This was mainly for pragmatic reasons- 
recruitment of patient under going colonoscopy to undergo an additional MRC was 
challenging. The number in each group precludes meaningful sub analysis of correlation 
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with the endoscopic and histological scores, but is possible the MRI parameters, which 
best correlate with clinical indices of inflammation will differ between patient with UC 
and CD.  
The MRI scoring was done by two research fellows rather than consultant radiologists, 
however, the scoring was closely monitored by the supervising radiologist, although a 
formal assessment of agreement between the observers and the radiologist would have 
been useful. Finally, several of the recruited patients had low level of activity and 
attracted zero scores. Although the statistical testing performed concurred with medical 
statistician advise, it is acknowledged that datasets with several zero scores may 
artificially increase correlation coefficients. A formal power calculation was not 
performed and it is possible the study was underpowered. Clearly a larger dataset is 
required containing patients with more active disease to test m conclusion, and this data 
can be used to inform calculation of an appropriate sample size for such a future study.  
In summary in this relatively small exploration study, all three qualitative MRI indices 
correlated with an endoscopic score of disease severity – CDEIS which itself is gold 
standard for endoscopic disease assessment. This suggests MRC assessment of disease 
activity is a viable proposition in clinical practice as a complementary tool in cases of 
incomplete colonoscopy but perhaps as an alternative to colonoscopy as a first line test. 
As later presented in chapters 4.1 & 4.2, patient experience of MRC and colonoscopy is 
an important consideration, but on diagnostic accuracy criteria, MRC performs well in 
assessing disease activity. 
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3.3 QUANTITATIVE MEASUREMENTS OF THE 
BOWEL WALL CHARACTERISTICS IN ACUTE 
COLITIS 
3.3.1 INTRODUCTION 
Assessment of disease severity, accurate monitoring of response to medical treatment 
and prediction of treatment failure are very important in management of acute colitis 
and its complications as discussed in chapter 3.3. 
In the previous chapter, I concentrated on a qualitative scoring system (TCIS) based on 
subjective assessment of T2 weighted images by reporting radiologists. This was 
successful, showing good correlation with clinical parameters and potentially acting as a 
new prognostic tool. Although I was able to demonstrate good interobserver agreement 
with the qualitative scoring system, in reality any score that relies upon the opinion of 
the reporting radiologist is subjective and at risk of observer bias. Furthermore I did not 
consider contrast enhancement in the tested score, which as we have seen likely does 
have utility. The use of diffusion-weighted imaging was also not considered. 
In this next study, I apply quantitative measurements via ROI placement in the same 
patient cohort described in the previous chapter. Considered sequences include dynamic 
contrast enhanced T1 weighted images, diffusion weighted images as well as T2 
weighted data. 
If MRI can reliably quantify disease severity in acute colitis and rapidly detect changes 
in response to therapy, it could have a useful role in informing clinical management 
decisions, providing more objective measurement of clinical progress.  
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The aim of this study is to establish if quantitative MRI mural parameters correlate with 
clinical markers of inflammation and to assess changes in these parameters in response 
to therapeutic intervention.  
3.3.2 MATERIAL AND METHODS  
Twenty one patients recruited for previous study  (Chapter 3.3) were also included in 
this study. Patient demographics have been described in detail in section 3.2.2. All these 
patients were admitted to hospital (UCLH) with acute colitis and satisfied the inclusion 
criteria of acute colitis of Truelove and Witt’s. 14 patients had an unprepared MRI 
within 48 hours of admission and 18 within 72 hours of admission while remaining 3 
patient had MRI after 5, 7 and 9 days respectively. They were started on medical 
therapy as described in table 31. As part of clinical assessment a daily stool chart was 
maintained and CRP level was checked regularly after initiation of medical therapy. 
These two clinical markers were used to calculate the fulminant clinical index FCI, 
which has been previously used as a predictor in clinical trials (250). 
FCI= Stools +0.14xCRP 
A repeat MRI was performed at a median of 5 days (range 3-7) after first MRI in 
fourteen patients. 
3.3.2.1 MRI protocol  
All patients were fasted for two hours prior to MRI and they all had intravenous 
spasmolytic Buscopan 0.3mg/kg (maximum 20 mg).  Images were acquired in the prone 
position with a 1.5T Siemens Avanto (Avanto; Siemens, Erlangen, Germany) magnet 
using the body and spine array coils.  
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• A coronal and axial Half Fourier Acquisition Single Shot Turbo Spin Echo 
(HASTE) of abdomen and pelvis  
• Axial and coronal T2 weighted dual spin Echo (T2 quantitation) 
• Coronal free-breathing echo planar diffusion weighted images (EPI-DWI) with 
incrementing ‘b’ values (0,50,200 and 400). 
• Pre – contrast three breath-hold coronal fat saturated 3D Fast Low Angle Shot 
(FLASH) images of the abdomen and pelvis with different excitation flip angles 
(flip angles 5°, 10°, and 35°) (table 23) 
• Prior to intravenous contrast administration, three 3D FLASH baseline sets of 
coronal images were acquired during suspended inspiration 
• A single dose of (0.2 mg/Kg) IV gadoterate meglumine (Dotarem; Guerbet 
Roissy, France) was then injected into an arm vein at 3 mL/sec, followed by a 
saline chaser (10 mL). 
• At injection the patient was asked to hold his/her breath for 20 seconds (during 
which a single 3D FLASH volume dataset was acquired), followed by 10 
seconds of gentle breathing, immediately followed by another 20 seconds breath 
hold acquisition and 10 seconds of gentle breathing. The acquisition protocol 
was repeated to generate a total of 8 post contrast 3D FLASH datasets. 
 
 
 
 
\ 
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 HASTE EPI-DWI 
FOV Variable* HASTE matched 
Slices 19-27 19-27 
Stacks 1-2 1 
TR (ms) 1200 7900 
TE (ms) 52 82 
Matrix 256x196 192x154 
Slice thickness (mm) 4 4 
Interslice gap (mm) 5.2 5.2 
Averages 4 1 
Echo train 256 n/a 
iPAT 2 2 
‘b’ value n/a 0,50,200,400 
*to encompass patient anatomy  
             Table 29: MRI protocol  
3.3.2.2 Data Analysis 
Data analysis was performed on Images using open source OsiriX medical imaging 
platform (http://www.osirix-viewer.com) as described in section 3.1.2.3 and 3.2.2.6 by 
thesis author (Rehana Hafeez) after dividing colon into six segments. Single freehand 
linear Regions of Interest (ROIs) were located in the colonic wall of all six segments on 
the T2 weighted, T1 weighted and diffusion weighted images as detailed below. In case 
of fourteen patients who had a repeat scan after medical treatment ROIs were placed 
carefully to match those placed pre treatment.    
 167 
3.3.2.2.1 T2 weighted images  
Pre treatment and post treatment ROIs were placed on T2-HASTE coronal fat saturated 
images in each of the 6 colonic segments. The mean ROI signal intensity (SI) was 
recorded for each of six segments in every patient. Average T2 signal intensity and 
Maximum T2 values for each patient were recorded. A single CSF- ROI was also 
placed in each patient and ratio between Av T2 and CSF SI was calculated (Figure 38).  
3.3.2.2.1 T1 weighted images  
Pre treatment ROIs were placed on T1 weighted images both pre contrast and post 
contrast in the 21 patients pre treatment and 14 patients had post treatment. As detailed 
in section 3.1.2.4, the signal from the three pre-contrast baseline acquisitions for a given 
ROI was averaged, provided a single pre –contrast ROI signal intensity for each colonic 
segment. T1 was calculated for each segment and at each of the 8 post contrast time 
points in Microsoft Excel for Mac (2011) using the expression for the evolution of 
signal intensity in spoiled gradient echo and solving for T1 (230). The T1 relaxation rate 
(R1) was derived by 1/T1 (Figure 25). 
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Figure 25 a & b: Pre treatment and post treatment T2- ROI 
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Figure 26: ROIs-Pre treatment pre contrast P0 (a) post contrast P3 (b) 
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Figure 26 c & d: Post treatment P0 and P3 
 
 
 171 
3.3.2.2.2 Diffusion weighted images 
Full diffusion weighted image datasets were available in 18 patients pre treatment, and 
13 post treatment. Single mural ROIs were placed in abnormal colonic segments after 
review of T2 weighted images. The average signal intensity from each ROI was 
recorded and apparent diffusion coefficient (ADS) was calculated by exponential fitting 
to the 4 increasing ‘b’ value signal intensities using a standard least squares regression 
model incorporated in Microsoft excel.  
 
 
Figure 27 a: Calculation of ACD by exponential fit of ROI signal intensity  
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Figure 27 b: 
ROI Sigmoid 
colon b0 
Figure 27 c: 
ROI- sigmoid 
colon b50 
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Figure 27 b-e: Sigmoid colon ROI’s on diffusion weighted imaging   
 
 
 
 
Figure 27 d: 
ROI- sigmoid 
colon b200 
Figure 27 e: 
ROI-sigmoid 
colon b400 
 174 
3.3.2.3 Statistical Analysis 
The MRI quantitative parameters were compared with the fulminant colitis index (FCI) 
before and after the treatment by using spearman rank correlation. 
In particular an average colonic T2 signal, maximum segmental T2 signal and ratio 
between T2 and CSF intensities were calculated for each patient. In addition based on 
the enhancement curves generated in normal colon (chapter 3.1), time point P3 post 
contrast was taken to represent the peak of contrast enhancement. The pre contrast (P0) 
R1, P3 R1 and P3-P0 R1 were calculated. The average and maximum colonic ADC was 
also calculated for correlation with the FCI 
MRI parameters were compared before and after treatment by using the paired t test. 
 
3.3.3 RESULTS 
Pre treatment and post treatment CRP and stool frequency was used to calculate a 
clinical index – 
FCI pre treatment= 16.65 (range 8.24-32.19) 
      FCI post treatment= 8.43 (range 3.7-16.96) 
3.3.3.1 Correlation between FCI and T2 weighted imaging  
FCI was not significantly correlated with Average T2 signal, Maximum T2 segmental 
signal or T2/CSF ratio (Table 30). 
 
 
 175 
 FCI Av T2 Max T2 T2/CSF 
Pre treatment (n) 16.65 
(21) 
309.366 
(21) 
456.211 
(21) 
0.4097 
(21) 
Correlation  r=  -0.133203 
p=0.5618 
r=0.051 
p=0.826 
r=0.155296 
p = 0.4983   
Post treatment (n) 8.43215 
(13) 
259.140 
(13) 
361.511 
(13) 
0.14558 
(13) 
Correlation  r=0.028 
p=0.928 
r=0.203297 
P = 0.4935  
 r= -0.120879 
P = 0.4935  
Table 30: Pre and post treatment correlation between FCI, Av T2, max T2 and T2/CSF 
 
3.3.3.2 Correlation between FCI and T1 weighted imaging 
No correlation was found between FCI and Average pre contrast R1 (P0) and post 
contrast R1 (P3) (table 39) However there was a significant correlation between (P3-P0) 
and FCI. Post treatment both pre (P0) and post contrast (P3) R1 correlated with FCI but 
not P3-P0. 
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 FCI P0 R1 P3 R1 P3-P0 R1 
Average Pre treatment (n) 16.65 
(18) 
367.781 
(18) 
196.065 
(18) 
163.241 
(18) 
Correlation   r=0.420 
p=0.074 
r=0.240491 
P =0.3467  
r=0.581612 
P = 0.0126   
 
Average Post treatment (n) 8.432 
(13) 
285.791 
(13) 
159.893 
(13) 
125.898 
(13) 
Correlation  r=0.634 
p=0.049 
r=0.872 
p=0.001 
r=0.427 
p=0.219 
Table 31: Pre and post treatment correlation between FCI, Av P0 R1, Av P3 R1 and P3-
P0 R1 
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Figure 28: scattered graph between pre treatment FCI and P3-P0 R1 
 
 
Figure 29: scattered graph between FCI and pre contrast (P0) R1 after medical treatment  
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Figure 30: post treatment scattered graph between FCI and P3 R1 
 
3.3.3.3 Correlation between FCI and Diffusion weighted imaging 
Average ADC and maximum ADC value was calculated for each patient (18 pre 
treatment and 13 post treatment). No significant correlation was found between FCI and 
ADC value (Average or Maximum) before or after medical treatment. 
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 FCI Av ADC Max ADC 
Pre treatment  
(n) 
15.6 
(18) 
0.001610 
(18) 
0.003572 
(18) 
Correlation  r=0.321 
P = 0.194 
r=-0.080 
P = 0.752 
Post treatment  
(n) 
8.432 
(13) 
0.001260  
(13) 
0.002777  
(13) 
Correlation  r=-0.453 
p=0.121 
r= -0.384615 
P = 0.195  
Table 32: Pre and post treatment correlation between FCI, Av ADC and max ADC 
values 
3.3.3.4 Change in MRI quantitative parameters after medical therapy 
There was significant difference in Av T2 values before and after the treatment in the 14 
patients who has repeat MRI (Mean of difference = 58.824, SD = 59.415, SE= 15.879, 
95% CI= 24.519 to 93.129 and p=0.003). Similarly, Max T2 fell significantly after 
treatment (Mean difference= 115.087, SD= 165.60, SE= 44.259, 95% CI= 19.470677 to 
210.704466 and p= 0.02). However, the T2/CSF ratio was not significantly different 
(Mean difference= 0.0419, SD= 0.1201, SE= 0.032,95% CI= -0.027467 to 0.111329 
and p= 0.21). There was no change in either Av or max ADC after treatment (p=0.85 
and p=0.24 respectively).  
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Pre contrast R1 decreased after medical therapy (Mean diff 121.960, SD= 96.78, SE= 
29.182, 95% CI = 56.939 to 186.98 and p=0.002), post contrast R1 at P3 also decreased 
significantly (Mean diff 79.091, SD=84.832, SE=28.277, 95% CI= 13.883 to 144.299 
and p=0.023) and similarly there was significant difference in P3-P0 R1 after treatment 
(Mean diff 55.137, SD=66.699, SE= 21.092, 95% CI= 7.4233 to 102.850 and p =0.028).  
 
 
 
Figure 31: AvT2, Max T2 and T2/CSF before and after treatment (with 95% CI).  
                Pre treatment  Post treatment  
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Figure 32: P0, P3 and P3-P0 before and after medical treatment (with 95% CI) 
                 Pre treatment  Post treatment  
 
 
Figure 33: Difference of Av ADC and Max ADC before and after medical therapy. 
                  Pre treatment  Post treatment  
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3.3.4 DISCUSSION  
The art of medical decision making between the gastroenterologists and surgeons in 
managing acute colitis is to avoid operating in a patient who would eventually have 
responded to medical therapy and also to avoid undue surgical delay with the associated 
higher rates of morbidity and mortality due to complications such as peritonitis, sepsis 
and organ failure. There is no universally accepted simple objective score or marker or 
modality that can reliably predict prognosis and thereby help in clinical decision 
making. 
In this study different quantitative MRI parameters have been analyzed with regards to 
their ability to assess disease activity in comparison to a clinical index based on stool 
frequency and CRP. No significant correlation is found except between fulminant 
clinical index and contrast enhancement.  
As noted in preceding chapters, the use of quantitative measures of contrast 
enhancement as a marker of inflammation is not clear cut. However this study clearly 
supports its use and concurs with several other studies in the literature. For example, 
Low et al (157) used wall thickness and mural enhancement as criteria and found 
superiority of MRI in comparison to CT for depiction of disease bowel segments even 
in those with mild disease. Similarly, Koh et al (158) also found bowel wall 
enhancement (particularly in a layered pattern) to be highly specific for active 
inflammation in CD. Miao et al (150) described bowel wall thickening, contrast 
enhancement and mesenteric stranding as the best MRI parameters to determine  CD 
activity and Laghi et al (151)  reported high concordance between parietal contrast 
enhancement and endoscopy and histological scoring of inflammation in children with 
CD. Maccioni and colleagues (139) also found positive correlation between biological 
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active disease and bowel wall contrast enhancement together with wall hyperintensity 
on T2 weighted fat suppressed images  
As noted in chapter 1.3, Rimola et al (16, 187) found relative contrast enhancement in 
addition to wall thickness as the independent predictor of endoscopic disease activity 
and for presence of ulcers. Conversely other studies have no such relationship between 
enhancement and activity. Schunk et al (149) found increased contrast enhancement in 
diseased segments of bowel in comparison to normal segments, but poor correlation 
with CDAI and CRP. Similarly, Taylor et al (154) found a positive correlation between 
disease chronicity and contrast enhancement ratio (correlation coefficient 0.82, p0.002) 
but not with acute or chronic inflammation scores.  
Neoangiogenesis is an intrinsic part of chronic inflammation and leads to structural 
changes including capillary and venule remodeling. This results in expansion of tissue 
microvascular bed and in increases microvascular permeability.  
The effect of increased vascularity on R1 after gadolinium administration is fully 
explored in the section 3.1, but to summarize an increase in vascular surface area and 
permeability in inflamed bowel will increase the intra and extra vascular water pool 
upon which gadolinium can act, thereby increasing relaxivity rate and increasing signal 
post contrast. In chapter 3.1 I presented data demonstrating inter segmental differences 
in mural enhancement of normal colon. It would be interesting to “correct” segmental 
enhancement for these difference to see if the correlation with clinical indices of activity 
becomes stronger. 
One perhaps unexpected finding was the fall in pre contrast R1 after treatment. 
Intuitively treatment should reduce mural edema and a rise in relaxivity rate and T1 
signal would perhaps be expected. It is possible however the pretreatment R1 was 
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influenced by mural hemorrhage -clearly bleeding is part and parcel of acute severe 
colitis. The degree of mural hemorrhage would be expected to decrease with treatment, 
perhaps explaining the observed drop in R1.  
The fall in mural T2 signal after treatment lends weight to the theory that it is a 
biomarker of inflammation (likely related to mural edema), despite the lack of direct 
correlation with the FCI. Punwani et al (212) have clearly demonstrated that T2 signal is 
a strong predictor of inflammatory activity in surgical resection specimens and the 
apparent robustness of the TCIS (chapter 3.3), which is heavily based on qualitative 
grading of mural T2 signal, also supports its role. Furthermore I have shown that the 
score of Steward et al (234),which is based on T2 signal and wall thickness alone 
correlated with endoscopic CDEIS (chapter 3.2). It is perhaps surprising therefore that 
the present study found no correlation between T2 signal and the FCI. By way of 
explanation, FCI is at best a rather imprecise reference standard, although in cases of 
severe acute colitis where colonoscopy is relatively contra-indicated there are few 
alternatives. Furthermore there are undoubted problems with quantitative measurements 
of bowel wall as it is thin and measurements are prone to error. I tried to limit this by 
using linear (rather than rounded) ROIs to fit the bowel wall contour, but clearly motion 
and partial volume artifacts will increase ROI errors. My data suggests that qualitative 
grading of the colon wall signal by radiologists may be more robust than quantitative 
measures based on ROI placement.  
Diffusion weighted imaging makes use of the variability of the “ Brownian motion of 
water molecules” in the tissues which is random. Water molecules are in continuous 
movement and the rate of this motion or diffusion depends on the kinetic energy of 
molecules and is temperature dependent. The concept of ADC was introduced to take in 
account the fact that the diffusion process is complex in biological tissues and can be 
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affected by many factors such as blood flow in small blood vessels and chemical 
interaction of water with other macromolecules, which can limit or restrict the amount 
of diffusion. A low ADC corresponds to high signal intensity/restricted diffusion and 
high ADC means low signal intensity/more diffusion on these images. Diffusion 
weighted imaging derives its image contrast from difference in the motion of water 
molecules between tissue so making ADC directly proportional to the amount of 
diffusion.   
Diffusion weighted imaging has developed a role in neuroimaging (251). Recently its 
role in assessment of colonic inflammation has been investigated. Kiryu et al (252) 
reported high accuracy of DWI in evaluation of disease activity as they found lower 
ADC values in active diseased segments than inactive segments. Oussalah et al (183) 
DWI hyperintensity as a predictor of colonic endoscopic inflammation with greater 
accuracy in UC than CD. Oto and colleagues (253) compared DWI with finding of 
colonoscopy and surgery in patients with CD and found decreased ADC values in 
inflamed bowel segment reflecting restricted diffusion. In the present study, there was 
no rise in the value of ADC after treatment and when compared to FCI no significant 
correlation was found. As mentioned above placement of ROI on bowel wall is prone to 
error and additional to that it is not easy to visualize minimally inflamed bowel or 
normal bowel wall on high ‘b’ value sequences. Furthermore, lack of correlation with 
FCI is partly due to the fact already discussed that FCI itself is not a sensitive predictor 
of colonic inflammation.  
In conclusion, contrast enhancement seems the most robust quantitative MRI 
parameters assessing activity of acute colitis in IBD. 
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4 SECTION FOUR: PATIENT EXPERIENCE 
AND ACCEPTABILITY OF MRI  
4.1 PATIENT EXPERIENCE OF 
MRCOLONOGRAPHY AND COLONOSOCPY- A 
QUALITATIVE STUDY 
4.1.1 INTRODUCTION 
Diagnostic performance is the major determinant for uptake of any radiological 
investigation but its acceptability to patients is also an important consideration. This is 
especially relevant in IBD, given the need for repeated colonic examination over the 
course of disease. Patient acceptance is influenced by several factors, including test 
expectations, comfort, overall satisfaction and diagnostic performance. Whilst it is 
assumed that patient acceptance of MRC is higher than colonoscopy, this is based on a 
limited number of studies as discussed in section 1.3.3.6.  
However, existing data has limitations. In particular, it is premature to use quantitative 
techniques whereby researchers create structured questionnaires based on their own pre-
conceived expectations of factors relevant to patients’ experiences. Such an approach 
prevents patients from describing expectations, experiences and preferences in their 
own words. For example, a recent qualitative investigation of patient experience of 
colonoscopy and CT colonography (254) revealed important differences in patient 
experience of staff interactions, previously not considered by the authors, but which had 
important implications for the associated test anxiety.    
Furthermore, the influence of clinical indication has received little attention to date. It is 
perfectly possible that IBD patients who undergo routine colonic surveillance will have 
different expectations and priorities than non IBD patients referred for one-off colonic 
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investigation. Baseline studies with less structured qualitative methods in different 
patient groups are therefore essential to develop comprehensive quantitative 
assessments for new diagnostic tests. The aim of this study was to apply qualitative 
techniques to assimilate data on patient experience and attitudes during MR 
Colonography and Colonoscopy and to evaluate how this is moderated by clinical 
indication.  
4.1.2 MATERIALS AND METHODS 
Between October 2007 and October 2008, 11 male and 7 female patients (median age 
40.5; range 17-65 years) were recruited from the MRC study described in chapter 3.2, 
comparing MRC with same day CC. Patients referred for routine CC were invited to 
undergo MRC approximately 2 hours beforehand. Of the 18, 10 patients had known 
colonic IBD, (8 ulcerative colitis and 2 = Crohn’s disease, 7 males and 3 females, 
median age 35 yrs.’; range 17-61), and were being assessed during a clinical flare (n=6) 
or undergoing general surveillance (n=4). Eight patients (4 males & 4 females, median 
age 48, range 26-65) were undergoing investigation for suspected colonic neoplasia 
(change in bowel habit n=3, rectal bleeding n=3, and prior history of colonic polyps 
n=2). All IBD patients experienced at least 1 prior CC compared to just 2 in the non 
IBD group (for polypectomy). None had undergone prior MRC; although 2 IBD 
patients had undergone MRI enterography before and 2 non IBD group patients had 
undergone MRI for other reasons (knee and spine). 
 
All patients underwent full bowel purgation the day before CC. (Appendix C) 
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4.1.2.1 Patient information 
Patients all received the standard colonoscopy information sheet, explaining the 
procedure including use of sedation and analgesia.  
The information sheet pertaining to MRC described the colonic distension with water, 
need for intravenous Gadolinium injection and the lack of ionizing radiation. The 
perforation risk from MRC was stated as less than 3 in 10,000 and total duration of test 
as 30 minutes (Appendix D).  
4.1.2.1.1 Procedures  
4.1.2.1.1.1 MR Colonography.  
The thesis author performed MRC 2 hours before subsequent CC. MRC technique and 
protocol described in appendix C.  
The procedure took between 20 -30 minutes after which the water was allowed to drain 
back into the enema bag. Patients were then escorted to endoscopy suite.  
4.1.2.1.1.2 Colonoscopy 
Colonoscopy was performed by experienced operators (2-10 years). Intravenous 
sedative (Midazolam 50 microgram/ kg, max 10mg and Fentanyl 100 mcg) was 
administered. Multiple biopsies were taken in those with IBD. Among non IBD 
patients, 3 had polypectomy and the remaining five had multiple ileocolonic biopsies to 
exclude microscopic colitis. The procedure took an average of 45 minutes. Patients 
were provided with refreshments prior to discharge.  
4.1.2.1.1.3 Patient Interviews 
All patients were interviewed by the thesis author prior to discharge. The interview 
schedule was constructed in collaboration with a health psychologist (C von Wagner) 
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with considerable experience of assessing patient experience of diagnostic procedures. 
Interviews were semi-structured allowing freedom of expression by patients regarding 
their experience and concerns. Key aspects of each procedure (e.g. anxiety, safety 
concerns, embarrassment, discomfort, interaction with staff and feedback of results) 
were identified prior to the interviews in order to allow direct questioning if not 
mentioned by the patient do novo.  
Interview transcripts were analyzed using standard thematic analysis (254) which is the 
most commonly used method of qualitative analysis which involves searching through 
the data to identify any recurrent patterns. A theme is a cluster of linked categories 
conveying similar meanings. Analysis was done by the thesis author and Christian Von 
Wagner, to assimilate individual patient experiences into broad descriptive groups of 
concerns and interests thus, facilitating overall interpretation of the data. In particular, 
the data was coded by identifying recurrent themes related to patient perception of their 
experiences. As codes were accumulated, they were grouped into more general themes 
by the researchers (thesis author and C von Wagner) 
4.1.3 RESULTS 
Three main themes emerged from the thematic analysis:  
• Physical experience  
• Information provision  
• Overall preference 
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4.1.3.1 MR Colonography  
4.1.3.1.1 Physical experience  
All patients in general expressed mixed views about the physical experience of MRC 
and several themes emerged. 
4.1.3.1.1.1 Water filling 
Most patients (both non-IBD, 4/8 and IBD 8/10) described water filling as either 
uncomfortable or painful and frequently described it as problematic. Filling was mainly 
associated with episodic cramps, which were mild and tolerable for most e.g. “For me 
whole procedure was ok, you do feel little pressure of water filling inside but no pain.” 
(IBD patient, male, 29). However, for a sub-group of patients it was intolerable e.g. “It 
became quite painful as water was filling in my stomach. It was not pleasant as pain 
was coming and going. They gave me some injection which made it better for some time 
but pain came back again and gradually became unbearable.” (Non-IBD patient, 
female, 26).  
In addition, three patients (2 IBD and 1 non-IBD) expressed anxiety and worry 
regarding potential incontinence of the water enema. For example “It was ok except the 
fluid part, its not a good feeling when water is filling and moving inside, giving the 
worry that I couldn’t hold it and mess can happen” (IBD patient, male, 44). Only one 
patient (non-IBD) actually suffered incontinence suggesting it was the fear of 
incontinence that was important.  
4.1.3.1.1.2 Breath holding  
Four patients (three IBD and one non-IBD) found it difficult to hold their breath and/or 
coordinate with the instructions and timings given “Sometime breathing was difficult to 
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coordinate as there was not much time in between for normal breath”(IBD patient, 
male, 34). “ Holding the breath was hard specially for such a long time, although near 
end it became easy, maybe I got use to it” (IBD patient, female, 36). 
4.1.3.1.1.3 Lying still in MRI scanner 
IBD patients (5/10) in particular described lying in the MRI scanner and restriction of 
movements as uncomfortable. One patient suggested the use of a TV as distraction 
“Lying in same position for an extensive time period and not been able to move is very 
uncomfortable and in addition there is some weight on your back for the scan, gets 
unbearable after approximately 20 minutes. There should be something in the room for 
distraction during scan, something like a TV even without the sound as you have to hear 
the breathing instruction as well” (IBD patient, male, 61). 
4.1.3.1.2 Information provision 
Patients mentioned that they would have preferred instructions about times during 
examination when they would be able to relax their posture.  
4.1.3.1.2.1 Scanner noise 
The noise of the scanner interfered with understanding of instructions, particularly 
amongst non-IBD patients (4/8) who may have been less familiar with diagnostic tests 
“The noise and vibration of the MRI machine, was surprising and disrupted 
communication of instructions” (Non IBD patient, male, 48).   
4.1.3.1.2.2 Information dissemination and uncertainty  
Patients expressed mixed opinions about feedback of the test result, although most did 
comment on the need to wait for the formal MRC report. Non-IBD patients (6/8) 
however expressed greater anxiety over this delay, “you don’t get any report, I have to 
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wait for my clinic appointment but If you can get report same day it can give some 
peace of mind” (Non-IBD patient, female, 34).  
Another mentioned: “There was no feedback, I have to wait for the report, but I would 
like to know as early as possible” (Non-IBD patient, female, 38).  
Conversely, the IBD group (4/10) expressed less anxiety, “They didn’t give me any 
feedback; I have to wait for my clinic appointment to discuss with the consultant. I know 
I have ulcerative colitis so, I am ok to wait to know how I am doing” (IBD patient, male 
40). 
4.1.3.1.2.3 Extra colonic findings 
Patients of both groups (12/18) were often of the view, that MRI was the more 
advanced, informative, and safe investigation. It is able to visualize extra-colonic 
organs, “There are few things about MRI- it is very advanced technology by which you 
can see not only one part of tummy but whole of it, which I think is very good to have at 
one time and there are fewer risk factors, as chance of perforation is very small” (Non-
IBD patient, male, 48).  
4.1.3.2 Colonoscopy 
4.1.3.2.1 Physical experience 
Opinions were mixed but compared to MRC the emerging themes were less varied and 
concentrated around; air insufflation, colonoscopic manipulation (particularly 
discomfort below the ribs), and taking of biopsies. As detailed below, despite their 
familiarity, IBD patients more frequently reported discomfort or pain during CC than 
non-IBD patients did, particularly during endoscope manipulation.  
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4.1.3.2.1.1 Pain during colonic insufflation 
 Patients in both groups (13/18) mentioned discomfort or pain to some degree during air 
insufflation. “It was painful continuously not like MR where cramps were episodic, it 
was severe and all over the tummy. Although it was intolerable they did complete the 
procedure” (IBD patient, female, 26).  
4.1.3.2.1.2 Colonoscopic manipulation 
Both IBD and non-IBD patients associated discomfort/pain with movement of scope 
particularly amongst the IBD group in which 9 of the 10 patients specifically mentioned 
painful episodes during the procedure “It was continuously painful- very bad pain and I 
think it was happening as they were moving that scope inside” (IBD patient, female, 
17). 
Fewer non IBD patients (4/8) also reported pain or discomfort.” There was discomfort 
few times during the test. I think it was due to movement of tube, for few minutes and 
not continuous.” (Non-IBD patient, female, 38).  
 
Sedation was important moderator of the experience “I went to sleep during the test but 
when I woke up at some point I felt some dull pain, only for 5-6 minutes” (IBD patient, 
male, 61). 
4.1.3.2.2 Information provision 
4.1.3.2.2.1 Test Result Feedback 
 Patients were more satisfied with the feedback they received during and after CC as 
compared to MRC. They noted the ability to observe the same screen as the physician, 
whilst, receiving an explanation from the medical team as well either immediately or 
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later in recovery. “I was able to see on screen which was fascinating and doctor did 
explain to me as well that everything was normal” (Non-IBD patient, female, 40). Some 
of the patients (both IBD and non-IBD) however, did not find this feedback particularly 
reassuring, in part due to persistent effects of sedation and lack of full comprehension 
“They did explain to me a few things but I can’t remember as I was not very alert due to 
sedation” (IBD patient, male, 44). 
4.1.3.3 Overall preference  
There were divergent views regarding which of the two procedures patients preferred 
overall and the most important factors influencing their choice.  
Of the 18 patients, 10 (56%) stated an overall preference for MRC and 5 (28%) 
preferred CC. Three patients (17%) did not express any preference, as both tests were 
very painful and preferred to leave the decision to the clinician. Among IBD group five 
patients (50%) preferred MRC, three (30%) preferred CC while two (20%) had no 
preference. On the other hand five non IBD patients (62.5%) had preference for MRC, 
two (25%) for CC and one patient (12.5%) expressed no preference.  
The reasons for preferences were mixed (Table 41). In particular, patients had differing 
views of which test was more uncomfortable and how this influenced their preference. 
Duration, safety, perceived diagnostic capability and ability to take biopsies were all  
noted as specific reasons underpinning stated preferences.    
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Preference for MRC Preference for CC 
After reading the information and having 
the both test I think MRI is safer and more 
informative. (Non IBD patient, male, 65) 
 
 
MRC was quicker than CC, no sedation was 
involved so nobody needs to come to take 
you home. (IBD patient, female, 36) 
 
One thing it was more comfortable and I 
think there are fewer risks with it as it is 
only water going into your body through a 
small tube but in colonoscopy tube is very 
big.  
(Non-IBD patient, male, 55) 
It can give more information and it is less 
invasive. (IBD patient, male, 63) 
After my experience I would prefer MR. 
They both are good and MR is more 
embarrassing but I think it can give more 
information as compared to colonoscopy. 
Colonoscopy. One reason is being less 
painful and other I think they can take 
biopsies, which can be more helpful for 
the diagnosis and treatment later. (Non 
IBD patient, female, 48) 
For me colonoscopy was easier and total 
time period for the test was shorter as 
compare to MR. Things during MRI like 
breathing instructions are difficult to 
follow specially being on your tummy. 
(IBD patient, male, 61) 
It was more comfortable 
 (Non-IBD patient, female, 36) 
For me both tests are ok but colonoscopy 
is more comfortable and you have 
sedation for it, which you don’t have in 
MRI. (IBD patient, male, 44) 
 
I would say both are good tests but MR is 
painful and colonoscopy more 
comfortable although I thing you can get 
more information through MR but I will 
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You can take a biopsy during colonoscopy, 
which is beneficial but dangerous as it can 
damage bowel. (Non-IBD patient, 38 
female) 
MRI was less invasive just a small tube and 
water but in colonoscopy one thing tube is 
bigger and then they take biopsy which is 
more invasive, there is more manipulation 
in it as well. MR (Non-IBD patient, male, 
57) 
prefer CC. (IBD patient, 41, male) 
 
 
 
Table 33: Example quotes pertaining to test preference  
4.1.4 DISCUSSION 
It is clear that patient experience of both MRC and CC is complex and influenced by 
many factors. The study included patients from two different groups, those with IBD 
and patients with clinical suspicion of bowel neoplasia (non IBD group).  
Most of the prior quantitative studies of MRC and CC experience have included 
questions on procedural discomfort. Achiam et al (124) used a 5- point pain scale and 
indicated significantly greater discomfort during CC than MRC, a similar finding to 
Florie et al (179) who also grouped pain into 5 categories from “none” to “extreme”. In 
this qualitative study, pain was mentioned more frequently with CC than MRC. All the 
IBD patients had at least one previous experience of CC but despite this familiarity, 
they more frequently reported discomfort during CC. The reported beneficial effect of 
sedation was a common theme and supported by findings from similar samples (181). 
However, colonic distension with water during MRC was very unpleasant for some, 
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although the differing degree between individuals was striking, ranging from “a little 
pressure” to “unbearable”. Using a structured questionnaire in 171 patients, Florie at el 
(179) also reported that 51% of patients felt colonic filling was the most “burdensome” 
part of MRC.  
I also found that the need to lie still during the MRI is more problematic than previously 
described, particularly for IBD patients. In addition, the intrusive nature of the MRI 
scanner noise was noted by several non IBD patients, again a facet of the examination 
not reported in prior quantitative work.  
 
Although only 1 of the 18 patients suffered any incontinence during MRC but fear of 
incontinence was stated by several, which is a disadvantage compared to CC. 
An interesting outcome of the study is the reported difference in perceived feedback 
during MRC and colonoscopy. The ability to view the procedure was a distinct 
advantage of colonoscopy, together with the immediate diagnostic feedback either 
during the procedure or before discharge. This was particularly noted by the non-IBD 
group, undergoing investigation for suspected colorectal neoplasia, supporting previous 
work describing patient’s preference for early feedback, especially in cases of suspected 
cancer (255). This may explain lower anxiety levels within IBD patients, with known 
diagnosis and generally not considering a diagnosis of cancer.  
 
An important limitation of the study is that patients were not provided with explicit 
information on the comparative diagnostic accuracy of MRC and CC. Previously in 
comparison of CT Colonography and CC, relative diagnostic performance had a major 
influence on overall patient preference (256). However, I was still able to elicit 
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interesting perceptions from patients about the diagnostic capabilities of MRI such as a 
“new”, “expensive” and “superior” technology as compared to CC.  
Patients perceived the ability of MRI to visualize beyond the colon as a definite 
advantage, along with its superior safety profile. This supports the findings of prior CT 
colonography research (254) that patients are intrigued by the ability of modern 
scanners to image organs outside the large bowel. However, patients are often unaware 
that this may sometimes trigger subsequent tests to investigate unexpected findings.  
There are of course strong parallels between CT colonography and MRC in this respect.  
 
Although there was a slight overall preference for MRC, this tendency was not strong. 
Furthermore, a large range of factors influenced patients’ preferences with marked 
inter-individual differences. Simply asking patients “preference” in quantitative studies 
is overly simplistic giving the complexity of underlying determinants of patient opinion.  
 
This study had built on the existing literature regarding comparative patient experience 
during MRC and CC. By using qualitative methods I have identified new aspects of 
MRC, which directly impact on patient preference including the need to lay still, noise 
from the scanner, fear of incontinence, delayed diagnostic feedback and perceived 
diagnostic performance of the “new technology”. Although the study included a small 
sample size, this is the norm for a qualitative study like this and useful information has 
been gleaned. However further study using a larger sample size may well be worthwhile 
given the wide range of patient opinions found. I also acknowledge that MRC is a 
developing technique with a multitude of approaches advocated for bowel preparation 
(full or reduced), colonic insufflation (liquid or gas) and MR sequence selection. This 
 199 
data may not therefore be directly applicable to institutions using differing MRC 
protocols. 
I did find clear differences in the importance of these factors to patients with differing 
clinical indications. Such data has important implications with regards to the provision 
of patient information for those undergoing MRC. Focus should be placed upon 
increasing the detail and relevance of information media. It can also assist the design of 
future quantitative measures of patient experience, by incorporating the additional 
dimensions and considering clinical indications to allow sub-group analysis. These 
findings should also be followed up by more direct ways of testing patient preferences 
using strategies such as conjoined analysis and discrete choice modeling, a procedure 
used frequently for health economic research. Data gathered in the study would be 
instrumental when asking people to balance risks and benefits associated with invasive 
and non-invasive testing modalities.   
 
In conclusion, patient experiences of MRC are complex. The assumption MRC is better 
tolerated and preferred to CC is not valid for all patients. Individuals place differing 
personal weightings on the relative importance of test attributes, which defines overall 
test preference. Informed discussion prior to requesting specific colonic investigations 
would likely improve current clinical practice.  
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4.2 ASSESSMENT OF PATIENT ACCEPTANCE OF 
MRCOLONOGRAPHY VS COLONOSCOPY  
 
4.2.1 INTRODUCTION 
In the previous chapter, I used interviews and qualitative techniques to identify which 
aspects of MRC and endoscopy were least acceptable to patients, and which factors 
influenced preference. 
My findings were that patient experience of investigations is complex and in part 
dependent on previous experience of investigation and the target lesion (i.e. potential of 
malignancy or know benign IBD). The potentially shorting comings of researcher-
designed questionnaires were also highlighted-important facets of patient experience are 
often excluded by questionnaire devised by medical staff. Never the less, patient 
experiences of colonoscopy have received considerable attention in the past. 
Questionnaires have been developed based on the process of principal component 
analysis following patient interview (as I did in the previous chapter for MRC). One 
such questionnaire is widely used in assessing experience of endoscopy has been 
devised by Salmon et al (244, 257). Indeed this questionnaire has also been applied to 
radiological tests of the colon, including barium enema and CT colonography (244, 257, 
258). As previously discussed in session 1.2.3, colonoscopy is the gold standard for 
diagnosis and disease assessment in IBD and other colonic pathologies but the 
procedure can have limited patient acceptance due the need of bowel preparation, pain 
and embarrassment.  If MRC is to be a viable alternative to colonoscopy, comparative 
patient acceptance must be at least as good as for colonoscopy, and ideally better due to 
its intrinsic limitations (e.g. inability to obtain biopsy tissue). In this chapter I formally 
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evaluate patient experience of MRColonography (MRC) in comparison to conventional 
Colonoscopy (CC) using the validated questionnaire devised by Salmon et al (244). 
4.2.2 MATERIALS AND METHODS 
Thirty one patients were recruited from the studies investigating the utility of MRC 
described in chapter 3.1 and 3.2. All patients underwent MRC prior to same day 
colonoscopy as described fully in these chapters. 
Among these nineteen patients were referred for colonoscopy for either confirmation of 
new clinical diagnosis of IBD or surveillance. Eight patients needed colonoscopy due to 
change in bowel habit and the remaining three patients had CC as part of polyp 
surveillance. 16 patients (13 IBD and 3 non IBD) had previous experience of CC but 
none of them had MRC before (Table 34). 
 
 IBD Non-IBD 
No of patients 19 12 
Age (mean, range) 25.5 (17-64) 42.33 (25-64) 
Females (mean age and 
range) 
9 (34.33, 17-50 yrs.)  6 (34.83, 25-47 yrs.) 
Males (mean age and 
range) 
10 (42.7, 30-64 yrs.)  6 (49.83, 40-64 yrs.) 
Table 34: Patient demographics  
 
A validated satisfaction questionnaire with 25 items (marked from 1to 7) presented 
together with their opposite was administrated after both tests (Appendix E). A higher 
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score reflects more positive response. These responses were grouped into 3 principal 
components (physical experience, worry and satisfaction) by the authors of the 
questionnaire. All the patients completed both the proformas before leaving the hospital 
and collected by thesis author. Overall patient preference was canvassed 2 weeks later 
(Appendix F). All patients were given the proforma to take home and were asked to 
post it after filling in stamped addressed envelope. In particular, the follow up 
questionnaire asked patients to grade the tolerance of both procedures  
Well/ fairly well/poorly/ very poorly 
They also selected the worst part of the procedure, noted the recovery time and listed 
any reasons for a longer time of recovery. Patients were also asked to express which 
investigation they found more acceptable and which they would prefer in future and if 
they would be willing to have each procedure again. 
4.2.2.1 Statistical Analysis 
Initial analysis of the seven-point questionnaire indicated that responses were skewed 
toward the upper end of the distribution so nonparametric methods were applied. Data 
regarding patient responses about MRC and CC was compared using Wilcoxon matched 
pairs and one-sample test of portions for follow up questionnaire.  
4.2.3 RESULTS 
All the patients filled the questionnaire before leaving the hospital and patient 
experience was grouped into three components  
1. Physical experience 
2. Patient worry 
3. Patient satisfaction 
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4.2.3.1 Physical experience 
Patients found CC overall physically less comfortable than MRC (Median 32 vs. 41, p 
0.031). For example, they reported they were more weary after CC (median 2 vs. 3 
p=0.05) had more soreness during the procedure (median 3 vs. 4 p=0.021), and 
preferred to be less awake during CC (1 vs. 3, p=0.007). They did however feel in better 
control during CC than MRC (median 6 vs. 7 p=0.053) (table 35, figure 34).  
Variable MRC 
Median  
(IQ) 
CC 
Median  
(IQ) 
Value of p 
Weary 3 (2,7) 2 (1,6) 0.05 
Pain 4(3,7) 3(2,7) 0.276 
Comfort 2(1,5) 2(1,3) 0.24 
Experience 4(3,7) 4(3,6) 0.107 
Control 7 (3,7) 6(3,7) 0.05 
Soreness 4 (2,7) 3 (2,7) 0.021 
Fool of self 7 (4,7) 7 (6,7) 0.211 
Relieved when 
over 
2 (1,4) 2 (1,3) 0.481 
Preferred to be 
more awake 
3 (1,4) 1(1,3) 0.007 
Sum 41(24,51) 32 (21,41) 0.031 
Table 35: Comparison of Patient’s physical experience during MRC and CC  
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Figure 34: Comparison of MRC and CC split according to the three main components  
 
4.2.3.2 Patient Worry  
Patients were considerably more worried during CC than MRC (2 vs. 6 p<0.001) and 
they were more concerned what would be found during CC than MRC (2 vs. 4 p= 0.01). 
However they did find MRC as not what they had expected compared to CC (3 vs. 1 
p=0.01). Overall patients were significantly more worried about CC than MRC (38 vs. 
46 p <0.001) (Table 36, figure 35). 
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Variable MRC 
Median  
(IQ) 
CC 
Median  
(IQ)  
Value of p 
Frightened 7 (4,7) 7 (2,7) 0.084 
Worried  6 (3,7) 2 (2,6) <0.001 
Agitated 7 (4,7) 7 (3,7) 0.22 
Worried what to 
find  
4 (2,6) 2 (2,6) 0.01 
As expected 3 (1,6) 1 (1,3) 0.01 
Understood 7 (4,7) 7 (5,7) 0.333 
Puzzled 7 (6,7) 7 (4,7) 0.221 
Confused 7 (6,7) 7 (5,7) 0.099 
Sum  46(37,50) 38 (29,47) <0.001 
Table 36: Comparison of patient worry about MRC and CC 
4.2.3.3 Patient satisfaction 
There was no significant difference in overall patient satisfaction after both procedures 
(p=0.17). They were equally satisfied about the staff interaction and information 
provision. They also expressed same level of confidence in staff for both the procedures 
and they felt equally dignified during both procedures as well (Table 37, figure 35). 
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Variable MRC 
Median  
(IQ) 
CC 
Median  
(IQ) 
Value of p 
Satisfied  7 (6,7) 7 (6,7) 0.068 
Staff interested  7 (7,7) 7 (7,7) 0.178 
Pleased 7 (6,7) 7 (7,7) 0.141 
Staff warm 7 (7,7) 7 (7,7) 0.109 
Staff 
informative 
7 (7,7) 7 (7,7) 0.028 
Dignified 7 (5,7) 7 (5,7) 1 
Interested  7 (7,7) 7 (7,7) 0.5 
Confidence 7 (7,7) 7 (7,7) 0.109 
Sum 53 (50,56) 55 (55,56) 0.177 
       Table 37: Comparison of patient satisfaction after MRC and CC 
4.2.3.4 Follow up Questionnaire  
Out of 31 total patients, the majority patients tolerated MRC well (17, 54.8%) or fairly 
well (7,22.6%) whereas 21(67.7%) tolerated CC well and 5 (16.1%) tolerated it fairly 
well (Figure 36). 
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Figure 36: Bar graph – patient tolerance for MRC and CC 
Regarding recovery time after MRC, the majority of patients recovered in less than one 
hour after the scan (18, 58.1%, p= 0.002). In comparison 12 (38.7%) patients took 
between 1-3 hours and 11 (35.5%) took more than 6 hours to recover after CC (Figure 
37 and 38). 
 
Figure 37: Bar graph representing patient recovery after MRC  
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Figure 38: Bar graph representing patient recovery after CC  
On inquiring about the worst part of these investigations, 23 (74.2%) patients found 
insufflation with water during MRC as the worst part while 14 (45.2%) patients found 
maneuvering of the colonoscope as the worst part of the procedure (figure 39 & 40). 
 
 
Figure 39: Bar graph representing worst part of MRC 
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Figure 40: Bar graph representing worst part of CC  
 
When patients asked about having either investigation again, 27 (87.1%) would have 
MRC again if required and 24 (77.4%) would have CC (p=0.3). For the majority of 
patients MRI was the most acceptable test (16, 51.6%) 11 patients (35.5%) viewed 
MRC and CC as equally acceptable and only 4 (12.9%) found CC as the most 
acceptable investigation (p=0.001) (figure 41). 
In terms of overall preference 14 (45.2%) patients selected MRC as the preferred 
investigation in comparison to (6, 19.4%) for CC whereas, 11 (35.5%) patient had no 
preference (Figure 42). 
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Figure 41: Bar graph representing patient’s selection of the most acceptable 
investigation 
 
 
 
Figure 42: Bar graph representing patients’ preference regarding future investigation.  
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4.2.4 DISCUSSION 
Different methods have been proposed for colonic examination with varying 
sensitivities and specificities. Colonoscopy stands as the gold standard at present both 
for IBD and non IBD patients. Despite its high sensitivity and specificity, the 
examination is invasive, with potentially serious complications. Furthermore, procedure 
related patient discomfort such as that caused by scope movement influences patient 
satisfaction and acceptance of test.  
Patient acceptance is influenced by several factors, notably anticipation about the 
investigation and previous experience. This has led to the assumption that patient 
acceptance would be higher with non-invasive examinations as compared to more 
invasive ones. 
Florie et al (179) used a five - point scale to assess physical experience of MRC (limited 
bowel cleansing) and CC (full bowel cleansing) and a seven - point scale to evaluate 
patient preference. Participants found MRC less burdensome and less painful (p<0.001). 
They also found higher patient preference for MRC immediately following (P<0.001, 
69% vs. 22%) as also five weeks after the investigation (p <0.00165% vs. 26%).  
Kinner et al (259) compared patient’ acceptance between MRC and optical colonoscopy 
(OC). The overall rating of OC and MRC was not significantly different, 46% of 
patients preferred MRC whilst 44% preferred OC. 
Achiam et al first in 2007 (124) and later in 2010 (180) compared MRC (with fecal 
tagging) with CC. In first study patients reported a preference for MRC for future 
investigation (66 % vs. 10%) and in second study they found same trend with 71% of 
patient preferring MRC to CC. When asked patient reported preference for MRC even if 
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done with bowel purgation (75% vs. 12%) as they found MRC less painful and less 
unpleasant.  
Hartman and colleagues (173) also compared patient acceptance of MRC and CC and 
reported higher preference for MRC over CC (58% vs.20.5% of patients).   
In the present study, patients found CC less comfortable and more painful than MRC. 
They also were more worried by the procedure. Patients in particular identified 
movement of scope and insufflation of gas as being the worst parts of CC. Similarly 
they noted insufflation of water during MRC as uncomfortable but overall MRC was 
reported to be less painful than CC. This data concurs with the literature – that CC in 
general is more uncomfortable than MRC despite use of sedation in the former. This 
also concurs with my qualitative interview study in chapter 4.1. 
Patients also expressed more worry about CC and concern about what could be found. 
Despite these differences between CC and MRC, patients were equally satisfied with 
the two tests. Notably they were equally pleased after the two tests, find staff generally 
warm and helpful and felt both procedure were dignified. 
The follow up questionnaire elicited patient’s views on overall test acceptability and 
preference. Akin to chapter 4.1, patients held mixed views with some preferring CC, 
some MRC and several having no preference. However in general patients tended to 
find MRC more acceptable than CC and preferred it over endoscopy. This again 
concurs with many of the previous questionnaire studies published in the literature as 
described above. However as I have presented in chapter 4.1, patient preference is much 
more complex than simply ticking one test over another. The drivers of preference 
cannot be elicited by standard questionnaires. Test safety, diagnostic accuracy, ability to 
see outside the colon etc. were all stated as drivers of patient preference during face to 
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face interviews as described in chapter 4.1 and it seems likely these were also 
considered as important by patients when they completed questionnaires. However the 
physical experience of the tests presumably also played an important part given patients 
reported more physical discomfort and worry during CC. 
Of course the study design has limitations. The patient experience and expectations of 
colonoscopy and MRI are highly dependent on the patient information given. Patients 
were given information sheets pertaining to colonoscopy and MRI and the risk of 
perforation mentioned in both. However it is possible difference in the information 
relayed to patients on these different sheets could influence their expectations and 
preferences. We also of course relied on patient assessment of the outcomes rather than 
using an independent reviewer. For example it is possible that if the MRI had missed 
important disease seen at colonoscopy this would have significantly affected the patient 
preference for the test had this information been given. As it was, this study assessed 
patient perceptions of the tests including their perceived advantages and disadvantages. 
Finally because of the study design MRI always preceded colonoscopy, which could 
have influenced patient experience. For example patients could have been tired 
following the MRI, which could adversely influence their experience of the 
colonoscopy. 	  
In summary, patients found MRC more comfortable and less painful than CC and they 
recovered quicker after the procedure. Although patient satisfaction and preference for 
diagnostic tests is complex but above features have translated into overall patient 
preference and acceptance of MRC. This suggest that from the point of view of patients, 
MRC is an acceptable and for some preferable alternative to CC. 
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5 CONCLUSION 
 
5.1 Introduction  
This thesis has examined the use of MRI in enteric inflammatory bowel disease 
including its level of dissemination in the NHS and its impact on the diagnostic 
confidence of clinicians and therapeutic strategy. The role of unprepared MRI in 
evaluation of acute colitis using both qualitative scores and quantitative parameters is 
assessed. An attempt is made to define post contrast perfusion kinetics of normal colon 
during MRC and to evaluate the utility of MRC to assess colonic disease activity 
against endoscopic and histological reference standards. Finally patient experience of 
MRC and CC is investigated with help of qualitative interviews and quantitative 
questionnaires.  
5.2 Discussion of Results  
Whilst European guidelines increasingly advocate the use of cross sectional techniques 
(particularly MRI and SbUS), barium studies remain the imaging investigation most 
commonly performed in both diagnosis and assessment of CD in all age groups in UK. 
Although the majority of UK radiology departments now have access to MRI, in my 
national survey only 38% offered small bowel MRI, and then mainly for patients with 
known CD or with a high clinical suspicion. Radiologists were more likely to use MRI 
than gastroenterologists request it. MR Enterography is more widely used than MR 
Enteroclysis despite the potential higher sensitivity of the latter (190). The level of 
dissemination of SbUS is also limited in UK as only 46% of departments perform it. CT 
is currently preferred mainly for detection of extraluminal complications. There is a 
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trend of using MRI and SbUS more frequently in younger patients instead of using 
tests, which impart ionizing radiation. I can thus conclude that at the time of my survey, 
a sizable minority was using MRI in clinical practice within the NHS. Possible barriers 
to implementation include lack of randomized trial data demonstrating its superiority 
over conventional tests, lack of MRI access and capacity, perceived expense and lack of 
experience amongst radiologists and requesting gastroenterologists. Given international 
committee recommendations that MRI should be used as a first line test in IBD it is 
likely UK departments must overcome these barriers as the technique disseminates.  
 
MRE is intuitively a very attractive proposition for management of CD but there is no 
robust reference standard to assess its diagnostic efficacy. A framework for assessing 
effectiveness of radiological investigations was proposed by Fryback and from this 
various methodologies have developed including the effect of tests on diagnostic 
decision making and treatment strategy. In an attempt to assess the therapeutic and 
diagnostic impact of MRE in CD I administered a detailed proforma to requesting 
clinicians. I found that a negative MRE report is highly effective in reassuring clinicians 
about the absence of small bowel disease. . Furthermore, changes in diagnostic 
confidence influences therapeutic strategy in around 50% of patients with suspected 
disease, in 77% of patients with a strong clinical suspicion and overall in 61% of 
patients.  
From this study, I can conclude that when used as part of an established service, MRE 
has a positive effect on clinician diagnostic confidence, which translates into real 
changes in therapeutic management in the majority of patients. This data should provide 
supporting evidence for those wishes to introduce MRE into their practice. 
 216 
MRColonography has been advocated as a potential safe and accurate diagnostic tool to 
accurately document the location, extent and severity of colonic inflammation. Various 
parameters have been reported to correlate with disease activity during 
MRColonography, particularly wall thickness, T2 signal and contrast enhancement. The 
literature is mixed regarding post gadolinium enhancement and one of the possible 
explanations for this is intersegmental difference in normal colon due to differing blood 
supplies. In an attempt to evaluate this potential difference, dark lumen MRC was 
performed in patients who had normal or non inflamed colon on endoscopy. No 
significant difference was seen in pre contrast R1 values between ascending colon (AC), 
descending colon (DC) and rectum but ΔR1 (change after contrast) was greater for the 
ascending than descending colon. AUC-R1 of the AC was also significantly greater than 
the DC and there also were differences between rectum and other colonic segments.  
The data may be explained by known anatomical differences in blood supply between 
the right and left colon. From this data I can conclude that segmental differences in 
colonic enhancement should be considered when using enhancement as biomarker for 
colonic inflammation. 
Three proposed qualitative MRI scores of IBD activity were then tested using dark 
lumen MRC against an endoscopic (CDEIS) and histological standard of reference. All 
three tested scores (Steward score, MRI activity index and MaRIA index) correlated 
significantly with CDEIS on per patient and per segment basis. Wall thickness and T2 
signal were common parameters in all these scores, with contrast enhancement also 
considered in calculating the MRI activity score and MaRIA score. The strength of 
correlation with CDEIS was not overtly less with the simple Steward score (based on 
just wall thickness and T2 signal) in comparison to the other two more complex scores, 
suggesting contrast enhancement may not add to accuracy when scores are based on 
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subjective assessments by radiologists. From this study I can conclude that enteric and 
extra-enteric parameters provided during MRC can be subjectively graded by reporting 
radiologists and act as robust biomarkers of disease activity. MRC may therefore have a 
role in not only staging disease, but also for therapeutic monitoring 
In patients with acute colitis, invasive tests just as endoscopy or full MRC are usually 
inappropriate. Unprepared MRI was tested as a rapid non invasive alternative of 
assessing disease severity. A Total colonic inflammatory score (TCIS) based on haustral 
loss, Mural T2 signals, wall thickness, pericolonic mesenteric edema, small bowel and 
colonic dilatation was derived, and correlated with clinical markers of disease severity. 
A significant correlation was seen between pre treatment TCIS and both CRP and stool 
frequency. Furthermore, there was significant reduction in TCIS, CRP and stool 
frequency after medical therapy. No correlation was found between TCIS, CRP and 
stool frequency after medical therapy. Interestingly admission TCIS showed a 
significant correlation with length of inpatient stay, suggesting it may have a potential 
role as new prognostic tool. In this regard it was superior to conventional AXR. Overall 
the MRI was reasonably acceptable to patients. 
From this study I can conclude that unprepared MRI is a valid alternative to 
conventional clinical markers of disease activity in acute severe colitis, providing 
information about the extent and severity of disease. The short 10 min protocol is 
tolerated by patients and clearly safer than invasive endoscopy. The use of unprepared 
MRI in assessing acute colitis is justified. 
In a further attempt to quantify disease severity in acute colitis quantitative, 
measurements via RIO placement was undertaken using dynamic contrast enhanced T1 
weighted images, diffusion weighted images and T2 weighted data before and after 
medical treatment. Data were correlated with Fulminant colitis index (a clinical 
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standard of reference based on CRP and stool frequency). No significant correlation was 
found between FCI and most parameters other than with contrast enhancement, where a 
positive correlation was confirmed. However, there was a significant fall in mural T2 
signal after treatment. Quantitative measurements of thin bowel wall are prone to error 
and motion and volume artifacts can increase these errors. In addition, FCI is an 
imprecise reference standard compared to colonoscopy but later is relatively contra 
indicated in acute colitis. The data in patients with acute colitis suggests that qualitative 
grading may be more robust than quantitative measurements based on ROI placement.  
Patient experience is complex and influenced by many factors. I investigated this by 
direct face to face patient interviews, and by use of a questionnaire validated for 
colonoscopy.  From the interview data I found that patients with IBD find the need to lie 
still difficult where as those without IBD in particular found the scanner noise intrusive. 
Some patients find the fear of incontinence during MRC as a disadvantage. The ability 
to view the procedure and immediate feedback during CC was seen distinct advantage 
especially amongst those without IBD. Conversely, patients perceived the ability of 
MRC to visualize beyond the colon as a definite advantage. Based on the questionnaire 
responses, it seems patients find MRC more comfortable and less painful than CC and 
they recovered quicker after it. I did find an overall slight preference for MRC in terms 
of perceived patient acceptability and preference, although many graded both tests as 
equal. It is clear however that patient experience is governed by many facets over and 
above the physical experience of the test.  
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5.3 Conclusion 
 
IBD is a lifelong condition that remains a diagnostic and therapeutic challenge and 
requires repeated assessment of disease extent and activity as part of management.  
The use of MRI for IBD has dramatically risen in recent years but in UK there is only 
moderate dissemination of MRI and SbUS as barium follow through remains the most 
frequently performed and requested examination for known or suspected luminal small 
bowel CD. However, MRE has a positive diagnostic impact in patients under 
investigation for small bowel CD and significantly influences in therapeutic strategy of 
these patients. 
There are inter segmental differences in colonic enhancement should be considered 
when using enhancement as a biomarker for colonic inflammation. Qualitative 
parameters particularly, wall thickness and T2 signal assessed during dark lumen MRC 
correlate well with endoscopic disease activity (CDEIS), suggesting MRC a 
complementary tool to CC in the follow up of patients with colitis.  
 
A MRI parameter scores (TCIS) derived from unprepared T2 weighted images in acute 
severe colitis performed well compared to conventional clinical markers of severity, and 
may act as a prognostic marker. Quantitative region of interest based measurements 
fared less well, although contrast enhancement was correlated with a fulminant colitis 
index. My data suggests that qualitative grading of colon wall is more robust than 
quantitative measures.  
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Patient experience during MRC is part dependent on the reason for colonic investigation 
(be it IBD or non IBD). Patients do find the some of the physical experiences during 
MRC as unpleasant (for example lying still, scanner noise, water instillation and fear of 
incontinence). However in general, they found MRC less uncomfortable than 
colonoscopy. Overall patient preference was mixed but there was a slight bias in favour 
of MRC. 
In summary, this thesis has shown MRI is a robust diagnostic technique, which has a 
valid clinical role in assessment of small bowel and large bowel in IBD. It can 
compliment endoscopy and other radiological modalities and can act as biomarker of 
disease activity. 
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APPENDIX  
Appendix A- Gastroenterologist Questionnaire 
1.  In a patient with newly diagnosed, biopsy proven, Crohn’s disease which test(s) 
would you normally request to assess small bowel involvement in the following age 
groups? (You may tick more than one test if multiple concurrent tests are normally 
requested.) 
Investigation Patient <20 
years old 
Patient 21 – 
40 years old 
Patient 41 – 
60 years old 
Patient >61 
years old 
Barium Follow 
Through/Enteroclysis 
    
Small Bowel 
Ultrasound 
    
Small bowel MRI     
CT +/- CT 
Enteroclysis 
    
Capsule Endoscopy     
2.  In a new patient with a high clinical suspicion of small bowel Crohn’s disease e.g. 
chronic diarrhea, abdominal pain and weight loss with anaemia, thrombocytosis and a 
raised CRP etc. which test would you normally request to establish a diagnosis of 
Crohn’s disease? (You may tick more than one test if multiple concurrent tests are 
normally requested.) 
Investigation Patient <20 
years old 
Patient 21 – 
40 years old 
Patient 41 – 
60 years old 
Patient >61 
years old 
Colonoscopy with 
ileoscopy and 
biopsies 
    
 252 
Barium Follow 
Through/Enteroclysis 
    
Small Bowel 
Ultrasound 
    
Small bowel MRI     
CT +/- CT 
Enteroclysis 
    
Capsule Endoscopy     
 
3.  In a new patient with a low clinical suspicion of small bowel Crohn’s disease e.g. 
with occasional diarrhoea, vague abdominal pain and no weight loss or anaemia, and a 
normal CRP which test would you normally request to exclude small bowel Crohn’s 
disease? (You may tick more than one test if multiple concurrent tests are normally 
requested.) 
Investigation Patient <20 
years old 
Patient 21 – 
40 years old 
Patient 41 – 
60 years old 
Patient >61 
years old 
Colonoscopy with 
ileoscopy and 
biopsies 
    
Barium Follow 
Through/Enteroclysis 
    
Small Bowel 
Ultrasound 
    
Small bowel MRI     
CT +/- CT 
Enteroclysis 
    
Capsule Endoscopy     
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4.  In a patient with known small bowel Crohn’s disease in whom an extraluminal 
complication such as fistula or abscess is suspected which of the following tests would 
you routinely request?  
Investigation Patient <20 
years old 
Patient 21 – 
40 years old 
Patient 41 – 
60 years old 
Patient >61 
years old 
Barium Follow 
Through/Enteroclysis 
    
Small Bowel 
Ultrasound 
    
Small bowel MRI     
CT +/- CT 
Enteroclysis 
    
Capsule Endoscopy     
5.  In an out-patient with known Crohn’s disease and symptoms suggestive of 
stricturing disease which of the following tests would you routinely request to 
determine the level of obstruction? (You may tick more than one test if multiple 
concurrent tests are routinely requested) 
Investigation Patient <20 
years old 
Patient 21 – 
40 years old 
Patient 41 – 
60 years old 
Patient >61 
years old 
Barium Follow 
Through/Enteroclysis 
    
Small Bowel 
Ultrasound 
    
Small bowel MRI     
CT +/- CT 
Enteroclysis 
    
Capsule Endoscopy     
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1. In a patient with known Crohn’s disease with a clinical flare-up of the disease 
which test would you routinely request to reassess the small bowel? (You may 
mark more than one test if multiple concurrent tests are routinely requested) 
 
Investigation Patient <20 
years old 
Patient 21 – 
40 years old 
Patient 41 – 
60 years old 
Patient >61 
years old 
Barium Follow 
Through/Enteroclysis 
    
Small Bowel 
Ultrasound 
    
Small bowel MRI     
CT +/- CT 
Enteroclysis 
    
Capsule Endoscopy     
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Appendix B- Radiologist Questionnaire 
1. In your department in a month, on average, how many of the following investigations 
do you perform for diagnosis or follow up of small bowel Crohn’s disease? (Please put 
numbers in the appropriate box, if none are performed pleased place a 0 in the 
appropriate box) 
Investigation 
 
Number performed for 
suspected diagnosis  
Number performed for 
follow up of disease 
Barium Follow Through   
Barium Enteroclysis   
Small Bowel Ultrasound   
Small bowel MRI (oral 
contrast) 
  
MRI Eneteroclysis   
CT (oral contrast)   
CT Enteroclysis   
Capsule Endoscopy   
If you perform small bowel MR please state 
Your preferred oral contrast agent if any?  _________________________
2.  In a patient with biopsy proven newly diagnosed Crohn’s disease which 
investigation would you normally use, if any, to assess small bowel involvement in the 
following age groups? (You may tick more than one investigation per age group if 
multiple concurrent investigations are usually performed.)  
Investigation Patient <20 
years old 
Patient 21 – 40 
years old 
Patient 41 – 60 
years old 
Patient >61 
years old 
Barium Follow     
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Through 
Barium 
Enteroclysis 
    
Small Bowel 
Ultrasound 
    
Small bowel 
MRI (oral 
contrast) 
    
Small bowel 
MRI (oral 
contrast) 
    
CT (oral 
contrast) 
    
CT 
Enteroclysis 
    
Capsule 
Endoscopy 
    
3.   In a patient with clinical suspicion of small bowel Crohn’s disease but no biopsy 
proof, which of the following investigations would you normally use for diagnosis in, 
in a patient with a) high clinical suspicion of disease and b) low clinical suspicion of 
disease? (You may tick more than one investigation per age group if multiple 
concurrent investigations are normally performed.) 
a) In a patient with high clinical suspicion of disease? 
Investigation Patient <20 
years old 
Patient 21 – 40 
years old 
Patient 41 – 60 
years old 
Patient >61 
years old 
Barium Follow 
Through 
    
Barium 
Enteroclysis 
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Small Bowel 
Ultrasound 
    
Small bowel 
MRI (oral 
contrast) 
    
MRI 
Enteroclysis 
    
CT (oral 
contrast) 
    
CT 
Enteroclysis 
    
Capsule 
Endoscopy 
    
b) In a patient with low clinical suspicion of disease? 
Investigation Patient <20 
years old 
Patient 21 – 40 
years old 
Patient 41 – 60 
years old 
Patient >61 
years old 
Barium Follow 
Through 
    
Barium 
Enteroclysis 
    
Small Bowel 
Ultrasound 
    
Small bowel 
MRI (oral 
contrast) 
    
MRI 
Enteroclysis 
    
CT (oral 
contrast) 
    
CT 
Enteroclysis 
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Capsule 
Endoscopy 
    
4.  In a patient with known Crohn’s disease in whom an extraluminal complication 
such as fistula or abscess is clinically suspected which of the following investigations 
perform to confirm this?   
Investigation Patient <20 
years old 
Patient 21 – 40 
years old 
Patient 41 – 60 
years old 
Patient >61 
years old 
Barium Follow 
Through 
    
Barium 
Enteroclysis 
    
Small Bowel 
Ultrasound 
    
Small bowel 
MRI (oral 
contrast) 
    
MRI 
Enteroclysis 
    
CT (oral 
contrast) 
    
CT 
Enteroclysis 
    
Capsule 
Endoscopy 
    
5.  In an out-patient with known Crohn’s disease and obstructive symptoms 
suggesting stricturing disease which of the following tests would you normally perform 
to determine the level of obstruction? (You may tick more than one investigation if 
multiple concurrent investigations are normally performed) 
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Investigation Patient <20 
years old 
Patient 21 – 40 
years old 
Patient 41 – 60 
years old 
Patient >61 
years old 
Barium Follow 
Through 
    
Barium 
Enteroclysis 
    
Small Bowel 
Ultrasound 
    
Small bowel 
MRI (oral 
contrast) 
    
MRI 
Enteroclysis 
    
CT (oral 
contrast) 
    
CT 
Enteroclysis 
    
Capsule 
Endoscopy 
    
 
 
 
2. In a patient with known Crohn’s disease with a clinical flare-up which test 
would you normally perform to reassess the small bowel disease?  (You may 
tick more than one investigation if multiple concurrent investigations are 
normally performed) 
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Investigation Patient <20 
years old 
Patient 21 – 40 
years old 
Patient 41 – 60 
years old 
Patient >61 
years old 
Barium Follow 
Through 
    
Barium 
Enteroclysis 
    
Small Bowel 
Ultrasound 
    
Small bowel 
MRI (oral 
contrast) 
    
MRI 
Enteroclysis 
    
CT (oral 
contrast) 
    
CT 
Enteroclysis 
    
Capsule 
Endoscopy 
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Appendix C- MR Colonography  
Patient preparation  
• All patients underwent solid food restriction from lunchtime the day before 
colonoscopy followed by full bowel purgation- 10 Senna tablets and two sachets 
of magnesium citrate (Citramag- Sanochemia Diagnostics, UK) dissolved in one 
litre of water.  
• Rehana Hafeez performed MRC 2 hours before colonoscopy in all patients.  
• Following rectal introduction of 16F Foley catheter, the colon was gently filled 
with 1.5l of warm tap water from an enema bag held at shoulder height (i.e. 
filling by gravity).  
• Bowel motility was abolished by intravenous spasmolytic (Buscopan, 
Boehringer Ingelheim, Germany) 0.3mg/kg (maximum 20 mg) immediately 
prior to abdominal imaging 
• Once the colon is distended, a standard MR scanning protocol was performed in 
all patients and the procedure took an average 30 minutes. 
 MRC protocol  
Images were acquired in the prone position with a 1.5T Siemens Avanto (Avanto; 
Siemens, Erlangen, Germany) magnet using the body and spine array coils.  
 
1. Coronal and axial Half Fourier Acquisition Single Shot Turbo Spin Echo 
(HASTE) images of the abdomen and pelvis were acquired during breathe hold 
with and without fat saturation  
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*coronal/axial acquisition 
**Grappa= generalized autocalibrating partially parallel acquisitions 
MR parameters-Coronal and axial Half Fourier RARE sequence 
 
 
 
 
FOV Variable 
No. of sections 20/26* 
Stacks 1/4 
TR (ms) 1200 
TE (ms) 86 
Matrix 256 x 195 
Slice thickness (mm) 4 
Section gap (mm) 1 
Averages 4 
Echo train 256 
Integrated parallel acquisition 
technique 
Grappa factor of 2 
Flip angle 50 degrees 
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2. 2nd dose Intravenous hyoscine butylbromide  
3. Diffusion weighted imaging of abdomen (WB-DWI) x 2 b-values (ADC 
quantitation) 
4. The pre – contrast T1 relaxation time of colon was measured by using three 
breath-hold coronal fat saturated 3D Fast Low Angle Shot (FLASH) images of 
the abdomen and pelvis with different excitation flip angles (flip angles 5°, 10°, 
and 35°) 
5. Prior to intravenous contrast administration, three 3D FLASH baseline sets of 
coronal images were acquired during suspended inspiration.  
6. A single dose of (0.2 mg/Kg) IV gadoterate meglumine (Dotarem; Guerbet 
Roissy, France) was then injected into an arm vein at 3 mL/sec, followed by a 
saline chaser (10 mL). 
7. At injection the patient was asked to hold his/her breath for 20 seconds (during 
which a single 3D FLASH volume dataset was acquired), followed by 10 
seconds of gentle breathing, immediately followed by another 20 seconds breath 
hold acquisition and 10 seconds of gentle breathing. The acquisition protocol 
was repeated to generate a total of 8 post contrast 3D FLASH datasets. 
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 *FLASH 3D 
(T1 calculation) 
*FLASH 3D 
(pre-contrast) 
*FLASH 3D 
(post-contrast) 
TE (ms) 2.4 2.4 2.4 
TR (ms) 5.15 5.15 5.15 
FA (degrees) 5°,10°,35° 35° 35° 
NEX 1 1 1 
iPAT 2 2 2 
FOV (mm) 500x500 500x500 500x500 
STH 3 3 3 
No. slices 48-60 48-60 48-60 
BW (Hz) 300 300 300 
Acq. Matrix 256x154 256x154 256x154 
Recon. Matrix 512x512 512x512 512x512 
TA (s) 17 17 17 
No. Acq. **1 3 8 
MR Acquisition Parameters 
*Breath held fat saturated coronal T1 weighed 3D Fast Low Angle Shot  
**Single acquisition at each flip angle 
TR- repetition time, TE- echo time, 
 FA- flip angle,  NEX- number of signal 
iPAT- parallel imaging factor 
FOV- field of view, STH- slice thickness 
BW- pixel bandwidth 
TA- time for single 3D FLASH acquisition. 
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APPENDIX D – Patient information sheet 
 
You are being invited to take part in a research study. Before you decide it is important 
for you to understand why the research is being done and what it will involve. Please 
take time to read the following information carefully and discuss it with others if you 
wish. Ask us if there is anything that is not clear or if you would like more information.   
Take time to decide whether or not you wish to take part.    
What is the purpose of the study? 
Endoscopy is a test used to examine the large bowel (colon) for polyps, tumours and 
inflammation. Endoscopy involves passing a tube into the large bowel in order to look 
around. Generally endoscopy is safe and not unduly uncomfortable but it is an 
expensive, time-consuming and difficult procedure and, very rarely, patients may be 
harmed by it. MRI scanning is a safe and less invasive way of imaging the body and 
produces images or pictures of the bowel without using X-rays. It may be possible to 
get much of the information given by endoscopy by using MRI (with a test called MR 
colonography). We are particularly interested to see if MR Colonography can detect 
inflammation in bowel (such as with Crohn’s disease or ulcerative colitis). This study 
will compare the ability of MR colonography to detect inflammation in the bowel 
compared to conventional colonoscopy with the aim of in part replacing endoscopy with 
MRI. 
Why have I been chosen? 
You have been chosen because you are due to undergo a conventional endoscopy to 
look inside your large bowel because your doctor thinks you may have inflammation of 
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the bowel. We would like to see how good MR Colonography is at assessing large 
bowel inflammation compared to conventional endoscopy.  
Do I have to take part? 
It is up to you to decide whether or not to take part. You have at least 48 hours to 
consider participation.  If you do decide to take part you will be given this information 
sheet to keep and be asked to sign a consent form.  A research doctor (Dr Rehana 
Hafeez) may ring you before the date of the endoscopy to explain the study in more 
detail and answer any questions or concerns you may have. In the mean time please feel 
free to contact Dr Hafeez on 07877 931 401 if you would like to discuss anything 
before this phone call 
If you decide to take part you are still free to withdraw at any time and without giving a 
reason.   A decision to withdraw at any time, or a decision not to take part, will not 
affect your future medical care. 
What is happen to me if I take part? 
We will ask you to come to the hospital for an MRI scan of the large bowel around 2 
hours before the time of your scheduled endoscopy. The scan will take about 30 
minutes. We will ask you to lie in the MR scanner and we will insert a small needle into 
a vein in your arm. We will leave this needle in so it can be used during your 
subsequent endoscopy. During the scan we will give you two small injections through 
this needle (the injections themselves will not hurt). One injection (“buscopan”) relaxes 
the bowel (and may temporally give you a dry mouth and slightly blurred vision). The 
second injection (“gadolinium”) is a special MRI contrast agent which helps highlight 
the wall of the bowel. It is unlikely you will notice anything during this injection, 
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although some people get a sweet taste in their mouth. Before we start the MRI scan, a 
small tube will be put just inside your bottom and some gas or water introduce through 
this, to distend your large bowel, just like happens during endoscopy. You may feel 
some abdominal bloating as the gas or water is put in the large bowel, but the procedure 
should not be painful.   
The main aim of the trial is to compare the MRI appearance of your bowel with that 
seen during your conventional endoscopy so we can learn what the MRI scan images 
mean. 
What do I have to do? 
You will need to follow the preparation instructions already needed for your 
conventional endoscopy. You will not have to do anything more because of the MRI 
scan. As explained above we may give you a small injection during the scan which may 
temporarily cause minimal blurring of your vision and affect your ability to drive for 
about on hour or so. If you are pregnant we will ask you not to take part in the study. 
After the MRI scan is complete we will escort you in your own time to the endoscopy 
department where you will be able to wait for your endoscopy appointment. We will ask 
you to fill out a short questionnaire after the MR scan and endoscopy so you can tell us 
how you found both tests. With your permission, we may telephone you afterwards to 
give us more detailed information about your experience during the scan. 
What is the drug or procedure that is being tested? 
MRI is an established imaging test and is increasingly used to look at the large bowel. 
However we are not completely sure what the abnormalities seen on MRI actually 
mean, and how good it is at showing the severity of inflammation. We ultimately would 
  
268 
like to use MRI as a reliable non invasive test to see whether the bowel is inflamed. By 
comparing MRI scans with endoscopy, we hope to gain important information which 
will be used to interpret scans in the future. 
What are the alternatives for diagnosis or treatment 
At the moment doctors try and assess if the large bowel is abnormal by inserting a 
endoscope and looking at the bowel directly.  
What are known risks of the study or the side effects of any treatment received? 
MRI is a safe test and importantly does not use X-rays which are theoretically harmful. 
There are no known adverse effects from MRI itself. However certain patients cannot 
have MRI (e.g. people with heart pacemakers) and we will ask you detailed questions to 
make sure it is safe for you to have the scan. Some people find being in the scanner a 
little claustrophobic. However modern scanners have a larger space to lie in and you 
will always be in contact with the person performing the scan via an intercom. The scan 
takes no more than 30 minutes and can be done in stages if you prefer. The injections 
we give have been used in day to day practice for a long time and are very safe. As 
mentioned above the buscopan injection may give you dry mouth and slightly blurred 
vision for a few minutes. Allergy to the gadolinium contrast is possible but very rare. 
Mild reactions (nausea, transient rash etc.) occur in less than 3% of patients and more 
serious reactions are much less common than this. The risk of causing damage to your 
bowel such as making a small hole by gently inflating with gas or water, is very small 
(less than 3 in 10,000 similar procedures i.e. 0.03%), and less than the risk of 
conventional endoscopy. 
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You are encouraged to contact Dr Hafeez on 07877 931 401if you have any problems 
after the scan.  
What are the possible disadvantages and risks of taking part? 
Because we are not totally sure if MRI is completely safe in the early stages of 
pregnancy, we asked pregnant women not to take part in the study. Women who are at 
risk of pregnancy may be asked to have a pregnancy test before taking part to exclude 
the possibility of pregnancy.   
The MRI scan will mainly look at the large bowel. However we will also obtain some 
imaging information about the other organs in your abdomen such as liver, kidneys etc. 
We may theoretically therefore detect an incidental abnormality in one of these organs 
which may need further investigation to clarify its nature. The vast majority of such 
findings are incidental to and of little importance. Your doctor will be informed of the 
finding via the clinical report we will provide for the MRI scan. If you have private 
medical insurance you are advised to check with the company before agreeing to take 
part in the trial.   
What are the possible benefits of taking part? 
By taking part in the study you will have an MRI scan which you otherwise would not 
have had. The scan will allow us to look at the extent of inflammation in you bowel and 
detect any associated complication such as abscess or fistulae (abnormal 
communications from the bowel). This information may be of use to your doctor, and 
we will provide a full clinical report for the scan so all the information is passed on. 
You may receive no direct benefit from taking part, but the information from this will 
be of use for patients in the future.  
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What if new information becomes available? 
Sometimes during the course of a research project, new information becomes available 
about the treatment that is being studied.   If this happens, your research doctor will tell 
you about it and discuss with you whether you want to continue in the study.   If you 
decide to withdraw your research doctor will make arrangements for your care to 
continue.  If you decide to continue in the study you will be asked to sign an updated 
consent form. 
Also, on receiving new information your research doctor might consider it to be in your 
best interest to withdraw you from the study. He/she will explain the reasons and 
arrange for your care to continue. 
What happens when the research study stops? 
After the study is complete we will aim to analyse the results, write them up in medical 
journals and hopefully change to way we interpret scans. We hope to use the 
information to start new trials looking at how we monitor the effect of medication given 
to treat colonic inflammation.  
What if something goes wrong? 
If you have a specific complaint against your treatment by a member of staff (doctors, 
nurses, etc.) you have the right to complain using the usual UCLH complaints 
procedure.    
If you are harmed by taking part in this research project, there are no special 
compensation arrangements.  If you are harmed due to someone’s negligence, then you 
may have grounds for a legal action but you may have to pay for it.  Regardless of this, 
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if you wish to complain, or have any concerns of this study, the normal National Health 
Service complaints mechanisms should be available to you. 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be 
kept strictly confidential.  Any information about you which leaves the hospital/surgery 
will have your name and address removed so that you cannot be recognized from it. We 
will need to look at you hospital notes, blood results and past x-ray tests, but only 
medically qualified doctors at UCH involved in this study will do this.  
With your permission, we will tell your GP that you are taking part in the trial and we 
will tell them the results of your MRI scan if you want them to know. The results of the 
MRI scan will be available to your GP and other hospital doctors looking after you by 
the usual hospital results system. Please tell us if you do not want your GP to be 
informed. 
 Your data  
 We will create a database for the trial. The data will be anonymised such that your 
name, hospital number date of birth and address will be fully removed and you will be 
given a unique trial identification number. The list of identification numbers will be 
held on a password protected secure computer separate from the database controlled by 
trial principal investigator (Dr Stuart Taylor). We will store basic information such as 
your age, as well as results of previous imaging/blood tests, the results of you MRI scan 
and pathology reports. The database will be stored on a password protected computer 
drive held by UCL who will collect, store, handle and process the data. Only the trial 
principal investigator (Dr Stuart Taylor) and nominated researchers will have access to 
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the data base and will be responsible for the safely and security of the data. With your 
permission will may use your data for future studies, although again it will be 
anonymised and handled as explained above. For this reason we expect to keep the 
database for 3 years. The study does not involve storage of any body tissue over and 
above your normal clinical care. 
 What will happen to the results of the research study? 
We aim to recruit around 55 patients for the study. When we have analyzed the results 
we will write them up and publish them in medical journals. It will probably take about 
a year from completing the trial to publishing the results. Your doctor at UCH will be 
able to tell you about the results when they are published so you can get a copy if you 
wish. In the mean time you will be able to discuss your MRI scan results with your 
doctor at UCH.  You will not be identified in any report/publication. 
Who is organizing and funding the research? 
The research is being funded via a research grants from the Royal College of 
Radiologists and the UCLH Trustees.  
No doctor is being paid for conducting the research. 
The costs of the MRI scan will be paid by the funding organizations. 
Who has reviewed the study? 
The study has been reviewed by University College Hospital Ethics Committee A 
Contact for Further Information 
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Thank you very much for considering taking part in the study. If you agree to take part 
we will provide you with copies of this information sheet and the consent form we will 
ask you to sign. 
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APPENDIX E- Patient Questionnaire 
 
We would like to thank you for taking part in the study comparing MRI colonography 
and colonoscopy. For each item below please place a cross in the box which you feel 
best reflects your experience of MRI/CC 
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        Dissatisfied n n n n n n n n Satisfied  
        Staff  not interested n n n n n n n nStaff interested 
        Displeased n n n n n n n nPleased 
         Staff cool n n n n n n n nStaff warm 
         Staff uninformative n n n n n n n nStaff informative  
        Undignified n n n n n n n n  Dignified  
        Uninterested n n n n n n n n Interested  
         Not confident n n n n n n n nConfident in Staff  
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APPENDIX F- Follow up questionnaire  
We would like to thank you again for taking part in our study comparing a MR 
colonography scan with endoscopy for looking at the large bowel. You have now had 
some time to recover from both tests. We would like to see how you think you tolerated 
the two tests and if you found one more acceptable than the other. Please answer the 
following questions: 
• I felt I tolerated the MRI scan (circle one response) 
 Well  Fairly well  Poorly  Very Poorly 
If you ringed poorly or very poorly please give the reasons: 
• What was the worst part of the MRI scan (circle one response) 
Injections  having gas put lying flat claustrophobia   
   In the bowel 
Other (please state) ----------------------------------------------------------  
• I felt I tolerated the colonoscopy (circle one response) 
    Well Fairly well  Poorly  Very Poorly 
If you ringed poorly or very poorly please give the reasons: 
• What was the worst part of the colonoscopy (circle one response) 
Injections  moving the  having gas  other (please state) 
   Colonoscope  put in the ______________ 
   In the bowel  bowel  ________________ 
How long did it take for you feel back to normal after the MRI scan (circle one 
response)? 
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Less than 1 hour  1-3 hours  3- 6 hours More than 6 hours 
Please state how long __________________________ 
• How long did it take for you feel back to normal after the colonoscopy? 
Less than 1 hour  1-3 hours  3- 6 hours More than 6 hours 
Please state how long_____________________________ 
If your recovery was more than 1 hour, please give the main reasons why you felt you 
were not back to normal _____________________________ 
• Would you have the endoscopy again? 
Yes    No   Maybe 
• Would you have the MRI again? 
Yes    No   Maybe 
• If you had to have just one of the tests again, which one would it be? 
MRI scan   Endoscopy  Don’t mind 
• Baring in mind all that you personally know about the risks and benefits for both 
tests, which one do you feel is the most acceptable? 
MRI scan   Endoscopy  About the same 
• If you found one of the tests more acceptable than the other, please write of few 
words below to give your reasons. 
_______________________________________________ 
Many thanks for your time. Please return this questionnaire in the enclosed SAE 
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